P01282450A01
Pain/NN management/NN ,/, nutritional/JJ support/NN ,/, and/CC psychosocial/JJ support/NN are/VBP fundamental/JJ services/NNS that/WDT enhance/VBP patients/NNS '/POS ability/NN to/TO cope/VB with/IN their/PRP$ cancer/NN and/CC its/PRP$ therapy/NN ./.
P01350716A05
Seven/CD trials/NNS of/IN beta-blockers/NNS and/CC 15/CD of/IN sclerotherapy/NN were/VBD published/VBN as/IN full/JJ papers/NNS ./.
P01421653A15
CONCLUSIONS/NNS :/: Although/IN more/RB well-designed/JJ clinical/JJ trials/NNS comparing/VBG pamidronate/NN with/IN standard/JJ therapies/NNS and/CC other/JJ available/JJ agents/NNS are/VBP necessary/JJ ,/, initial/JJ results/NNS indicate/VBP that/IN pamidronate/NN is/VBZ an/DT effective/JJ and/CC promising/JJ alternative/NN for/IN use/NN in/IN the/DT treatment/NN of/IN HCM/NN ./.
P01462793A01
BACKGROUND/NN :/: More/RB than/IN 11/CD million/CD people/NNS in/IN the/DT United/JJ States/NNS have/VBP moderate/JJ or/CC severe/JJ migraine/NN resulting/VBG in/IN much/DT suffering/NN and/CC millions/NNS of/IN lost/JJ work/NN days/NNS annually/RB ./.
P01533416A11
Thirty-eight/CD of/IN 44/CD effect/NN sizes/NNS indicated/VBD that/IN SMT/NN was/VBD better/JJR than/IN the/DT comparison/NN treatment/NN ./.
P01538563A14
There/EX has/VBZ been/VBN an/DT exponential/JJ increase/NN in/IN knowledge/NN regarding/VBG the/DT interactions/NNS among/IN the/DT components/NNS of/IN the/DT stress/NN system/NN and/CC between/IN the/DT stress/NN system/NN and/CC other/JJ brain/NN elements/NNS involved/VBN in/IN the/DT regulation/NN of/IN emotion/NN ,/, cognitive/JJ function/NN ,/, and/CC behavior/NN ,/, as/RB well/RB as/IN with/IN the/DT axes/NNS responsible/JJ for/IN reproduction/NN ,/, growth/NN ,/, and/CC immunity/NN ./.
P01595772A01
Gastroesophageal/JJ reflux/NN disease/NN (/( GERD/NN )/) remains/VBZ a/DT ubiquitous/JJ problem/NN ,/, although/IN therapeutic/JJ options/NNS continue/VBP to/TO evolve/VB ./.
P01616217A13
Medical/JJ interventions/NNS that/WDT effectively/RB halt/VBP the/DT progression/NN or/CC prevent/VBP the/DT development/NN of/IN diabetic/JJ retinopathy/NN are/VBP needed/VBN ./.
P01658404A08
Because/IN PID/NN is/VBZ polymicrobial/JJ in/IN cause/NN ,/, recommended/JJ antimicrobial/JJ regimens/NNS are/VBP broad-spectrum/NN in/IN coverage/NN ./.
P01726215A18
The/DT modest/JJ ,/, reversible/JJ risk/NN of/IN neutropenia/NN ,/, affecting/VBG less/RB than/IN 1/CD %/SYM of/IN patients/NNS ,/, makes/VBZ the/DT benefit/NN :/SYM risk/NN ratio/NN a/DT reasonable/JJ one/PRP ./.
P01767696A02
Central/JJ to/TO the/DT debate/NN are/VBP the/DT results/NNS of/IN the/DT major/JJ placebo-controlled/JJ clinical/JJ trials/NNS of/IN pharmacologic/JJ treatment/NN of/IN hypercholesterolemia/NN ./.
P01828529A09
In/IN the/DT case/NN of/IN comparative/JJ studies/NNS the/DT relative/JJ risks/NNS of/IN severe/JJ reactions/NNS in/IN low-risk/NN versus/CC high-risk/NN patients/NNS and/CC with/IN LOCM/NN compared/VBN with/IN HOCM/NN were/VBD treated/VBN for/IN homogeneity/NN ,/, and/CC pooled/JJ odds/NNS ratios/NNS and/CC 95/CD %/SYM confidence/NN intervals/NNS (/( CI/NN )/) were/VBD calculated/VBN by/IN combining/NN the/DT logarithms/NNS of/IN the/DT odds/NNS ratios/NNS weighted/VBN by/IN their/PRP$ variances/NNS ./.
P01934395A12
The/DT consensus/NN was/VBD that/IN a/DT very/RB restrictive/JJ and/CC cautious/JJ attitude/NN to/TO the/DT newer/JJR settings/NNS is/VBZ appropriate/JJ at/IN this/DT time/NN ./.
P02050423A02
Although/IN there/EX are/VBP differences/NNS in/IN pathogens/NNS by/IN age/NN ,/, the/DT importance/NN of/IN nosocomial/JJ pneumonia/NN is/VBZ apparent/JJ in/IN the/DT adult/NN population/NN as/RB well/RB as/IN in/IN the/DT pediatric/JJ patient/NN groups/NNS ./.
P02206035A07
In/IN the/DT United/JJ States/NNS ,/, lovastatin/NN will/MD be/VBP used/VBN in/IN a/DT double-blind/JJ ,/, placebo-controlled/JJ ,/, primary/JJ prevention/NN trial/NN involving/VBG 8,000/CD patients/NNS without/IN clinical/JJ evidence/NN of/IN CAD/NN ,/, slight/JJ to/TO moderate/JJ elevations/NNS of/IN total/JJ cholesterol/NN ,/, and/CC low-/JJ and/CC high-density/NN lipoprotein/NN cholesterol/NN to/TO establish/VB whether/IN 5/CD years/NNS of/IN treatment/NN will/MD decrease/VBP the/DT rate/NN of/IN fatal/JJ CAD/NN or/CC nonfatal/JJ myocardial/JJ infarction/NN ./.
P02491421A14
In/IN many/DT patients/NNS with/IN renal/JJ disease/NN ,/, ACE/NN inhibitors/NNS dramatically/RB reduce/VBP proteinuria/NN ,/, but/CC whether/IN they/PRP also/RB reduce/VBP the/DT rate/NN of/IN progression/NN of/IN renal/JJ disease/NN remains/VBZ unproved/VBN ./.
P02656825A15
7./CD Finally/RB ,/, in/IN this/DT era/NN of/IN quality/NN assurance/NN ,/, professional/JJ review/NN and/CC cost/NN containment/NN ,/, it/PRP behooves/VBZ each/DT physician/NN to/TO ask/VB whether/IN the/DT data/NNS provided/VBN by/IN the/DT particular/JJ tests/NNS were/VBD worth/IN the/DT cost/NN ,/, inconvenience/NN and/CC risk/NN for/IN that/DT particular/JJ patient/NN ./.
P02864682A09
The/DT success/NN of/IN captopril/NN ,/, the/DT first/JJ oral/JJ agent/NN of/IN this/DT class/NN ,/, promises/VBZ to/TO hold/VB true/JJ for/IN other/JJ ACE/NN inhibitors/NNS (/( such/JJ as/IN enalapril/NN )/) ,/, which/WDT have/VBP similar/JJ activities/NNS but/CC differing/JJ pharmacokinetic/JJ properties/NNS and/CC will/MD soon/RB be/VBP available/JJ for/IN clinical/JJ use/NN ./.
P03414608A08
The/DT ATP/NN 's/POS report/NN established/VBD criteria/NNS that/WDT define/VBP candidates/NNS with/IN high/JJ blood/NN cholesterol/NN levels/NNS who/WP should/MD receive/VBP medical/JJ intervention/NN and/CC provided/VBD guidelines/NNS on/IN how/WRB to/TO detect/VB ,/, set/VB goals/NNS ,/, treat/VB ,/, and/CC monitor/VB these/DT patients/NNS over/IN time/NN ./.
P07474194A07
CONCLUSIONS/NNS --/: Sympathetic/JJ nervous/JJ system/NN activation/NN in/IN patients/NNS with/IN chronic/JJ heart/NN failure/NN is/VBZ a/DT major/JJ contributor/NN to/TO the/DT severity/NN of/IN disease/NN as/RB well/RB as/IN its/PRP$ progression/NN over/IN time/NN ./.
P07486487A12
The/DT pooled/JJ sensitivity/NN was/VBD 66/CD %/SYM (/( 95/CD %/SYM CI/NN ,/, 57/CD %/SYM to/TO 74/CD %/SYM )/) ,/, and/CC the/DT pooled/JJ specificity/NN was/VBD 98/CD %/SYM (/( CI/NN ,/, 96/CD %/SYM to/TO 99.5/CD %/SYM )/) ./.
P07503088A01
Some/DT aspects/NNS of/IN thyroid/NN nodule/NN evaluation/NN and/CC management/NN remain/VBP controversial/JJ ./.
P07527326A07
Titrating/NN quinapril/NN dosages/NNS from/IN 10/CD to/TO 40/CD mg/NN //SYM day/NN increased/VBD response/NN rates/NNS without/IN increasing/NN the/DT incidence/NN or/CC severity/NN of/IN adverse/JJ events/NNS ./.
P07563563A09
Thereafter/RB ,/, the/DT panel/NN resolved/VBD conflicting/JJ recommendations/NNS and/CC released/VBD a/DT revised/JJ statement/NN at/IN the/DT end/NN of/IN the/DT conference/NN ./.
P07587242A08
Experts/NNS in/IN closed/JJ loop/NN systems/NNS were/VBD then/RB added/VBN to/TO the/DT group/NN to/TO review/VB the/DT summary/NN provided/VBN by/IN the/DT task/NN force/NN ./.
P07596718A18
Five/CD trials/NNS reporting/VBG deaths/NNS from/IN tuberculosis/NN showed/VBD a/DT BCG/NN protective/JJ effect/NN of/IN 0.65/CD (/( 95/CD %/SYM CI/NN ,/, 0.12/CD to/TO 0.86/CD )/) ,/, five/CD studies/NNS reporting/VBG on/IN meningitis/NN showed/VBD a/DT protective/JJ effect/NN of/IN 0.64/CD (/( 95/CD %/SYM CI/NN ,/, 0.30/CD to/TO 0.82/CD )/) ,/, and/CC three/CD studies/NNS of/IN disseminated/JJ tuberculosis/NN showed/VBD a/DT protective/JJ effect/NN of/IN 0.78/CD (/( 95/CD %/SYM CI/NN ,/, 0.58/CD to/TO 0.88/CD )/) ./.
P07606076A04
DATA/NNS EXTRACTION/NN :/: The/DT most/RBS recent/JJ clinical/JJ trials/NNS that/WDT evaluated/VBD cytotoxic/JJ chemotherapy/NN or/CC hormonal/JJ therapy/NN in/IN patients/NNS with/IN node-negative/JJ breast/NN cancer/NN were/VBD chosen/VBN ./.
P07639445A03
Five/CD major/JJ areas/NNS were/VBD identified/VBN and/CC searched/VBN :/: cardiomyopathies/NNS ,/, atrial/JJ fibrillation/NN ,/, the/DT long/JJ QT/NN syndrome/NN ,/, cardiac/JJ transplantation/NN ,/, and/CC vasovagal/JJ syncope/NN ./.
P07650455A11
One/CD technique/NN ,/, atherectomy/NN ,/, has/VBZ been/VBN shown/VBN to/TO be/VB no/RB more/RB effective/JJ ,/, and/CC more/RB expensive/JJ ,/, than/IN conventional/JJ balloon/NN angioplasty/NN ./.
P07663033A01
OBJECTIVE/NN :/: To/TO discuss/VB the/DT role/NN of/IN amiodarone/NN for/IN the/DT maintenance/NN of/IN normal/JJ sinus/NN rhythm/NN in/IN patients/NNS with/IN atrial/JJ fibrillation/NN (/( AF/NN )/) and/CC review/VB the/DT clinical/JJ trial/NN data/NNS evaluating/VBG the/DT efficacy/NN and/CC safety/NN of/IN amiodarone/NN in/IN patients/NNS with/IN AF/NN ./.
P07674695A10
The/DT most/RBS recent/JJ data/NNS from/IN the/DT 4S/NN trial/NN have/VBP unequivocally/RB demonstrated/VBN the/DT benefits/NNS of/IN treatment/NN with/IN HMG/NN coenzyme-A/NN reductase/NN inhibitors/NNS in/IN reducing/NN the/DT risk/NN of/IN future/JJ coronary/JJ events/NNS and/CC improving/NN the/DT overall/JJ survival/NN in/IN patients/NNS with/IN established/JJ CHD/NN ./.
P07700062A05
Are/VBP ACE/NN inhibitors/NNS beneficial/JJ in/IN mild-to-moderate/JJ heart/NN failure/NN ?/.
P07726699A06
To/TO our/PRP$ knowledge/NN ,/, no/DT randomized/JJ ,/, placebo-controlled/JJ trials/NNS of/IN amiodarone/NN therapy/NN for/IN atrial/JJ fibrillation/NN have/VBP been/VBN published/VBN ./.
P07752668A09
There/EX are/VBP also/RB promising/JJ data/NNS suggesting/VBG that/IN beta-blockade/NN is/VBZ useful/JJ in/IN endothelial/JJ protection/NN and/CC atheroma/NN prevention/NN ,/, and/CC benefits/VBZ patients/NNS with/IN hypertrophic/JJ cardiomyopathy/NN and/CC heart/NN failure/NN ./.
P07786840A10
More/RB recently/RB ,/, preliminary/JJ results/NNS from/IN the/DT third/JJ Gruppo/NN Italiano/NN per/IN lo/DT Studio/NN della/IN Sopravvivenza/NN nell'Infarto/NN Miocardico/NN (/( GISSI-3/NN )/) ,/, the/DT Fourth/JJ International/JJ Study/NN of/IN Infarct/NN Survival/NN (/( ISIS-4/NN )/) ,/, and/CC the/DT Chinese/NN Captopril/NN Trial/NN suggested/VBD that/IN angiotensin-converting/JJ enzyme/NN (/( ACE/NN )/) inhibitor/NN mortality/NN benefits/NNS post-myocardial/JJ infarction/NN would/MD be/VBP detected/VBN in/IN these/DT megatrials/NNS as/RB early/RB as/IN 35/CD days/NNS after/IN the/DT event/NN ./.
P07805271A02
The/DT American/JJ Heart/NN Association/NN assembled/VBD a/DT group/NN of/IN experts/NNS in/IN a/DT multidisciplinary/JJ consensus/NN conference/NN to/TO develop/VB this/DT statement/NN ./.
P07826548A10
The/DT panel/NN believes/VBZ that/IN whereas/IN many/DT different/JJ drugs/NNS can/MD produce/VBP effective/JJ blood/NN pressure/NN reduction/NN ,/, the/DT modern/JJ primary/JJ goal/NN of/IN antihypertensive/JJ drug/NN therapy/NN is/VBZ to/TO select/VB a/DT regimen/NN most/RBS likely/RB to/TO prolong/VB the/DT quality/NN and/CC duration/NN of/IN life/NN ./.
P07850886A09
Peluso/NNP and/CC colleagues/NNS (/( 1993/CD )/) have/VBP performed/VBN a/DT recent/JJ meta-analysis/NN of/IN available/JJ therapies/NNS in/IN fibromyalgia/NN syndrome/NN and/CC found/VBD that/IN the/DT effect-size/NN (/( a/DT standardized/JJ measure/NN of/IN the/DT efficacy/NN of/IN a/DT given/JJ therapy/NN )/) of/IN several/JJ non-medication/NN therapies/NNS such/JJ as/IN electroacupuncture/NN exceeded/VBD that/PRP of/IN traditional/JJ medication/NN therapies/NNS ./.
P07867364A10
CONCLUSION/NN :/: Recommendations/NNS for/IN the/DT design/NN ,/, conduct/NN and/CC analysis/NN of/IN future/JJ trials/NNS of/IN sepsis/NN therapies/NNS were/VBD summarized/VBN ./.
P07882203A09
At/IN the/DT conclusion/NN ,/, the/DT students/NNS will/MD have/VBP encountered/VBN all/PDT the/DT information/NN necessary/JJ to/TO solve/VB the/DT case/NN and/CC ,/, in/IN so/RB doing/NN ,/, will/MD have/VBP gained/VBN knowledge/NN that/WDT in/IN a/DT conventional/JJ curriculum/NN would/MD usually/RB have/VBP been/VBN disseminated/VBN by/IN lecture/NN ./.
P07905143A11
This/DT overview/NN indicates/VBZ that/IN fibrinolytic/JJ therapy/NN is/VBZ beneficial/JJ in/IN a/DT much/RB wider/JJR range/NN of/IN patients/NNS than/IN is/VBZ currently/RB given/VBN such/DT treatment/NN routinely/RB ./.
P07922426A04
These/DT considerations/NNS have/VBP led/VBN to/TO pressure-limited/JJ mechanical/JJ ventilation/NN strategies/NNS ,/, including/VBG pressure-controlled/JJ ,/, inverse-ratio/NN ventilation/NN ./.
P07939748A04
The/DT presentation/NN of/IN advanced/JJ disease/NN is/VBZ also/RB unusual/JJ ,/, in/IN that/IN the/DT vast/JJ majority/NN of/IN patients/NNS do/VBP not/RB have/VBP measurable/JJ disease/NN suitable/JJ for/IN traditional/JJ studies/NNS of/IN new/JJ chemotherapy/NN agents/NNS ./.
P07966873A01
OBJECTIVE/NN --/: This/DT article/NN reviews/VBZ the/DT incidence/NN of/IN arterial/JJ thromboembolism/NN in/IN patients/NNS with/IN heart/NN failure/NN who/WP are/VBP not/RB receiving/VBG anticoagulants/NNS ./.
P08011827A20
More/RB reliable/JJ administration/NN of/IN antimicrobial/JJ agents/NNS according/VBG to/TO recognized/JJ guidelines/NNS should/MD prevent/VBP some/DT postoperative/JJ wound/NN infections/NNS while/IN lowering/VBG the/DT total/JJ quantity/NN of/IN these/DT drugs/NNS used/VBN ./.
P08017749A09
The/DT clinical/JJ presentations/NNS of/IN nonvalvular/JJ endovascular/JJ infections/NNS are/VBP subtle/JJ and/CC diagnoses/NNS are/VBP difficult/JJ to/TO make/VB ,/, often/RB requiring/VBG not/RB only/RB a/DT high/JJ index/NN of/IN suspicion/NN but/CC also/RB the/DT use/NN of/IN sophisticated/JJ radiologic/JJ techniques/NNS ./.
P08055409A10
The/DT clinical/JJ judgment/NN of/IN the/DT practising/JJ clinician/NN ,/, however/WRB ,/, must/MD always/RB be/VBP incorporated/VBN into/IN any/DT diagnostic/JJ or/CC therapeutic/JJ decision/NN ./.
P08080494A10
Unfortunately/RB ,/, these/DT conditions/NNS are/VBP extremely/RB frequent/JJ and/CC carry/VBP high/JJ mortality/NN rates/NNS ./.
P08085692A07
Single/JJ and/CC combined/JJ chemotherapeutic/JJ agents/NNS produce/VBP high/JJ response/NN rates/NNS ./.
P08120703A06
DATA/NNS SYNTHESIS/NN :/: The/DT spontaneous/JJ rate/NN of/IN primary/JJ control/NN --/: without/IN antibiotics/NNS or/CC tympanocentesis/NN --/: was/VBD 81/CD %/SYM (/( 95/CD %/SYM confidence/NN interval/NN ,/, 69/CD %/SYM to/TO 94/CD %/SYM )/) ./.
P08147551A11
Perhaps/RB more/RB accurate/JJ clinical/JJ and/CC laboratory/NN predictors/NNS are/VBP needed/VBN to/TO identify/VB patients/NNS who/WP may/MD benefit/VBP from/IN a/DT given/JJ treatment/NN strategy/NN ./.
P08173141A17
Failure/NN to/TO respond/VB to/TO treatment/NN of/IN recurrent/JJ ventricular/JJ tachycardia/NN //SYM fibrillation/NN to/TO usual/JJ antiarrhythmic/JJ therapy/NN in/IN patients/NNS with/IN acute/JJ myocardial/JJ infarction/NN ,/, idiopathic/JJ dilated/JJ cardiomyopathy/NN ,/, and/CC congestive/JJ heart/NN failure/NN should/MD alert/VBP the/DT clinician/NN to/TO consider/VB administering/NN intravenous/JJ Mg/NN ./.
P08207176A07
EVIDENCE/NN :/: Many/DT prospective/JJ ,/, randomized/JJ ,/, controlled/JJ trials/NNS comparing/VBG placebo/NN with/IN antibiotic/NN and/CC comparing/VBG one/CD antibiotic/NN with/IN another/PRP have/VBP been/VBN conducted/VBN ./.
P08221424A15
The/DT CMA/NN 's/POS guidelines/NNS on/IN this/DT topic/NN should/MD be/VBP evaluated/VBN to/TO see/VB whether/IN they/PRP are/VBP effective/JJ in/IN controlling/NN physician-industry/NN interactions/NNS ./.
P08234776A08
The/DT creation/NN of/IN this/DT ideal/JJ ICD/NN will/MD obviously/RB require/VBP continued/JJ technological/JJ advances/NNS ;/: however/WRB ,/, given/VBN the/DT tremendous/JJ improvements/NNS realized/VBN over/IN the/DT first/JJ three/CD generations/NNS of/IN ICD/NN systems/NNS ,/, optimism/NN for/IN the/DT future/NN seems/VBZ warranted/VBN ./.
P08281682A07
Data/NNS on/IN each/DT procedure/NN were/VBD recorded/VBN on/IN a/DT unique/JJ modular/JJ database/NN that/WDT captured/VBD the/DT reason/NN for/IN (/( and/CC interim/JJ result/NN after/IN )/) each/DT device/NN use/NN ./.
P08305784A06
Clinical/JJ trials/NNS were/VBD assessed/VBN primarily/RB for/IN comparative/JJ efficacy/NN and/CC toxicity/NN ./.
P08329800A23
Based/VBN on/IN the/DT CONSENSUS/NN II/CD results/NNS ,/, enalapril/NN therapy/NN immediately/RB following/VBG AMI/NN can/MD not/RB be/VBP recommended/VBN ./.
P08357116A08
For/IN most/DT patients/NNS ,/, therapy/NN can/MD be/VBP initiated/VBN with/IN a/DT full/JJ replacement/NN dosage/NN (/( 1.6/CD micrograms/NNS //SYM kg/NN body/NN weight/NN )/) ,/, which/WDT is/VBZ usually/RB 75/CD to/TO 100/CD micrograms/NNS //SYM day/NN for/IN women/NNS and/CC 100/CD to/TO 150/CD micrograms/NNS //SYM d/NN for/IN men/NNS ./.
P08379605A13
After/IN one/CD negative/JJ result/NN of/IN a/DT 3-year/NN examination/NN ,/, the/DT interval/NN can/MD be/VBP increased/VBN to/TO 5/CD years/NNS ./.
P08410406A02
DESIGN/NN AND/CC DATA/NNS IDENTIFICATION/NN :/: English-language/NN literature/NN search/NN using/VBG MEDLINE/NN ,/, Index/NN Medicus/NN ,/, and/CC bibliographic/JJ reviews/NNS of/IN texts/NNS and/CC all/DT pertinent/JJ articles/NNS to/TO perform/VB a/DT quantitative/JJ and/CC methodologic/JJ analysis/NN of/IN all/DT studies/NNS from/IN 1983/CD (/( the/DT original/JJ publication/NN )/) assessing/VBG the/DT association/NN under/IN study/NN ./.
P08439699A08
Trials/NNS were/VBD assessed/VBN by/IN design/NN ,/, sample/NN size/NN ,/, types/NNS of/IN seizures/NNS of/IN the/DT subjects/NNS ,/, and/CC clinical/JJ response/NN ./.
P08472581A13
In/IN recognition/NN of/IN these/DT complex/JJ issues/NNS (/( including/VBG potential/JJ conflicts/NNS among/IN ICUs/NNS ,/, hospital/NN administration/NN ,/, individual/JJ physicians/NNS ,/, and/CC the/DT various/JJ medical/JJ and/CC surgical/JJ programs/NNS feeding/VBG patients/NNS into/IN special/JJ care/NN units/NNS )/) ,/, the/DT Society/NN of/IN Critical/JJ Care/NN Medicine/NN has/VBZ organized/VBN a/DT Task/NN Force/NN on/IN the/DT legal/JJ and/CC ethical/JJ justification/NN for/IN triage/NN ./.
P08520092A11
CONCLUSIONS/NNS :/: Desogestrel/NN ,/, norgestimate/NN ,/, and/CC gestodene/NN appear/VBP to/TO offer/VB clinical/JJ advantages/NNS because/IN of/IN their/PRP$ decreased/JJ androgenicity/NN ./.
P08544272A14
Sucralfate/NN may/MD be/VBP as/RB effective/JJ in/IN reducing/NN bleeding/NN as/IN gastric/JJ pH-altering/JJ drugs/NNS and/CC is/VBZ associated/VBN with/IN lower/JJR rates/NNS of/IN pneumonia/NN and/CC mortality/NN ./.
P08564995A04
Much/DT progress/NN has/VBZ been/VBN made/VBN in/IN altering/NN practices/NNS such/JJ as/IN under-prescribing/NN and/CC underdosing/NN that/WDT have/VBP adversely/RB affected/VBD adequate/JJ control/NN of/IN pain/NN in/IN children/NNS ./.
P08576513A20
Research/NN questions/NNS might/MD be/VBP guided/VBN by/IN the/DT biopsychosocial/JJ conceptual/JJ context/NN described/VBN above/RB ./.
P08591547A22
The/DT candidate/NN obtains/VBZ information/NN by/IN "/`` mouse-clicking/NN ,/, "/'' so/IN it/PRP is/VBZ not/RB necessary/JJ to/TO be/VB a/DT computer/NN expert/NN to/TO use/VB the/DT system/NN ./.
P08593127A12
Possible/JJ adverse/JJ effects/NNS of/IN the/DT fibric-acid/NN derivatives/NNS include/VBP abdominal/JJ discomfort/NN ,/, nausea/NN ,/, flatulence/NN ,/, increased/JJ lithogenicity/NN of/IN bile/NN ,/, liver/NN enzyme/NN elevations/NNS and/CC creatine/NN kinase/NN elevations/NNS ./.
P08601930A08
RESULTS/NNS :/: A/DT total/NN of/IN 8676/CD admissions/NNS with/IN unstable/JJ angina/NN or/CC non-Q-wave/NN MI/NN were/VBD enumerated/VBN and/CC ,/, of/IN these/PRP ,/, 3318/CD patients/NNS were/VBD selected/VBN for/IN the/DT prospective/JJ study/NN ./.
P08604723A17
Other/JJ treatment/NN modalities/NNS ,/, including/VBG tissue/NN transplants/NNS and/CC cytokine-modulating/JJ drugs/NNS ,/, are/VBP emerging/VBG for/IN the/DT potential/JJ therapy/NN of/IN OA/NN ./.
P08608668A13
Patients/NNS who/WP present/VBP 1-6/CD months/NNS after/IN angioplasty/NN with/IN typical/JJ anginal/JJ symptoms/NNS have/VBP a/DT high/JJ likelihood/NN of/IN having/NN angiographic/JJ restenosis/NN ./.
P08615705A02
It/PRP is/VBZ unknown/VBN how/WRB the/DT effectiveness/NN and/CC costs/NNS of/IN such/PDT an/DT approach/NN (/( "/`` stepped/JJ care/NN "/'' )/) compare/VBP in/IN typical/JJ clinical/JJ practice/NN to/TO those/PRP of/IN initial/JJ therapy/NN with/IN lovastatin/NN ./.
P08625645A02
To/TO examine/VB the/DT available/JJ evidence/NN that/WDT supports/VBZ or/CC refutes/VBZ goal-directed/JJ therapy/NN toward/IN supranormal/JJ oxygen/NN transport/NN in/IN optimizing/NN the/DT outcome/NN of/IN critically/RB ill/JJ sepsis/NN syndrome/NN patients/NNS ./.
P08633831A06
RESULTS/NNS :/: Forty-two/CD studies/NNS were/VBD reviewed/VBN for/IN possible/JJ inclusion/NN ./.
P08653655A03
At/IN the/DT same/JJ time/NN ,/, many/DT interventions/NNS are/VBP associated/VBN with/IN increased/JJ risks/NNS in/IN the/DT elderly/NN ,/, so/IN that/IN individualization/NN of/IN treatment/NN is/VBZ essential/JJ in/IN all/DT patients/NNS ./.
P08658222A21
A/DT large/JJ American/JJ intergroup/NN trial/NN is/VBZ underway/VBN testing/VBG the/DT concept/NN of/IN postoperative/JJ adjuvant/NN chemoradiation/NN ./.
P08673987A05
The/DT role/NN of/IN cyclooxygenase-2/NN (/( COX-2/NN )/) versus/CC COX-1/NN inhibiting/JJ agents/NNS was/VBD also/RB examined/VBN ./.
P08677863A05
Clinicians/NNS must/MD therefore/RB decide/VBP what/WP their/PRP$ practice/NN will/MD be/VBP on/IN the/DT basis/NN of/IN data/NNS that/WDT are/VBP currently/RB available/JJ ./.
P08686979A02
The/DT review/NN consists/VBZ of/IN two/CD parts/NNS ./.
P08703521A03
AIM/NN :/: The/DT aim/NN of/IN the/DT study/NN was/VBD to/TO assess/VB the/DT effectiveness/NN of/IN corticosteroid/NN injections/NNS in/IN the/DT treatment/NN of/IN lateral/JJ epicondylitis/NN (/( tennis/NN elbow/NN )/) by/IN systematic/JJ review/NN of/IN the/DT available/JJ randomized/JJ clinical/JJ trials/NNS ./.
P08729587A01
Both/CC the/DT European/JJ Atherosclerosis/NN Society/NN and/CC the/DT US/NNP National/JJ Cholesterol/NN Education/NN Program/NN have/VBP issued/VBN revised/JJ guidelines/NNS for/IN the/DT prevention/NN of/IN coronary/JJ heart/NN disease/NN (/( CHD/NN )/) ,/, based/VBN on/IN a/DT multitude/NN of/IN recent/JJ epidemiological/JJ and/CC angiographic/JJ studies/NNS ./.
P08736614A24
In/IN comparison/NN with/IN haloperidol/NN ,/, it/PRP appears/VBZ to/TO be/VB associated/VBN with/IN a/DT lower/JJR prevalence/NN of/IN acute/JJ extrapyramidal/JJ adverse/JJ effects/NNS in/IN dosages/NNS </SYM or/CC =/SYM 10/CD mg/NN //SYM day/NN ,/, the/DT most/RBS potentially/RB important/JJ component/NN of/IN which/WDT is/VBZ its/PRP$ reportedly/RB insignificant/JJ likelihood/NN of/IN promoting/NN akathisia/NN ./.
P08754362A14
Amiodarone/NN unlike/IN other/JJ antiarrhythmic/JJ drugs/NNS does/VBZ not/RB seem/VBP depress/VB left/VBD ventricular/JJ function/NN ,/, and/CC may/MD be/VBP the/DT best/JJS drug/NN in/IN patients/NNS with/IN CHF/NN and/CC symptomatic/JJ arrhythmias/NNS ./.
P08780375A04
The/DT literature/NN was/VBD searched/VBN through/IN Medline/NN and/CC an/DT extensive/JJ bibliography/NN of/IN references/NNS was/VBD provided/VBN to/TO the/DT panel/NN and/CC the/DT conference/NN audience/NN ./.
P08792953A07
DATA/NNS SYNTHESIS/NN :/: Production/NN of/IN viscous/JJ respiratory/JJ secretion/NN is/VBZ a/DT hallmark/NN phenomenon/NN of/IN cystic/JJ fibrosis/NN ,/, leading/VBG to/TO a/DT variety/NN of/IN symptoms/NNS ./.
P08826564A01
OBJECTIVE/NN :/: To/TO review/VB the/DT pathophysiology/NN of/IN hypertension/NN and/CC complications/NNS in/IN patients/NNS with/IN diabetes/NN mellitus/NN ,/, specifically/RB focusing/VBG on/IN diabetic/JJ nephropathy/NN ;/: to/TO evaluate/VB the/DT current/JJ clinical/JJ literature/NN regarding/VBG the/DT appropriate/JJ management/NN of/IN hypertension/NN in/IN this/DT patient/NN group/NN ;/: and/CC to/TO offer/VB treatment/NN recommendations/NNS ./.
P08827194A19
And/CC it/PRP would/MD be/VBP even/RB more/RB peculiar/JJ if/IN various/JJ other/JJ antidepressant/NN medications/NNS chemically/RB unrelated/VBN to/TO fluoxetine/NN also/RB ,/, by/IN chance/NN alone/JJ ,/, benefited/VBD all/PRP of/IN these/DT same/JJ disorders/NNS via/IN still/RB other/JJ independent/JJ mechanisms/NNS ./.
P08837541A11
RECOMMENDATIONS/NNS :/: Bone/NN mineral/NN density/NN should/MD be/VBP measured/VBN only/RB to/TO assist/VB in/IN making/NN a/DT clinical/JJ management/NN choice/NN ./.
P08841011A01
Role/NN of/IN ACE/NN inhibitors/NNS in/IN the/DT management/NN of/IN asymptomatic/JJ or/CC symptomatic/JJ left/JJ ventricular/JJ (/( LV/NN )/) dysfunction/NN after/IN acute/JJ myocardial/JJ infarction/NN (/( AMI/NN )/) is/VBZ well/RB established/VBN ./.
P08853610A07
Although/IN successful/JJ for/IN some/PRP ,/, this/DT approach/NN increases/VBZ risk/NN for/IN ineffective/JJ interventions/NNS accompanied/VBN by/IN side/NN effects/NNS ./.
P08873639A05
OUTCOMES/NNS :/: Prevention/NN of/IN loss/NN of/IN bone/NN mineral/NN density/NN and/CC fracture/NN ;/: increased/JJ bone/NN mass/NN ;/: and/CC improved/JJ quality/NN of/IN life/NN ./.
P08876861A08
The/DT attenuation/NN of/IN ventricular/JJ remodeling/NN that/WDT occurs/VBZ with/IN ACE/NN inhibition/NN does/VBZ not/RB fully/RB explain/VBP the/DT results/NNS of/IN clinical/JJ trials/NNS in/IN patients/NNS after/IN MI/NN ./.
P08888782A14
Early/JJ intervention/NN has/VBZ been/VBN shown/VBN to/TO reduce/VB the/DT rate/NN of/IN vertebral/JJ and/CC hip/NN fractures/NNS by/IN 50/CD -/CC 70/CD %/SYM ./.
P08893123A27
Therapy/NN must/MD be/VBP individualized/VBN according/VBG to/TO the/DT patient/NN 's/POS disease/NN course/NN and/CC other/JJ patient-specific/JJ factors/NNS ./.
P08900335A03
Most/PRP of/IN the/DT atherosclerotic/JJ regression/NN trials/NNS were/VBD too/RB small/JJ and/CC of/IN too/RB short/JJ duration/NN to/TO demonstrate/VB a/DT significant/JJ difference/NN in/IN hard/JJ coronary/JJ events/NNS between/IN patients/NNS receiving/VBG cholesterol-lowering/JJ intervention/NN and/CC controls/NNS ./.
P08903273A12
Return/NN to/TO sinus/NN rhythm/NN may/MD be/VBP difficult/JJ to/TO achieve/VB early/JJ after/IN surgery/NN ,/, so/IN opting/NN for/IN rate/NN control/NN is/VBZ the/DT best/RBS initial/JJ approach/NN ./.
P08913409A03
;/: published/JJ articles/NNS and/CC abstracts/NNS ;/: and/CC review/NN chapters/NNS from/IN medical/JJ textbooks/NNS ./.
P08918275A05
The/DT population/NN studied/VBN comprised/VBD subgroups/NNS of/IN patients/NNS with/IN atherosclerotic/JJ vascular/JJ disease/NN manifested/VBN as/IN either/CC recent/JJ ischaemic/JJ stroke/NN ,/, recent/JJ myocardial/JJ infarction/NN ,/, or/CC symptomatic/JJ peripheral/JJ arterial/JJ disease/NN ./.
P08934387A13
Lipid-lowering/JJ drugs/NNS improve/VBP endothelium-dependent/JJ vasodilation/NN in/IN the/DT coronary/JJ and/CC forearm/NN circulation/NN of/IN patients/NNS with/IN hyperlipidemia/NN and/CC atherosclerosis/NN ./.
P08968429A04
It/PRP is/VBZ our/PRP$ opinion/NN ,/, however/WRB ,/, that/IN there/EX are/VBP no/DT data/NNS that/WDT support/VBP the/DT extrapolation/NN of/IN these/DT untoward/JJ effects/NNS to/TO the/DT more/RB contemporary/JJ ,/, long-acting/JJ dihydropyridines/NNS (/( eg/NN ,/, amlodipine/NN )/) or/CC ,/, especially/RB ,/, to/TO the/DT non-dihydropyridine/NN (/( heart/NN rate-lowering/NN )/) calcium/NN antagonists/NNS ,/, such/JJ as/IN diltiazem/NN or/CC verapamil/NN ./.
P08974727A09
Weight-bearing/JJ exercise/NN is/VBZ important/JJ throughout/IN life/NN ./.
P08990407A06
TIMI/NN grade/NN 2/CD or/CC 3/CD flow/NN at/IN 90/CD minutes/NNS when/WRB compared/VBN with/IN accelerated/JJ alteplase/NN ./.
P09002496A13
CONCLUSIONS/NNS :/: The/DT results/NNS of/IN this/DT meta-analysis/NN indicate/VBP that/IN in/IN patients/NNS undergoing/VBG CABG/NN surgery/NN ,/, treatment/NN with/IN acadesine/NN before/IN and/CC during/IN surgery/NN can/MD reduce/VBP early/RB cardiac/JJ death/NN ,/, MI/NN ,/, and/CC combined/JJ adverse/JJ cardiovascular/JJ outcomes/NNS ./.
P09023821A08
The/DT panel/NN composed/VBD a/DT draft/JJ statement/NN that/WDT was/VBD read/VBN in/IN its/PRP$ entirety/NN and/CC circulated/VBN to/TO the/DT experts/NNS and/CC the/DT audience/NN for/IN comment/NN ./.
P09029428A15
Simply/RB developing/NN and/CC publishing/NN guidelines/NNS has/VBZ not/RB resulted/VBN in/IN improvement/NN in/IN practice/NN ./.
P09036802A07
Platelet/NN hyperactivity/NN ,/, reduced/JJ fibrinolytic/JJ capacity/NN ,/, increased/JJ concentrations/NNS of/IN hemostatic/JJ proteins/NNS ,/, and/CC endothelial/JJ dysfunction/NN promote/VBP thrombosis/NN at/IN the/DT site/NN of/IN plaque/NN rupture/NN ./.
P09054283A09
Educational/JJ interventions/NNS with/IN physicians/NNS led/VBD to/TO increased/JJ use/NN of/IN patient/NN preferences/NNS ,/, but/CC sophisticated/JJ educational/JJ techniques/NNS were/VBD needed/VBN to/TO motivate/VB physicians/NNS to/TO change/VB their/PRP$ behavior/NN ./.
P09063282A02
STUDY/NN SELECTION/NN //SYM DATA/NNS ABSTRACTION/NN :/: MEDLINE/NN searches/NNS for/IN literature/NN on/IN prevention/NN and/CC screening/NN with/IN regard/NN to/TO older/JJR adults/NNS as/RB well/RB as/IN each/DT individual/JJ condition/NN reviewed/VBN ;/: bibliographical/JJ reviews/NNS of/IN textbooks/NNS ,/, journal/JJ articles/NNS ,/, government/NN and/CC advocacy/NN organization/NN task/NN force/NN reports/NNS ,/, and/CC recommendations/NNS ./.
P09072935A03
STUDY/NN SELECTION/NN :/: Probabilities/NNS for/IN individual/JJ clinical/JJ outcomes/NNS were/VBD derived/VBN from/IN various/JJ sources/NNS ,/, including/VBG the/DT largest/JJS screening/JJ study/NN of/IN community/NN volunteers/NNS to/TO data/NNS ,/, analyses/NNS of/IN Medicare/NN claims/NNS ,/, and/CC recently/RB published/JJ meta-analyses/NNS of/IN the/DT outcomes/NNS of/IN alternative/JJ treatment/NN strategies/NNS ./.
P09092324A01
PURPOSE/NN :/: To/TO review/VB the/DT literature/NN on/IN risk/NN stratification/NN after/IN acute/JJ myocardial/JJ infarction/NN in/IN the/DT reperfusion/NN era/NN and/CC to/TO propose/VB an/DT algorithm/NN for/IN early/JJ and/CC continual/JJ risk/NN assessment/NN ./.
P09101399A10
For/IN example/NN ,/, in/IN the/DT GISSI/NN 3/CD study/NN ,/, treatment/NN with/IN lisinopril/NN was/VBD associated/VBN with/IN a/DT decreased/JJ 6-week/NN mortality/NN in/IN both/CC IDD/NN (/( 11.8/CD %/SYM versus/CC 21.1/CD ,/, p/NN </SYM 0.05/CD )/) and/CC non-IDD/NN (/( 8.0/CD %/SYM versus/CC 10.6/CD %/SYM ,/, p/NN </SYM 0.05/CD )/) patients/NNS corresponding/VBG to/TO a/DT 44.1/CD %/SYM and/CC 24.5/CD %/SYM reduction/NN ,/, respectively/RB ./.
P09110119A02
For/IN example/NN 1/CD out/IN of/IN 5/CD ,/, and/CC even/RB as/RB many/JJ as/IN 1/CD out/IN of/IN 3/CD ,/, fatal/JJ cardiovascular/JJ events/NNS can/MD be/VBP prevented/VBN by/IN some/DT treatments/NNS ./.
P09112710A23
These/DT impressions/NNS justify/VBP additional/JJ research/NN efforts/NNS on/IN this/DT topic/NN ./.
P09118820A13
Evidence/NN is/VBZ now/RB available/JJ to/TO show/VB a/DT beneficial/JJ effect/NN of/IN bezafibrate/NN on/IN retarding/NN atherosclerotic/JJ processes/NNS and/CC in/IN reducing/NN risk/NN of/IN coronary/JJ heart/NN disease/NN ./.
P09132880A12
However/WRB ,/, there/EX are/VBP still/RB many/DT methodological/JJ questions/NNS regarding/VBG the/DT validity/NN and/CC sensitivity/NN of/IN quality/NN of/IN life/NN measurement/NN an/DT optimal/JJ study/NN design/NN calls/VBZ for/IN caution/NN in/IN the/DT interpretation/NN of/IN current/JJ results/NNS and/CC makes/VBZ refinement/NN of/IN methodological/JJ issues/NNS a/DT desirable/JJ goal/NN ./.
P09158559A12
Of/IN the/DT 639/CD patients/NNS who/WP may/MD have/VBP received/VBN electrolyte-free/JJ solutions/NNS ,/, 16/CD patients/NNS (/( 2.5/CD %/SYM )/) reported/VBD adverse/JJ effects/NNS ,/, 8/CD of/IN which/WDT were/VBD severe/JJ ./.
P09165992A16
The/DT results/NNS of/IN the/DT 26/CD randomised/JJ trials/NNS that/WDT have/VBP been/VBN carried/VBN out/RP to/TO date/NN ,/, suggest/VBP that/IN NSAIDs/NNS might/MD be/VBP effective/JJ for/IN short-term/NN symptomatic/JJ relief/NN in/IN patients/NNS with/IN uncomplicated/JJ low/JJ back/NN pain/NN ,/, but/CC are/VBP less/RB effective/JJ or/CC ineffective/JJ in/IN patients/NNS with/IN low/JJ back/NN pain/NN with/IN sciatica/NN and/CC patients/NNS with/IN sciatica/NN with/IN nerve/NN root/NN symptoms/NNS ./.
P09187830A14
Pilot/NN studies/NNS suggest/VBP that/IN QOL/NN can/MD be/VBP enhanced/VBN prior/RB to/TO transplant/NN ,/, and/CC that/IN health-related/JJ QOL/NN prior/RB to/TO transplant/NN may/MD predict/VBP survival/NN and/CC clinical/JJ outcomes/NNS ./.
P09198254A06
Estrogen/NN replacement/NN therapy/NN is/VBZ associated/VBN with/IN decreased/JJ atherosclerosis/NN in/IN several/JJ animal/NN models/NNS ./.
P09207617A10
When/WRB all/DT 17/CD reports/NNS were/VBD combined/VBN ,/, beta-blockade/NN significantly/RB reduced/VBD all-cause/NN mortality/NN (/( random/JJ effect/NN odds/NNS ratio/NN [/( OR/NN ]/) 0.69/CD ,/, 95/CD %/SYM confidence/NN interval/NN [/( CI/NN ]/) 0.54/CD to/TO 0.88/CD )/) ./.
P09214253A08
For/IN acute/JJ mono-/JJ and/CC oligoarthritis/NN ,/, rheumatologists/NNS performed/VBD arthrocentesis/NN more/RB appropriately/RB than/IN nonrheumatologists/NNS and/CC produced/VBD shorter/JJR durations/NNS of/IN hospitalization/NN ./.
P09220052A08
A/DT pharmacoeconomic/JJ analysis/NN estimated/VBD that/IN continuation/NN of/IN digoxin/NN in/IN patients/NNS with/IN stable/JJ congestive/JJ heart/NN failure/NN could/MD save/VBP the/DT healthcare/NN system/NN an/DT estimated/JJ $/SYM 400/CD million/CD ,/, based/VBN on/IN costs/NNS from/IN one/CD hospital/NN ./.
P09222261A05
Physician/NN advice/NN to/TO stop/VB smoking/NN substantially/RB increases/VBZ the/DT likelihood/NN of/IN smoking/JJ cessation/NN and/CC long-term/NN abstinence/NN ./.
P09230868A09
The/DT ABCs/NNS recently/RB have/VBP been/VBN seriously/RB challenged/VBN on/IN the/DT basis/NN of/IN results/NNS of/IN both/CC experimental/JJ and/CC clinical/JJ studies/NNS ./.
P09235072A20
The/DT primary/JJ outcome/NN is/VBZ the/DT development/NN of/IN NIDDM/NN according/VBG to/TO WHO/WP criteria/NNS (/( fasting/JJ plasma/NN glucose/NN level/NN 140/CD mg/NN //SYM dL/NN or/CC 2-hour/NN plasma/NN glucose/NN 200/CD mg/NN //SYM dL/NN after/IN a/DT 75/CD g/NN OGTT/NN )/) ./.
P09257080A08
Since/IN causes/NNS of/IN sudden/JJ death/NN are/VBP heterogeneous/JJ ,/, the/DT clinician/NN should/MD pursue/VBP a/DT multifactorial/JJ approach/NN to/TO its/PRP$ prevention/NN ./.
P09264420A10
Treatment/NN of/IN this/DT population/NN is/VBZ likely/RB to/TO realize/VB the/DT greatest/JJS cumulative/JJ long-term/NN benefit/NN in/IN the/DT prevention/NN of/IN acute/JJ major/JJ coronary/JJ events/NNS ./.
P09274899A01
PURPOSE/NN :/: To/TO review/VB information/NN on/IN the/DT implications/NNS of/IN insulin/NN resistance/NN for/IN type/NN II/CD diabetes/NN mellitus/NN (/( non-insulin-dependent/JJ diabetes/NN mellitus/NN )/) and/CC coronary/JJ heart/NN disease/NN ,/, and/CC to/TO derive/VB guidance/NN from/IN this/DT information/NN for/IN the/DT management/NN of/IN these/DT conditions/NNS ./.
P09286833A06
DATA/NNS SYNTHESIS/NN :/: While/IN nearly/RB all/DT medical/JJ schools/NNS offer/VBP some/DT formal/JJ teaching/NN about/IN end-of-life/NN care/NN ,/, there/EX is/VBZ considerable/JJ evidence/NN that/IN current/JJ training/NN is/VBZ inadequate/JJ ,/, most/RBS strikingly/RB in/IN the/DT clinical/JJ years/NNS ./.
P09294665A11
To/TO date/NN ,/, no/DT other/JJ antiarrhythmic/JJ drug/NN has/VBZ shown/VBN benefit/NN ,/, while/IN several/PRP have/VBP been/VBN shown/VBN to/TO be/VB harmful/JJ ./.
P09299869A10
EVIDENCE/NN AND/CC INFORMATION/NN SOURCES/NNS :/: The/DT method/NN used/VBN for/IN preparing/NN this/DT review/NN was/VBD an/DT informal/JJ consensus/NN development/NN ./.
P09309458A20
Attention/NN to/TO factors/NNS that/WDT may/MD predispose/VBP an/DT individual/NN to/TO fall/VB ,/, such/JJ as/IN her/PRP$ balance/NN ,/, eyesight/NN ,/, stairs/NNS ,/, and/CC bathtubs/NNS that/WDT are/VBP difficult/JJ to/TO get/VB into/IN and/CC out/IN of/IN ,/, are/VBP all/PRP items/NNS that/WDT need/VBP attention/NN ./.
P09327800A07
VALUES/NNS :/: High/JJ priority/NN was/VBD given/VBN to/TO prevention/NN of/IN adverse/JJ maternal/JJ and/CC neonatal/JJ outcomes/NNS in/IN pregnancies/NNS with/IN established/JJ hypertension/NN and/CC in/IN those/PRP at/IN high/JJ risk/NN of/IN gestational/JJ hypertension/NN through/IN the/DT provision/NN of/IN effective/JJ nonpharmacologic/JJ management/NN ./.
P09337293A02
All/DT organizations/NNS recommend/VBP against/IN any/DT efforts/NNS to/TO detect/VB early/JJ lung/NN cancer/NN because/IN each/PRP of/IN four/CD randomized/JJ controlled/JJ trials/NNS (/( RCTs/NNS )/) has/VBZ failed/VBN to/TO demonstrate/VB a/DT significant/JJ reduction/NN in/IN lung/NN cancer/NN mortality/NN as/IN a/DT result/NN of/IN screening/NN ./.
P09337449A02
DATA/NNS SOURCES/NNS :/: A/DT MEDLINE/NN search/NN encompassing/VBG the/DT years/NNS 1966-1996/CD was/VBD used/VBN to/TO identify/VB pertinent/JJ literature/NN for/IN discussion/NN ./.
P09347000A13
Caution/NN is/VBZ warranted/VBN in/IN interpreting/NN these/DT results/NNS because/RB :/: 1/CD )/) the/DT treatment/NN is/VBZ not/RB blinded/VBN and/CC this/PRP could/MD affect/VBP some/DT outcomes/NNS ;/: 2/CD )/) except/IN for/IN one/CD small/JJ trial/NN postneonatal/JJ survival/NN ,/, lung/NN function/NN ,/, and/CC neurodevelopment/NN have/VBP not/RB been/VBN reported/VBN from/IN HVS/NN trials/NNS ;/: and/CC 3/CD )/) the/DT benefits/NNS and/CC disadvantages/NNS have/VBP not/RB been/VBN reported/VBN in/IN infants/NNS born/VBN at/IN different/JJ gestational/JJ ages/NNS or/CC different/JJ birth/NN weights/NNS ./.
P09357708A02
Small/JJ groups/NNS of/IN senior/JJ medical/JJ students/NNS under/IN the/DT direction/NN of/IN a/DT multidisciplinary/JJ team/NN (/( behavioral/JJ scientist/NN ,/, information/NN specialist/NN ,/, physician/NN )/) facilitate/VBP discussions/NNS of/IN clinical/JJ articles/NNS using/VBG checklists/NNS designed/VBN to/TO evaluate/VB their/PRP$ quality/NN ./.
P09366779A08
Finally/RB ,/, the/DT relevance/NN of/IN this/DT information/NN (/( or/CC lack/NN thereof/RB )/) to/TO clinical/JJ practice/NN needs/VBZ to/TO be/VB determined/VBN ./.
P09374952A01
OBJECTIVES/NNS :/: To/TO review/VB prospective/JJ epidemiological/JJ studies/NNS and/CC randomized/JJ clinical/JJ trials/NNS regarding/VBG the/DT role/NN of/IN antioxidant/NN vitamins/NNS (/( vitamins/NNS E/NN and/CC C/NN and/CC beta-carotene/NN )/) in/IN the/DT prevention/NN of/IN cardiovascular/JJ diseases/NNS ./.
P09388153A11
As/IN a/DT result/NN ,/, society/NN could/MD expect/VBP to/TO gain/VB 1.7/CD million/CD new/JJ quitters/NNS at/IN an/DT average/JJ cost/NN of/IN $/SYM 3779/CD per/IN quitter/NN ,/, $/SYM 2587/CD per/IN life-year/NN saved/VBN ,/, and/CC $/SYM 1915/CD for/IN every/DT QALY/NN saved/VBN ./.
P09393381A02
Studies/NNS were/VBD identified/VBN through/IN a/DT MEDLINE/NN search/NN of/IN all/DT English-language/NN publications/NNS between/IN 1970/CD and/CC 1996/CD in/IN which/WDT the/DT words/NNS estrogen/NN and/CC cognition/NN or/CC estrogen/NN and/CC memory/NN appeared/VBD ./.
P09397232A11
Primary/JJ angioplasty/NN may/MD have/VBP a/DT role/NN in/IN selected/JJ patients/NNS ./.
P09414540A11
The/DT inclusion/NN criteria/NNS were/VBD fairly/RB broad/JJ because/IN of/IN the/DT quality/NN of/IN the/DT studies/NNS located/VBN ./.
P09416913A03
The/DT fact/NN that/IN many/DT practitioners/NNS do/VBP not/RB pursue/VBP a/DT proven/JJ treatment/NN strategy/NN in/IN patients/NNS who/WP qualify/VBP must/MD be/VBP redressed/VBN through/IN education/NN and/CC reinforcement/NN of/IN existing/JJ recommendations/NNS ./.
P09426711A02
The/DT experimental/JJ observation/NN that/IN low-fat/NN diets/NNS and/CC soy/NN protein/NN extracts/NNS may/MD influence/VBP the/DT progression/NN of/IN established/JJ tumors/NNS ,/, rather/RB than/IN inhibiting/NN etiologic/JJ factors/NNS ,/, is/VBZ particularly/RB intriguing/VBG because/IN it/PRP may/MD serve/VBP to/TO help/VB explain/VB the/DT paradox/NN whereby/WRB the/DT incidence/NN of/IN clinical/JJ prostate/NN cancer/NN shows/VBZ wide/JJ geographic/JJ variation/NN ,/, yet/CC the/DT evidence/NN persists/VBZ that/IN the/DT incidence/NN of/IN microfocal/JJ tumors/NNS is/VBZ essentially/RB the/DT same/JJ worldwide/JJ ./.
P09438745A03
Additional/JJ data/NNS sources/NNS included/VBD bibliographies/NNS of/IN papers/NNS identified/VBN on/IN MEDLINE/NN and/CC bibliographies/NNS in/IN textbooks/NNS on/IN substance/NN abuse/NN ./.
P09445511A09
The/DT risk/NN of/IN methemoglobinemia/NN (/( defined/VBN as/IN methemoglobin/NN concentration/NN >/SYM 5/CD %/SYM and/CC requiring/NN medical/JJ intervention/NN )/) was/VBD estimated/VBN from/IN all/DT prospective/JJ studies/NNS ./.
P09457159A16
Individuals/NNS infected/VBN with/IN the/DT hepatitis/NN C/NN virus/NN should/MD not/RB donate/VBP blood/NN ,/, organs/NNS ,/, tissues/NNS ,/, or/CC semen/NN ./.
P09469146A07
DATA/NNS EXTRACTION/NN :/: The/DT following/JJ information/NN was/VBD extracted/VBN from/IN the/DT 11/CD studies/NNS :/: characteristics/NNS of/IN the/DT study/NN population/NN ,/, number/NN of/IN participants/NNS (/( and/CC number/NN followed/VBN to/TO completion/NN )/) ,/, length/NN of/IN follow-up/NN ,/, type/NN of/IN intervention/NN ,/, outcome/NN measures/NNS and/CC results/NNS ./.
P09476302A01
Improvement/NN of/IN symptoms/NNS and/CC ,/, accordingly/RB ,/, quality/NN of/IN life/NN ,/, as/RB well/RB as/IN prolongation/NN of/IN life/NN ,/, are/VBP the/DT objectives/NNS of/IN drug/NN therapy/NN in/IN congestive/JJ heart/NN failure/NN patients/NNS ./.
P09479406A11
Designing/VBG tolerable/JJ ,/, effective/JJ regimens/NNS will/MD require/VBP careful/JJ monitoring/NN for/IN compliance/NN ,/, adverse/JJ effects/NNS ,/, and/CC potential/JJ drug/NN interactions/NNS ./.
P09483156A06
To/TO make/VB recommendations/NNS for/IN the/DT future/JJ development/NN and/CC organisation/NN of/IN neonatal/JJ screening/NN for/IN inborn/NN errors/NNS of/IN metabolism/NN in/IN the/DT UK/NNP ./.
P09483159A28
Other/JJ studies/NNS that/WDT provide/VBP some/DT natural/JJ history/NN data/NNS suggest/VBP that/IN mild/JJ degrees/NNS of/IN amblyopia/NN may/MD resolve/VBP spontaneously/RB ./.
P09483162A02
To/TO try/VB to/TO identify/VB the/DT optimal/JJ time/NN at/IN which/WDT to/TO start/VB assessing/NN new/JJ and/CC fast-evolving/JJ health/NN technologies/NNS ./.
P09483436A22
But/CC what/WP is/VBZ the/DT better/JJR solution/NN for/IN thrombosis/NN and/CC which/PRP for/IN plaque/NN disruption/NN ?/.
P09484275A08
For/IN accurate/JJ staging/NN and/CC to/TO reduce/VB the/DT risk/NN of/IN recurrence/NN in/IN the/DT axilla/NN ,/, level/NN 1/CD and/CC level/NN 2/CD nodes/NNS should/MD be/VBP removed/VBN ./.
P09484278A18
Tamoxifen/NN should/MD normally/RB be/VBP administered/VBN daily/RB for/IN 5/CD years/NNS ./.
P09484281A18
Intramuscular/JJ administration/NN of/IN opioids/NNS is/VBZ not/RB recommended/VBN ./.
P09496407A07
It/PRP is/VBZ most/RBS commonly/RB caused/VBN by/IN dermatophytes/NNS ,/, but/CC yeasts/NNS and/CC molds/NNS can/MD also/RB be/VBP involved/VBN ./.
P09499674A15
Finally/RB ,/, the/DT Italian/JJ Federation/NN of/IN Centers/NNS for/IN the/DT Surveillance/NN of/IN Anticoagulant/NN (/( FCSA/NN )/) therapies/NNS was/VBD founded/VBN in/IN 1989/CD ./.
P09505959A06
Scientific/JJ evidence/NN was/VBD given/VBN precedence/NN over/IN clinical/JJ anecdotal/JJ experience/NN ./.
P09516096A11
If/IN applied/VBN appropriately/RB ,/, they/PRP can/MD ensure/VBP that/IN management/NN of/IN patients/NNS is/VBZ based/VBN on/IN clinically/RB useful/JJ diagnostic/JJ tests/NNS and/CC treatments/NNS that/WDT have/VBP been/VBN shown/VBN to/TO be/VB effective/JJ and/CC not/RB harmful/JJ ./.
P09526814A02
The/DT diabetic/JJ dyslipidemia/NN in/IN these/DT patients/NNS is/VBZ characterized/VBN by/IN moderately/RB high/JJ levels/NNS of/IN (/( 1/CD )/) serum/NN cholesterol/NN and/CC triglycerides/NNS ;/: (/( 2/CD )/) small/JJ ,/, dense/JJ low-density/NN lipoprotein/NN (/( LDL/NN )/) particles/NNS ;/: and/CC (/( 3/CD )/) low/JJ high-density/NN lipoprotein/NN (/( HDL/NN )/) cho-lesterol/NN concentrations/NNS ./.
P09537220A13
A/DT short-term/NN reduction/NN on/IN markers/NNS like/IN ventricular/JJ ectopic/JJ beats/NNS ,/, for/IN example/NN ,/, does/VBZ not/RB translate/VBP into/IN a/DT long-term/NN decrease/NN in/IN arrhythmia-related/JJ mortality/NN ./.
P09539499A08
The/DT currently/RB available/JJ data/NNS concerning/VBG the/DT efficacy/NN ,/, safety/NN ,/, and/CC cost/NN provide/VBP a/DT compelling/JJ argument/NN for/IN embracing/NN abciximab/NN therapy/NN in/IN the/DT treatment/NN of/IN patient/NN subsets/NNS where/WRB it/PRP will/MD be/VBP a/DT cost-saving/JJ or/CC cost-neutral/JJ adjunct/NN to/TO percutaneous/JJ coronary/JJ intervention/NN ./.
P09550500A02
The/DT Scandinavian/NN Simvastatin/NN Survival/NN Study/NN (/( 4S/NN )/) ,/, the/DT West/NN of/IN Scotland/NNP Coronary/JJ Prevention/NN Study/NN (/( WOSCOPS/NN )/) ,/, and/CC the/DT Cholesterol/NN and/CC Recurrent/JJ Events/NNS (/( CARE/NN )/) trial/NN ,/, as/RB well/RB as/IN numerous/JJ other/JJ investigations/NNS ,/, have/VBP established/VBN that/IN decreasing/NN elevated/JJ levels/NNS of/IN low-density/NN lipoprotein/NN (/( LDL/NN )/) cholesterol/NN will/MD result/VBP in/IN a/DT reduction/NN in/IN CAD/NN risk/NN ./.
P09560079A08
Older/JJR age/NN was/VBD also/RB sometimes/NNS associated/VBN with/IN decreased/JJ participation/NN in/IN research/NN ./.
P09578541A02
Patients/NNS and/CC doctors/NNS seek/VBP evidence-based/JJ clinical/JJ information/NN ,/, regulatory/JJ agencies/NNS look/VBP for/IN efficacy/NN and/CC safety/NN ,/, and/CC the/DT health-care/NN industry/NN demands/VBZ data/NNS on/IN the/DT risk-benefit/NN ratio/NN attached/VBN to/TO a/DT product/NN ./.
P09586593A16
Transurethral/JJ microwave/NN thermotherapy/NN of/IN the/DT prostate/NN (/( TUMT/NN )/) and/CC radiofrequency/NN transurethral/JJ needle/NN ablation/NN (/( TUNA/NN )/) are/VBP minimally/RB invasive/JJ ,/, safe/JJ new/JJ therapies/NNS ./.
P09597223A04
The/DT published/JJ literature/NN was/VBD reviewed/VBN and/CC classified/VBN into/IN one/CD of/IN four/CD categories/NNS ,/, according/VBG to/TO study/NN design/NN and/CC scientific/JJ value/NN ./.
P09606473A06
Cumulative/JJ outcomes/NNS were/VBD considered/VBN up/IN to/TO 6/CD months/NNS after/IN initial/JJ PTCA/NN ./.
P09615298A03
With/IN funding/NN from/IN the/DT Office/NN of/IN Alternative/JJ Medicine/NN ,/, National/JJ Institutes/NNS of/IN Health/NN ,/, our/PRP$ goal/NN was/VBD to/TO identify/VB the/DT type/NN and/CC prevalence/NN of/IN complementary/JJ and/CC alternative/JJ treatments/NNS for/IN asthma/NN in/IN use/NN in/IN the/DT United/JJ States/NNS in/IN order/NN to/TO establish/VB a/DT research/NN agenda/NN for/IN the/DT study/NN of/IN the/DT most/RBS promising/JJ therapies/NNS ./.
P09625664A03
DATA/NNS SOURCES/NNS :/: Published/JJ reports/NNS of/IN clinical/JJ studies/NNS were/VBD found/VBN by/IN searching/NN MEDLINE/NN and/CC selected/JJ bibliographies/NNS ./.
P09636826A08
DATA/NNS SYNTHESIS/NN :/: Specialized/JJ centres/NNS //SYM clinicians/NNS fared/VBD better/RBR both/CC when/WRB process/NN and/CC outcome/NN indicators/NNS were/VBD used/VBN ./.
P09644351A25
Provision/NN of/IN quality/NN ,/, cost-effective/JJ care/NN for/IN patients/NNS requiring/VBG prolonged/JJ ventilation/NN is/VBZ a/DT true/JJ clinical/JJ challenge/NN ./.
P09649257A02
It/PRP is/VBZ associated/VBN with/IN a/DT considerable/JJ burden/NN of/IN suffering/NN ./.
P09663319A04
The/DT interventional/JJ therapies/NNS include/VBP permanent/JJ pacing/NN for/IN bradyarrhythmias/NNS ,/, arrhythmia/NN surgery/NN for/IN arrhythmias/NNS ,/, percutaneous/JJ catheter/NN ablation/NN and/CC implantable/JJ devices/NNS for/IN tachyarrhythmias/NNS ./.
P09676168A16
STUDY/NN IMPLICATIONS/NNS :/: The/DT trial/NN will/MD demonstrate/VBP whether/IN the/DT use/NN of/IN a/DT heparin-bonded/JJ stent/NN can/MD improve/VBP long/JJ term/NN patency/NN and/CC clinical/JJ outcome/NN in/IN patients/NNS undergoing/VBG clinically/RB indicated/JJ PTCA/NN of/IN totally/RB occluded/JJ coronary/JJ arteries/NNS ./.
P09684847A09
This/DT collective/JJ new/JJ knowledge/NN provides/VBZ the/DT basis/NN for/IN a/DT shift/NN in/IN the/DT management/NN of/IN CAD/NN from/IN an/DT invasive/JJ ,/, procedure-oriented/JJ viewpoint/NN currently/RB dominant/JJ in/IN cardiology/NN toward/IN a/DT noninvasive/JJ orientation/NN that/WDT views/VBZ the/DT problem/NN as/IN a/DT graded/JJ ,/, continuous/JJ ,/, heterogeneously/RB diffuse/JJ disease/NN process/NN for/IN which/WDT reversal/NN treatment/NN is/VBZ optimal/JJ ./.
P09705684A07
RESULTS/NNS :/: A/DT total/NN of/IN 10,948/CD patients/NNS were/VBD enrolled/VBN between/IN November/NN 1995/CD and/CC January/NN 1997/CD ./.
P09707957A04
Major/JJ hypertension/NN texts/NNS were/VBD also/RB reviewed/VBN for/IN information/NN on/IN combination/NN therapy/NN ./.
P09712593A15
Benefits/NNS were/VBD not/RB restricted/VBN to/TO particular/JJ patient/NN groups/NNS ./.
P09727542A04
The/DT primary/JJ efficacy/NN end/NN point/NN was/VBD death/NN ,/, reinfarction/NN ,/, or/CC any/DT (/( urgent/JJ or/CC elective/JJ )/) target/NN vessel/NN revascularization/NN (/( TVR/NN )/) at/IN 6/CD months/NNS by/IN intention-to-treat/NN (/( ITT/NN )/) analysis/NN ./.
P09738589A07
Panel/NN members/NNS also/RB considered/VBD the/DT effect/NN of/IN CID/NN on/IN quality/NN of/IN life/NN and/CC the/DT cost-effectiveness/NN and/CC efficacy/NN of/IN different/JJ pharmacologic/JJ approaches/NNS ./.
P09743780A08
As/IN a/DT first/JJ step/NN ,/, many/DT medical/JJ schools/NNS introduce/VBP students/NNS to/TO on-line/NN databases/NNS ,/, most/RBS notably/RB MEDLINE/NN ./.
P09753529A08
Level/NN 1/CD :/: Evidence/NN from/IN at/IN least/JJS one/CD randomized/JJ ,/, controlled/JJ trial/NN ./.
P09759577A09
For/IN patients/NNS with/IN local-regional/JJ disease/NN (/( stage/NN III/CD ,/, satellites/NNS ,/, and/CC local/JJ recurrence/NN )/) ,/, a/DT selective/JJ approach/NN to/TO imaging/JJ studies/NNS is/VBZ warranted/VBN ./.
P09765748A16
Most/PRP of/IN the/DT patients/NNS with/IN local/JJ recurrence/NN in/IN these/DT trials/NNS underwent/VBD mastectomy/NN ./.
P09765759A19
Therefore/RB ,/, if/IN the/DT outcome/NN of/IN interest/NN is/VBZ a/DT reduction/NN in/IN the/DT frequency/NN of/IN local/JJ tumour/NN recurrence/NN ,/, radiotherapy/NN is/VBZ recommended/VBN ./.
P09765768A25
Patient/NN or/CC tumour/NN factors/NNS (/( number/NN of/IN involved/JJ sites/NNS ,/, location/NN of/IN involved/JJ sites/NNS or/CC level/NN of/IN pain/NN control/NN )/) that/WDT are/VBP relative/JJ contraindications/NNS to/TO the/DT use/NN of/IN multiple/JJ single/JJ fields/NNS of/IN radiation/NN as/IN an/DT alternative/NN ./.
P09777140A08
Recent/JJ trials/NNS have/VBP been/VBN performed/VBN in/IN patients/NNS with/IN unstable/JJ angina/NN ,/, and/CC trials/NNS of/IN adjunctive/JJ therapy/NN are/VBP currently/RB underway/VBP in/IN patients/NNS receiving/VBG thrombolysis/NN for/IN AMI/NN ,/, and/CC for/IN secondary/JJ prevention/NN ./.
P09783489A08
Each/PRP of/IN the/DT guidelines/NNS acknowledged/VBD the/DT important/JJ effect/NN of/IN associated/JJ cardiovascular/JJ disease/NN (/( CVD/NN )/) risk/NN factors/NNS on/IN the/DT likely/JJ benefits/NNS of/IN treatment/NN ,/, but/CC did/VBD not/RB expand/VBP on/IN the/DT magnitude/NN of/IN this/DT effect/NN ./.
P09793596A02
DATA/NNS SOURCES/NNS :/: A/DT MEDLINE/NN search/NN (/( January/NN 1960-April/NN 1998/CD )/) ,/, Current/JJ Contents/NNS search/NN ,/, additional/JJ references/NNS listed/VBN in/IN articles/NNS ,/, and/CC unpublished/JJ data/NNS obtained/VBN from/IN the/DT manufacturer/NN were/VBD used/VBN to/TO identify/VB data/NNS from/IN scientific/JJ literature/NN ./.
P09794095A02
The/DT radiologist/NN who/WP performs/VBZ percutaneous/JJ breast/NN biopsies/NNS assumes/VBZ an/DT increased/JJ level/NN of/IN responsibility/NN for/IN the/DT patient/NN regarding/VBG patient/NN selection/NN ,/, lesion/NN selection/NN ,/, performance/NN of/IN the/DT biopsy/NN procedure/NN ,/, interpretation/NN of/IN results/NNS ,/, and/CC patient/NN follow-up/NN ./.
P09794982A06
The/DT goals/NNS of/IN such/DT studies/NNS would/MD be/VBP to/TO understand/VB better/RBR the/DT acute/JJ HHE/NN event/NN and/CC to/TO evaluate/VB the/DT possibility/NN of/IN long-term/NN sequelae/NNS ./.
P09806109A02
Primarily/RB ,/, the/DT drug/NN inhibits/VBZ platelet/NN aggregation/NN ,/, but/CC it/PRP may/MD also/RB have/VBP anticoagulant/NN activity/NN and/CC other/JJ beneficial/JJ effects/NNS ,/, such/JJ as/IN inhibiting/NN migration/NN and/CC promoting/NN apoptosis/NN of/IN smooth/JJ muscle/NN cells/NNS ./.
P09809771A17
An/DT automatic/JJ implantable/JJ cardioverter-defibrillator/NN should/MD be/VBP used/VBN in/IN persons/NNS who/WP have/VBP a/DT history/NN of/IN ventricular/JJ fibrillation/NN or/CC serious/JJ sustained/JJ ventricular/JJ tachycardia/NN or/CC who/WP are/VBP at/IN very/RB high/JJ risk/NN for/IN developing/NN sudden/JJ cardiac/JJ death/NN ./.
P09819098A02
Abundant/JJ clinical/JJ trial/NN evidence/NN supports/VBZ the/DT importance/NN of/IN LDL/NN cholesterol-lowering/NN in/IN decreasing/NN CAD/NN risk/NN ,/, both/CC in/IN angiographic/JJ trials/NNS ,/, which/WDT measure/VBP CAD/NN progression/NN ,/, and/CC in/IN trials/NNS with/IN morbidity/NN and/CC mortality/NN endpoints/NNS ./.
P09821012A05
However/WRB ,/, the/DT extent/NN of/IN LDL-C/NN reduction/NN achieved/VBN often/RB fell/VBP short/JJ of/IN LDL-C/NN treatment/NN targets/NNS recommended/VBN in/IN national/JJ and/CC international/JJ guidelines/NNS ./.
P09825877A13
Drug/NN interactions/NNS involving/VBG atorvastatin/NN can/MD be/VBP expected/VBN to/TO parallel/VB those/PRP of/IN other/JJ statins/NNS metabolized/VBN via/IN CYP3A4/NN ./.
P09832669A05
In/IN addition/NN ,/, emerging/JJ evidence/NN suggests/VBZ a/DT future/JJ role/NN for/IN GP/NN IIb/NN //SYM IIIa/NN receptor/NN inhibitors/NNS as/IN an/DT adjunct/NN to/TO low-dose/NN fibrinolytic/JJ therapy/NN in/IN patients/NNS with/IN acute/JJ MI/NN ./.
P09852937A05
Multiple/JJ randomized/JJ and/CC nonrandomized/JJ trials/NNS indicate/VBP that/IN prehospital/JJ care/NN providers/NNS (/( including/VBG paramedics/NNS ,/, nurses/NNS and/CC doctors/NNS )/) are/VBP able/JJ to/TO acquire/VB prehospital/JJ ECGs/NNS with/IN negligible/JJ increases/NNS in/IN on-scene/NN time/NN ,/, ranging/VBG from/IN 30/CD s/NNS to/TO 7/CD mins/NNS ./.
P09858958A03
Currently/RB ,/, pneumonia/NN patients/NNS are/VBP classified/VBN as/IN having/NN either/CC community-acquired/JJ or/CC hospital-acquired/JJ infection/NN rather/RB than/IN typical/JJ versus/CC atypical/JJ ./.
P09861792A05
Review/NN of/IN meta-analyses/NNS of/IN clinical/JJ trials/NNS showed/VBD that/IN ERT/NN //SYM HRT/NN ever-users/NNS (/( patients/NNS who/WP have/VBP ever/RB used/VBN ERT/NN //SYM HRT/NN )/) did/VBD not/RB have/VBP an/DT increased/JJ risk/NN of/IN breast/NN cancer/NN ,/, but/CC current/JJ users/NNS did/VBD have/VBP an/DT increased/JJ risk/NN ,/, with/IN some/DT studies/NNS reporting/NN increasing/JJ risk/NN with/IN duration/NN of/IN ERT/NN ./.
P09870124A01
OBJECTIVE/NN :/: To/TO review/VB and/CC recognize/VB how/WRB presentation/NN ,/, investigation/NN ,/, risk/NN factor/NN modification/NN ,/, and/CC treatment/NN of/IN coronary/JJ artery/NN disease/NN (/( CAD/NN )/) is/VBZ different/JJ for/IN women/NNS than/IN for/IN men/NNS ./.
P09878986A07
There/EX was/VBD no/DT reduction/NN in/IN the/DT rate/NN of/IN death/NN at/IN day/NN 30/CD or/CC nonfatal/JJ MI/NN in/IN patients/NNS who/WP received/VBD lamifiban/NN ;/: however/WRB ,/, at/IN 6/CD months/NNS a/DT significant/JJ treatment/NN effect/NN was/VBD seen/VBN in/IN patients/NNS who/WP received/VBD low/JJ dose/NN lamifiban/NN (/( 13.7/CD %/SYM ,/, p/NN =/SYM 0.02/CD )/) but/CC not/RB high/JJ dose/NN lamifiban/NN (/( 16.4/CD %/SYM ,/, p/NN =/SYM 0.38/CD )/) compared/VBN with/IN those/PRP who/WP received/VBD heparin/NN alone/JJ (/( 18.1/CD %/SYM )/) ./.
P09891161A21
If/IN more/RB rigorous/JJ study/NN designs/NNS were/VBD required/VBN for/IN publication/NN ,/, radiology/NN outcomes/NNS research/NN would/MD probably/RB improve/VBP drastically/RB ./.
P09915665A22
At/IN the/DT same/JJ time/NN ,/, it/PRP is/VBZ presently/RB unknown/VBN whether/IN improved/JJ glycemic/JJ control/NN decreases/VBZ coronary/JJ artery/NN disease/NN risk/NN in/IN such/DT patients/NNS ./.
P09920227A05
DATA/NNS EXTRACTION/NN :/: Study/NN design/NN ,/, inclusion/NN and/CC exclusion/NN criteria/NNS ,/, setting/NN ,/, sample/NN size/NN ,/, response/NN rate/NN ,/, mean/NN age/NN ,/, method/NN of/IN medication/NN verification/NN and/CC fall/NN assessment/NN ,/, fall/NN definition/NN ,/, and/CC the/DT number/NN of/IN fallers/NNS and/CC non-fallers/NNS taking/VBG specific/JJ classes/NNS of/IN psychotropic/JJ drugs/NNS ./.
P09924156A18
CONCLUSIONS/NNS :/: The/DT results/NNS of/IN this/DT study/NN demonstrate/VBP that/IN GP/NN IIb/NN //SYM IIIa/NN antagonists/NNS are/VBP able/JJ to/TO prevent/VB vessel/NN occlusion/NN after/IN PTCA/NN complicated/VBN by/IN subsequent/JJ threatened/JJ or/CC abrupt/JJ vessel/NN closure/NN ./.
P09934917A14
Crystalloid/NN resuscitation/NN is/VBZ associated/VBN with/IN a/DT lower/JJR mortality/NN in/IN trauma/NN patients/NNS ./.
P09972388A08
CONCLUSIONS/NNS :/: In/IN general/NN ,/, the/DT small/JJ amount/NN of/IN published/JJ literature/NN supports/VBZ the/DT empirical/JJ use/NN of/IN levodopa/NN //SYM carbidopa/NN as/IN a/DT safe/JJ and/CC effective/JJ therapy/NN to/TO manage/VB the/DT distressing/JJ symptoms/NNS of/IN RLS/NN in/IN a/DT hemodialysis/NN population/NN ./.
P10026768A08
Men/NNS with/IN high-grade/NN tumors/NNS (/( Gleason/NNP score/NN >/SYM or/CC =/SYM 7/CD )/) or/CC with/IN seminal/JJ vesicle/NN or/CC lymph/NN node/NN involvement/NN in/IN whom/WP disease/NN recurs/VBZ within/IN 2/CD years/NNS of/IN radical/JJ prostatectomy/NN are/VBP most/RBS appropriately/RB observed/VBN or/CC treated/VBN with/IN early/JJ hormonal/JJ therapy/NN ./.
P10047618A08
Sotalol/NN was/VBD 1/CD of/IN 2/CD drugs/NNS selected/VBN for/IN comparison/NN with/IN implantable/JJ defibrillators/NNS in/IN the/DT recent/JJ National/JJ Institutes/NNS of/IN Health/NN Antiarrhythmics/NNS versus/CC Implantable/JJ Defibrillator/NN (/( AVID/NN )/) study/NN ./.
P10069357A02
The/DT traditional/JJ management/NN of/IN type/NN 2/CD diabetes/NN has/VBZ been/VBN ineffective/JJ in/IN altering/NN this/DT dismal/JJ prognosis/NN ./.
P10079780A01
OBJECTIVE/NN :/: To/TO estimate/VB the/DT magnitude/NN of/IN the/DT clinical/JJ benefits/NNS that/WDT may/MD result/VBP from/IN use/NN of/IN abciximab/NN at/IN the/DT time/NN of/IN angioplasty/NN and/CC the/DT cost/NN of/IN achieving/NN them/PRP ./.
P10082589A23
The/DT structured/JJ review/NN provides/VBZ a/DT concise/JJ analysis/NN of/IN these/DT books/NNS to/TO allow/VB readers/NNS to/TO determine/VB application/NN of/IN these/DT publications/NNS to/TO their/PRP$ needs/NNS ./.
P10085198A03
In/IN contrast/NN to/TO other/JJ major/JJ chronic/JJ diseases/NNS such/JJ as/IN heart/NN disease/NN and/CC cancer/NN ,/, medical/JJ treatments/NNS for/IN COPD/NN have/VBP not/RB made/VBN decisive/JJ inroads/NNS into/IN its/PRP$ morbidity/NN or/CC death/NN rates/NNS over/IN the/DT last/JJ 20/CD years/NNS ,/, resulting/VBG in/IN continuing/JJ efforts/NNS to/TO reduce/VB disability/NN in/IN patients/NNS with/IN established/JJ disease/NN ./.
P10089844A12
Nevertheless/RB ,/, in/IN comparison/NN with/IN amiodarone/NN ,/, treatment/NN of/IN MADIT/NN patients/NNS with/IN ICDs/NNS seems/VBZ to/TO be/VB cost-effective/JJ ,/, especially/RB if/IN ICDs/NNS are/VBP implanted/VBN transvenously/RB and/CC have/VBP the/DT improved/JJ battery/NN longevity/NN of/IN the/DT current/JJ devices/NNS ./.
P10092711A02
The/DT most/RBS common/JJ pathology/NN of/IN vascular/JJ diseases/NNS is/VBZ occlusion/NN ./.
P10094222A03
This/DT review/NN was/VBD undertaken/VBN to/TO evaluate/VB the/DT relationship/NN of/IN allergic/JJ rhinitis/NN to/TO these/DT diseases/NNS and/CC to/TO provide/VB support/NN for/IN proposing/NN national/JJ guidelines/NNS for/IN managing/NN rhinitis/NN ./.
P10103321A17
The/DT probability/NN of/IN UTI/NN in/IN each/PRP of/IN these/DT groups/NNS depends/VBZ not/RB only/RB on/IN the/DT sensitivity/NN and/CC specificity/NN of/IN the/DT test/NN ,/, but/CC also/RB on/IN the/DT prior/JJ probability/NN of/IN the/DT UTI/NN among/IN the/DT children/NNS being/VBG tested/VBN ./.
P10140233A08
Rates/NNS of/IN performance/NN of/IN tasks/NNS of/IN smoking/JJ cessation/NN by/IN healthcare/NN professionals/NNS ,/, including/VBG offering/NN counselling/NN ,/, setting/NN dates/VBZ to/TO stop/VB smoking/NN ,/, giving/NN follow/NN up/RP appointments/NNS ,/, distributing/NN self/PRP help/NN materials/NNS ,/, and/CC recommending/NN nicotine/NN gum/NN ./.
P10147240A19
(/( ABSTRACT/NN TRUNCATED/VBD AT/IN 400/CD WORDS/NNS )/)
P10160469A15
Although/IN limited/JJ formulary/NN choices/NNS have/VBP been/VBN used/VBN in/IN the/DT hospital/NN setting/NN for/IN years/NNS ,/, and/CC are/VBP now/RB becoming/VBG popular/JJ in/IN managed/JJ care/NN ,/, there/EX is/VBZ no/DT proof/NN that/IN this/DT mechanism/NN saves/VBZ money/NN when/WRB looking/VBG at/IN the/DT overall/JJ picture/NN ./.
P10169000A05
If/IN current/JJ clinical/JJ information/NN is/VBZ unreliable/JJ ,/, then/RB healthcare/NN risk/NN management/NN strategies/NNS for/IN LBP/NN must/MD be/VBP revised/VBN ./.
P10172669A12
In/IN subgroup/NN analyses/NNS ,/, alteplase/NN was/VBD a/DT cost-effective/JJ treatment/NN option/NN for/IN all/DT elderly/JJ patients/NNS (/( >/SYM 60/CD years/NNS of/IN age/NN )/) and/CC all/DT patients/NNS >/SYM 40/CD years/NNS of/IN age/NN with/IN anterior/JJ infarction/NN ./.
P10182193A02
Some/DT preventive/JJ approaches/NNS are/VBP both/CC inexpensive/JJ and/CC effective/JJ ;/: others/NNS are/VBP expensive/JJ while/IN their/PRP$ effectiveness/NN is/VBZ slight/JJ or/CC unproven/VBN ./.
P10186462A18
These/DT benefits/NNS come/VBP at/IN a/DT substantial/JJ economic/JJ cost/NN ,/, but/CC one/CD that/WDT is/VBZ in/IN line/NN with/IN accepted/JJ costs/NNS for/IN other/JJ medical/JJ interventions/NNS ./.
P10190758A06
Of/IN these/DT nine/CD ,/, four/CD controlled/JJ studies/NNS were/VBD chosen/VBN based/VBN upon/IN their/PRP$ large/JJ patient/NN populations/NNS and/CC their/PRP$ consistency/NN in/IN brand/NN and/CC dosage/NN of/IN St./NN John/NN 's/POS wort/NN used/VBN ./.
P10196487A01
EXECUTIVE/NN SUMMARY/NN The/DT "/`` Guideline/NN for/IN Prevention/NN of/IN Surgical/JJ Site/NN Infection/NN ,/, 1999/CD "/'' presents/VBZ the/DT Centers/NNS for/IN Disease/NN Control/NN and/CC Prevention/NN (/( CDC/NN )/) 's/POS recommendations/NNS for/IN the/DT prevention/NN of/IN surgical/JJ site/NN infections/NNS (/( SSIs/NNS )/) ,/, formerly/RB called/VBN surgical/JJ wound/NN infections/NNS ./.
P10203636A07
Participants/NNS reported/VBD using/NN EBM/NN in/IN their/PRP$ clinical/JJ practice/NN always/RB (/( 33/CD ,/, 11/CD %/SYM )/) ,/, often/RB (/( 173/CD ,/, 59/CD %/SYM )/) ,/, sometimes/NNS (/( 80/CD ,/, 27/CD %/SYM )/) ,/, or/CC rarely/RB //SYM never/RB (/( 8/CD ,/, 3/CD %/SYM )/) ./.
P10209667A20
Many/DT patients/NNS will/MD have/VBP primary/JJ refractory/JJ of/IN relapsing/JJ disease/NN in/IN whom/WP survival/NN is/VBZ short/JJ despite/IN all/DT current/JJ therapeutic/JJ modalities/NNS ./.
P10220238A03
A/DT good/JJ example/NN is/VBZ the/DT concern/NN about/IN using/NN oral/JJ cobalamin/NN when/WRB treating/VBG pernicious/JJ anemia/NN ./.
P10228456A11
CONSENSUS/NN PROCESS/NN :/: The/DT panel/NN ,/, answering/VBG predefined/JJ questions/NNS ,/, developed/VBD their/PRP$ conclusions/NNS based/VBN on/IN the/DT scientific/JJ evidence/NN presented/VBN in/IN open/JJ forum/NN and/CC the/DT scientific/JJ literature/NN ./.
P10321422A13
In/IN adapting/NN the/DT findings/NNS on/IN cholesterol-lowering/JJ efficacy/NN from/IN this/DT analysis/NN to/TO our/PRP$ lipid/NN clinic/NN ,/, we/PRP concluded/VBD that/IN the/DT most/RBS cost-effective/JJ treatment/NN approach/NN is/VBZ to/TO individualize/VB the/DT selection/NN of/IN an/DT HMG-CoA/NN reductase/NN inhibitor/NN based/VBN on/IN both/CC coronary/JJ risk/NN and/CC the/DT LDL-C/NN reduction/NN required/VBN to/TO achieve/VB NCEP/NN ATP-II/NN goals/NNS ./.
P10332429A12
For/IN prostate/NN cancer/NN strong/JJ evidence/NN exists/VBZ for/IN a/DT preventive/JJ effect/NN of/IN reduced/JJ fat/NN intake/NN ,/, vitamin/NN E/NN ,/, selenium/NN and/CC soy/NN proteins/NNS ./.
P10333848A16
(/( 2/CD )/) To/TO reduce/VB blood/NN pressure/NN in/IN the/DT population/NN at/IN large/JJ ,/, it/PRP is/VBZ recommended/VBN that/IN Canadians/NNS attain/VBP and/CC maintain/VBP a/DT healthy/JJ BMI/NN (/( 20-25/CD )/) ./.
P10333852A14
(/( 2/CD )/) For/IN normotensive/JJ people/NNS obtaining/VBG on/IN average/NN 60/CD mmol/NN of/IN potassium/NN daily/RB through/IN dietary/JJ intake/NN ,/, potassium/NN supplementation/NN is/VBZ not/RB recommended/VBN as/IN a/DT means/NNS of/IN preventing/NN an/DT increase/NN in/IN blood/NN pressure/NN ./.
P10340840A14
Treatment/NN alone/JJ is/VBZ not/RB enough/PRP ;/: treatment/NN to/TO goal/NN blood/NN pressure/NN is/VBZ an/DT essential/JJ first/JJ step/NN towards/IN optimal/JJ target-organ/NN protection/NN ./.
P10346425A02
US/NNP National/JJ Cholesterol/NN Education/NN Program/NN (/( NCEP/NN )/) guidelines/NNS recommend/VBP aggressive/JJ lipid-modifying/JJ therapy/NN for/IN individuals/NNS at/IN highest/JJS risk/NN for/IN CHD/NN ./.
P10353983A05
The/DT therapeutic/JJ approaches/NNS considered/VBN included/VBD continuous/JJ anticonvulsant/JJ therapies/NNS ,/, intermittent/JJ therapy/NN ,/, or/CC no/DT anticonvulsant/JJ therapy/NN ./.
P10359204A09
RESULTS/NNS :/: As/IN of/IN March/NN 1/CD ,/, 1998/CD ,/, there/EX are/VBP 9,373/CD references/NNS ,/, excluding/VBG citations/NNS of/IN letters/NNS or/CC comments/NNS ,/, contained/VBD in/IN the/DT core/NN pediatric/JJ surgery/NN literature/NN ,/, as/IN provided/VBN through/IN Medline/NN ./.
P10365602A08
In/IN patients/NNS with/IN symptomatic/JJ CHF/NN due/JJ to/TO systolic/JJ dysfunction/NN the/DT addition/NN of/IN diuretics/NNS and/CC digoxin/NN appears/VBZ to/TO reducing/NN worsening/JJ CHF/NN without/IN improving/NN survival/NN ./.
P10366798A05
RESULTS/NNS :/: In/IN patients/NNS with/IN symptoms/NNS or/CC signs/NNS suggestive/JJ of/IN DVT/NN ,/, compression/NN ultrasound/NN (/( CUS/NN )/) appears/VBZ to/TO be/VB the/DT diagnostic/JJ test/NN of/IN first/JJ choice/NN ,/, since/IN it/PRP is/VBZ a/DT noninvasive/JJ test/NN with/IN high/JJ specificity/NN and/CC sensitivity/NN for/IN proximal/JJ DVT/NN (/( about/RB 97/CD %/SYM )/) ./.
P10372678A04
With/IN the/DT recognition/NN of/IN that/DT reality/NN comes/VBZ a/DT variety/NN of/IN challenges/NNS to/TO clinicians/NNS and/CC investigators/NNS ./.
P10381989A12
When/WRB these/DT data/NNS were/VBD combined/VBN using/VBG effect/NN size/NN as/IN a/DT common/JJ measure/NN ,/, the/DT use/NN of/IN ipratropium/NN was/VBD associated/VBN with/IN a/DT summary/NN effect/NN size/NN of.38/CD (/( 95/CD %/SYM CI.27/CD to.48/CD )/) ./.
P10387403A01
BACKGROUND/NN :/: Although/IN the/DT randomised/JJ controlled/JJ trial/NN (/( RCT/NN )/) is/VBZ regarded/VBN as/IN the/DT '/`` gold/NN standard/NN '/'' in/IN terms/NNS of/IN evaluating/NN the/DT effectiveness/NN of/IN interventions/NNS ,/, it/PRP is/VBZ susceptible/JJ to/TO challenges/NNS to/TO its/PRP$ external/JJ validity/NN if/IN those/PRP participating/VBG are/VBP unrepresentative/JJ of/IN the/DT reference/NN population/NN for/IN whom/WP the/DT intervention/NN in/IN question/NN is/VBZ intended/VBN ./.
P10387985A21
The/DT methods/NNS used/VBN to/TO detect/VB responses/NNS in/IN solid/JJ tumours/NNS and/CC metastases/NNS are/VBP crude/JJ ,/, and/CC it/PRP is/VBZ likely/JJ that/IN many/DT useful/JJ drugs/NNS are/VBP missed/VBN ./.
P10387991A14
He/PRP first/RB came/VBD to/TO the/DT NCI/NN as/IN a/DT Clinical/JJ Associate/NN in/IN 1967/CD ./.
P10388002A33
Further/RB ,/, the/DT list/NN above/JJ does/VBZ not/RB include/VBP his/PRP$ personal/JJ labortory/NN and/CC clinical/JJ accomplishments/NNS ,/, some/PRP of/IN which/WDT are/VBP :/: */SYM Development/NN of/IN the/DT principles/NNS of/IN use/NN of/IN important/JJ antimetabolites/NNS ,/, such/JJ as/IN methotrexate/NN ./.
P10388010A16
The/DT survey/NN of/IN 20/CD patients/NNS conducted/VBN by/IN Dr./NN Quah/NN represents/VBZ a/DT substantial/JJ portion/NN of/IN the/DT literature/NN on/IN the/DT subject/NN of/IN alternative/JJ therapy/NN use/NN for/IN children/NNS with/IN cancer/NN ./.
P10388013A07
As/IN the/DT famed/JJ radiotherapist/NN and/CC Founding/JJ Editor/NN ,/, Eli/NNP Glatstein/NNP ,/, summarized/VBD ,/, "/`` The/DT Oncologist/NN emphasizes/VBZ the/DT interpretation/NN rather/RB than/IN the/DT data./NNS "/'' The/DT Oncologist/NN to/TO date/NN has/VBZ published/VBN more/RB than/IN forty/CD manuscripts/NNS from/IN international/JJ authorities/NNS ./.
P10388030A26
In/IN fact/NN ,/, the/DT growth/NN of/IN radiosurgery/NN has/VBZ made/VBN radiation/NN oncologists/NNS re-think/VBP their/PRP$ own/JJ practice/NN of/IN conventional/JJ radiation/NN therapy/NN ./.
P10388041A16
This/PRP explains/VBZ the/DT difficulties/NNS one/PRP encounters/VBZ in/IN the/DT correct/JJ evaluation/NN of/IN relevant/JJ data/NNS of/IN one/CD specific/JJ patient/NN ./.
P10388095A19
The/DT preferred/JJ sequence/NN of/IN treatment/NN has/VBZ been/VBN suggested/VBN to/TO be/VB tamoxifen/NN followed/VBN by/IN selective/JJ aromatase/NN inhibitor/NN and/CC then/RB a/DT progestin/NN ./.
P10388128A06
How/WRB far/RB this/DT lymph/NN node/NN dissection/NN is/VBZ directly/RB therapeutic/JJ is/VBZ a/DT source/NN of/IN controversy/NN ./.
P10391814A03
With/IN appropriate/JJ multidisciplinary/JJ care/NN ,/, pain/NN can/MD be/VBP controlled/VBN in/IN 90/CD %/SYM of/IN patients/NNS who/WP have/VBP advanced/JJ malignant/JJ conditions/NNS ,/, and/CC 90/CD %/SYM of/IN ambulatory/JJ patients/NNS with/IN spinal/JJ cord/NN compression/NN can/MD remain/VBP ambulatory/JJ ./.
P10404937A01
OBJECTIVE/NN :/: To/TO review/VB the/DT prognosis/NN and/CC management/NN of/IN ventricular/JJ arrhythmias/NNS (/( VA/NN )/) in/IN persons/NNS with/IN and/CC without/IN heart/NN disease/NN ,/, with/IN emphasis/NN on/IN older/JJR adults/NNS ./.
P10410186A01
OBJECTIVE/NN :/: To/TO briefly/RB discuss/VB the/DT pathophysiology/NN of/IN acute/JJ coronary/JJ syndromes/NNS (/( ACS/NN )/) and/CC to/TO present/VB the/DT clinical/JJ data/NNS currently/RB available/JJ regarding/VBG the/DT use/NN of/IN platelet/NN glycoprotein/NN (/( GP/NN )/) IIb/NN //SYM IIIa/NN inhibitors/NNS in/IN the/DT management/NN of/IN ACS/NN ./.
P10412759A09
RESULTS/NNS :/: Most/DT studies/NNS showed/VBD that/IN 3-hydroxy-3-methylglutaryl/NN coenzyme/NN A/NN (/( HMG-CoA/NN )/) reductase/NN inhibitors/NNS reduce/VBP cholesterol-rich/JJ apolipoprotein/NN (/( apo/NN )/) B-containing/JJ lipoproteins/NNS with/IN no/DT effects/NNS on/IN renal/JJ function/NN or/CC proteinuria/NN among/IN patients/NNS with/IN progressive/JJ renal/JJ disease/NN ./.
P10423049A14
Symptomatic/JJ measures/NNS in/IN addition/NN to/TO specific/JJ treatments/NNS for/IN the/DT underlying/JJ cancer/NN and/or/CC other/JJ pulmonary/JJ and/CC cardiovascular/JJ diseases/NNS are/VBP indicated/VBN ./.
P10426859A15
It/PRP is/VBZ hoped/VBN that/IN advances/NNS in/IN molecular/JJ approach/NN to/TO cardiovascular/JJ disease/NN ,/, molecular/JJ genetics/NNS and/CC transgenic/JJ techniques/NNS will/MD allow/VBP better/RBR understanding/NN and/CC more/RB effective/JJ therapeutic/JJ strategies/NNS to/TO prevent/VB and/CC control/VB IHD/NN ./.
P10433350A16
Combined/JJ therapy/NN with/IN sulphonylureas/NNS may/MD be/VBP more/RB expensive/JJ and/CC clear/JJ clinical/JJ advantages/NNS have/VBP not/RB been/VBN consistently/RB demonstrated/VBN ./.
P10439825A01
To/TO help/VB family/NN physicians/NNS manage/VBP patients/NNS with/IN irritable/JJ bowel/NN syndrome/NN (/( IBS/NN )/) ,/, a/DT consensus/NN conference/NN was/VBD convened/VBN in/IN June/NN 1997/CD at/IN which/WDT 5/CD internationally/RB recognized/JJ experts/NNS in/IN IBS/NN presented/VBD position/NN papers/NNS on/IN selected/JJ topics/NNS previously/RB circulated/VBN to/TO the/DT conference/NN participants/NNS ./.
P10448335A02
METHODS/NNS :/: Articles/NNS were/VBD selected/VBN from/IN a/DT review/NN of/IN Medline/NN ,/, accessed/VBN with/IN the/DT OVID/NN search/NN engine/NN ./.
P10449891A06
Certain/JJ inotropic/JJ drugs/NNS may/MD reduce/VBP symptoms/NNS but/CC shorten/VBP life/NN expectancy/NN ./.
P10453829A22
The/DT data/NNS at/IN present/JJ are/VBP not/RB robust/JJ enough/RB to/TO address/VB the/DT issue/NN of/IN safety/NN ./.
P10467222A11
It/PRP is/VBZ essential/JJ that/IN future/JJ intervention/NN strategies/NNS focus/VBP on/IN improving/NN adoption/NN of/IN new/JJ therapies/NNS into/IN clinical/JJ practice/NN ./.
P10473016A03
In/IN addition/NN ,/, morbidity/NN and/CC mortality/NN benefits/NNS have/VBP been/VBN suggested/VBN ,/, specifically/RB with/IN the/DT non-selective/JJ vasodilating/JJ agent/NN ,/, carvedilol/NN ./.
P10474762A17
The/DT evidence/NN supports/VBZ the/DT use/NN dexrazoxane/NN to/TO provide/VB protection/NN against/IN the/DT cardiotoxicity/NN associated/VBN with/IN conventional-dose/NN epirubicin/NN in/IN patients/NNS with/IN advanced/JJ but/CC anthracycline-sensitive/JJ cancer/NN ,/, in/IN whom/WP the/DT continued/JJ use/NN of/IN anthracycline-containing/JJ chemotherapy/NN is/VBZ indicated/VBN in/IN the/DT opinion/NN of/IN the/DT treating/JJ physicians/NNS ./.
P10484239A04
According/VBG to/TO estimates/NNS based/VBN on/IN phase-2/NN NHANES/NN III/CD data/NNS (/( 1991-1994/CD )/) ,/, only/RB 1.4/CD million/CD (/( 6.6/CD %/SYM )/) of/IN 21.1/CD million/CD American/JJ adults/NNS eligible/JJ for/IN cholesterol-lowering/JJ drug/NN therapy/NN by/IN NCEP/NN guidelines/NNS were/VBD receiving/VBG such/DT therapy/NN ,/, including/VBG 14/CD %/SYM of/IN those/PRP eligible/JJ in/IN secondary/JJ prevention/NN and/CC 4/CD %/SYM of/IN those/PRP eligible/JJ in/IN primary/JJ prevention/NN ./.
P10488367A02
The/DT target/NN group/NN for/IN guideline/NN use/NN included/VBD general/JJ practitioners/NNS and/CC other/JJ primary/JJ health/NN care/NN providers/NNS in/IN the/DT public/JJ and/CC private/JJ sectors/NNS ./.
P10494519A04
The/DT primary/JJ goal/NN of/IN these/DT analyses/NNS is/VBZ to/TO maximize/VB value/NN and/CC efficiency/NN ,/, not/RB necessarily/RB to/TO decrease/VB spending/NN ./.
P10502233A06
Over/IN the/DT past/JJ 2/CD years/NNS ,/, 4/CD major/JJ trials/NNS involving/VBG more/RB than/IN 18,000/CD patients/NNS have/VBP evaluated/VBN the/DT therapeutic/JJ potential/NN of/IN 3/CD small-molecule/NN ,/, intravenous/JJ GP/NN IIb-IIIa/NN inhibitors/NNS as/IN a/DT component/NN of/IN first-line/NN management/NN of/IN unstable/JJ angina/NN or/CC non-ST-segment/NN elevation/NN myocardial/JJ infarction/NN ./.
P10505286A09
In/IN this/DT registry/NN ,/, the/DT success/NN rate/NN of/IN direct/JJ PTCA/NN was/VBD 87/CD %/SYM as/IN defined/VBN by/IN a/DT final/JJ TIMI-grade/NN 3/CD perfusion/NN of/IN the/DT infarct/NN vessel/NN which/WDT is/VBZ close/JJ to/TO the/DT data/NNS of/IN the/DT MITI-registry/NN and/CC the/DT GUSTO/NN IIb/NN study/NN ./.
P10507632A04
DATA/NNS SYNTHESIS/NN :/: In/IN the/DT ICU/NN ,/, life/NN and/CC death/NN decisions/NNS are/VBP often/RB made/VBN in/IN a/DT crisis/NN mode/NN or/CC in/IN the/DT face/NN of/IN uncertainty/NN ,/, and/CC may/MD necessitate/VBP the/DT withholding/NN and/CC withdrawal/NN of/IN life-supporting/JJ technologies/NNS ./.
P10516909A07
In/IN contrast/NN ,/, when/WRB clinical/JJ improvement/NN has/VBZ not/RB occurred/VBN and/CC chest/NN radiographs/NNS are/VBP unchanged/VBN or/CC worse/JJ ,/, a/DT more/RB aggressive/JJ approach/NN is/VBZ warranted/VBN ./.
P10517720A07
DATA/NNS EXTRACTION/NN :/: The/DT sample/NN size/NN and/CC number/NN of/IN subjects/NNS who/WP developed/VBD preeclampsia/NN in/IN the/DT calcium/NN supplementation/NN group/NN vs/CC a/DT control/NN group/NN were/VBD recorded/VBN and/CC analyzed/VBN on/IN an/DT intent-to-treat/NN basis/NN ./.
P10526699A07
Beta/NN blockers/NNS can/MD also/RB improve/VBP the/DT intrinsic/JJ contractile/JJ function/NN of/IN cardiomyocytes/NNS and/CC have/VBP also/RB been/VBN shown/VBN to/TO improve/VB myocardial/JJ energetics/NNS in/IN HF/NN ,/, possibly/RB through/IN desirable/JJ changes/NNS in/IN substrate/NN utilization/NN ./.
P10533351A07
Because/IN of/IN its/PRP$ short/JJ half-life/NN ,/, zaleplon/NN will/MD be/VBP useful/JJ in/IN patients/NNS experiencing/VBG difficulty/NN in/IN falling/NN asleep/JJ and/CC in/IN those/PRP who/WP wake/VBP up/IN at/IN night/NN and/CC have/VBP trouble/JJ falling/NN back/IN to/TO sleep/VB ./.
P10534233A11
Pharmacological/JJ stress/NN testing/NN has/VBZ high/JJ clinical/JJ use/NN for/IN risk/NN stratifying/JJ patients/NNS with/IN known/JJ or/CC suspected/JJ CAD/NN ,/, in/IN patients/NNS after/IN myocardial/JJ infarction/NN ,/, and/CC in/IN patients/NNS needing/VBG noncardiac/JJ surgery/NN ./.
P10538854A11
A/DT mini-pharmacoeconomic/JJ analysis/NN based/VBN on/IN claims/NNS data/NNS over/IN a/DT 6-month/NN period/NN from/IN HMO/NN Colorado/NNP ,/, a/DT health/NN maintenance/NN organization/NN ,/, shows/VBZ that/IN switching/NN patients/NNS on/IN dual/JJ therapy/NN with/IN a/DT calcium/NN channel/NN blocker/NN and/CC an/DT ACE/NN inhibitor/NN to/TO 1-pill/NN combination/NN therapy/NN with/IN both/CC agents/NNS can/MD result/VBP in/IN substantial/JJ cost/NN savings/NNS ./.
P10545862A18
There/RB have/VBP already/RB been/VBN several/JJ visits/NNS from/IN senior/JJ NCI/NN personnel/NN to/TO Ireland/NNP including/VBG Dr./NN Klausner/NN ,/, the/DT Director/NN of/IN the/DT NCI/NN ,/, to/TO determine/VB the/DT potential/JJ impact/NN of/IN this/DT agreement/NN and/CC to/TO identify/VB the/DT most/RBS productive/JJ areas/NNS of/IN interaction/NN between/IN the/DT NCI/NN and/CC the/DT Irish/NN Cancer/NN Community/NN ./.
P10550165A06
RESULTS/NNS :/: The/DT lack/NN of/IN a/DT clearly/RB defined/JJ treatment/NN approach/NN to/TO patients/NNS with/IN locally/RB advanced/JJ prostate/NN cancer/NN stems/VBZ from/IN multiple/JJ factors/NNS ,/, including/VBG ambiguities/NNS in/IN clinical/JJ staging/NN ,/, inadequate/JJ knowledge/NN of/IN the/DT natural/JJ history/NN of/IN the/DT cancer/NN ,/, and/CC a/DT dearth/NN of/IN comparative/JJ randomized/JJ trials/NNS evaluating/VBG efficacy/NN of/IN different/JJ therapies/NNS ./.
P10551433A04
These/DT benefits/NNS are/VBP sustained/VBN at/IN 6/CD months/NNS ./.
P10561236A04
EVIDENCE/NN :/: A/DT comprehensive/JJ ,/, formal/JJ literature/NN review/NN was/VBD conducted/VBN for/IN tamoxifen/NN and/CC raloxifene/NN on/IN the/DT following/JJ topics/NNS :/: breast/NN cancer/NN risk/NN reduction/NN ;/: tamoxifen/NN side/NN effects/NNS and/CC toxicity/NN ,/, including/VBG endometrial/JJ cancer/NN risk/NN ;/: tamoxifen/NN influences/NNS on/IN nonmalignant/JJ diseases/NNS ,/, including/VBG coronary/JJ heart/NN disease/NN and/CC osteoporosis/NN ;/: and/CC decision/NN making/NN by/IN women/NNS at/IN risk/NN for/IN breast/NN cancer/NN ./.
P10568677A14
Pharmacologic/JJ therapy/NN is/VBZ likely/RB to/TO be/VB dominated/VBN by/IN compounds/NNS that/WDT exert/VBP their/PRP$ predominant/JJ effect/NN by/IN prolonging/NN atrial/JJ repolarization/NN ./.
P10577465A08
In/IN addition/NN ,/, intramural/JJ delivery/NN of/IN enoxaparin/NN to/TO achieve/VB a/DT locally/RB high/JJ concentration/NN is/VBZ being/VBG investigated/VBN for/IN the/DT prevention/NN of/IN restenosis/NN after/IN coronary/JJ stenting/NN ./.
P10583795A03
Various/JJ surveys/NNS have/VBP shown/VBN that/IN residents/NNS are/VBP under-trained/VBN in/IN managed/JJ care/NN principles/NNS and/CC practice/NN ./.
P10588173A08
Other/JJ patient/NN characteristics/NNS that/WDT may/MD be/VBP useful/JJ in/IN the/DT future/NN in/IN deciding/NN suitability/NN for/IN a/DT trial/NN ,/, or/CC predicting/NN response/NN ,/, include/VBP symptom/NN pattern/NN ,/, length/NN of/IN symptom/NN history/NN ,/, whether/IN the/DT condition/NN was/VBD triggered/VBN by/IN enteric/JJ infection/NN ,/, whether/IN a/DT patient/NN is/VBZ in/IN primary/JJ ,/, secondary/JJ ,/, or/CC tertiary/JJ care/NN ,/, psychological/JJ characteristics/NNS ,/, a/DT history/NN of/IN physical/JJ or/CC sexual/JJ abuse/NN ,/, and/CC possibly/RB visceral/JJ sensitivity/NN testing/NN or/CC autonomic/JJ dysfunction/NN ./.
P10591384A09
MAIN/JJ OUTCOME/NN MEASURES/NNS :/: Primary/JJ efficacy/NN was/VBD an/DT excellent/JJ neurologic/JJ recovery/NN at/IN day/NN 90/CD (/( National/JJ Institutes/NNS of/IN Health/NN Stroke/NN Scale/NN [/( NIHSS/NN ]/) score/NN of/IN </SYM or/CC =1/CD )/) ;/: secondary/JJ end/NN points/NNS included/VBD excellent/JJ recovery/NN on/IN functional/JJ outcome/NN measures/NNS (/( Barthel/NNP index/NN ,/, modified/JJ Rankin/NNP scale/NN ,/, and/CC Glasgow/NNP Outcome/NN Scale/NN )/) at/IN days/NNS 30/CD and/CC 90/CD ./.
P10595286A07
RESULTS/NNS :/: Twenty-two/CD trials/NNS ,/, including/VBG a/DT total/NN of/IN 1042/CD patients/NNS (/( median/NN 36/CD ,/, range/NN 10-150/CD )/) ,/, met/VBD the/DT inclusion/NN criteria/NNS ./.
P10599376A25
It/PRP was/VBD extremely/RB effective/JJ ,/, and/CC most/DT dermatologists/NNS who/WP used/VBD it/PRP have/VBP patients/NNS who/WP consider/VBP it/PRP the/DT most/RBS effective/JJ therapy/NN in/IN the/DT last/JJ year/NN ./.
P10605194A03
Over/IN the/DT last/JJ two/CD decades/NNS ,/, a/DT marked/JJ shift/NN in/IN the/DT spectrum/NN of/IN causative/JJ organisms/NNS towards/IN a/DT gram-positive/JJ predominance/NN has/VBZ been/VBN the/DT main/JJ factor/NN influencing/VBG therapeutic/JJ approaches/NNS ./.
P10612273A05
Unfortunately/RB ,/, adverse/JJ effects/NNS may/MD limit/VBP compliance/NN in/IN some/DT patients/NNS ./.
P10624417A04
The/DT choice/NN of/IN a/DT specific/JJ antihypertensive/JJ drug/NN is/VBZ dependent/JJ upon/IN the/DT severity/NN of/IN the/DT hypertension/NN and/CC the/DT presence/NN of/IN other/JJ cardiovascular/JJ risk/NN factors/NNS and/CC concurrent/JJ diseases/NNS ./.
P10630795A01
OBJECTIVE/NN :/: To/TO determine/VB the/DT effect/NN of/IN reamed/JJ versus/CC nonreamed/JJ intramedullary/JJ (/( IM/NN )/) nailing/NN of/IN lower/JJR extremity/NN long/JJ bone/NN fractures/NNS on/IN the/DT rates/NNS of/IN nonunion/NN ,/, implant/NN failure/NN ,/, malunion/NN ,/, compartment/NN syndrome/NN ,/, pulmonary/JJ embolus/NN ,/, and/CC infection/NN ./.
P10632305A04
METHODS/NNS :/: We/PRP conducted/VBD a/DT retrospective/JJ cohort/NN study/NN using/VBG the/DT SAGE/NN database/NN ,/, a/DT long-term/NN care/NN database/NN linking/VBG patient/NN information/NN with/IN drug/NN utilization/NN data/NNS ./.
P10635046A21
The/DT explosive/JJ expansion/NN of/IN information/NN now/RB available/JJ to/TO ,/, and/CC frequently/RB quoted/VBN by/IN ,/, HCV/NN patients/NNS seeking/VBG treatment/NN will/MD increasingly/RB make/VBP this/DT option/NN less/RB acceptable/JJ to/TO a/DT great/JJ many/PRP of/IN this/DT group/NN ./.
P10646698A02
The/DT clinical/JJ goal/NN of/IN peri-menopause/NN therapy/NN is/VBZ to/TO optimize/VB the/DT woman/NN 's/POS health/NN during/IN and/CC after/IN this/DT transitional/JJ period/NN ./.
P10651602A03
This/DT paper/NN reviews/VBZ the/DT clinical/JJ characteristics/NNS of/IN normal/JJ grief/NN and/CC clinical/JJ depression/NN and/CC explains/VBZ strategies/NNS for/IN differential/JJ diagnosis/NN ./.
P10653213A12
The/DT methodologic/JJ quality/NN of/IN all/DT trials/NNS was/VBD assessed/VBN ./.
P10665250A03
STUDY/NN SELECTION/NN :/: Clinical/JJ trials/NNS and/CC pertinent/JJ review/NN articles/NNS that/WDT discussed/VBD the/DT pharmacology/NN ,/, pharmacokinetics/NNS ,/, efficacy/NN ,/, and/CC safety/NN of/IN PPIs/NNS in/IN the/DT management/NN of/IN acid-related/JJ disease/NN ./.
P10674059A08
Patient-reported/JJ outcomes/NNS were/VBD more/RB optimistic/JJ for/IN sleep/NN latency/NN ;/: those/PRP randomized/VBN to/TO benzodiazepine/NN treatment/NN estimated/VBD a/DT sleep/NN latency/NN decrease/NN of/IN 14.3/CD minutes/NNS (/( 95/CD %/SYM CI/NN 10.6/CD to/TO 18.0/CD )/) ./.
P10678340A04
DATA/NNS COLLECTION/NN //SYM ANALYSIS/NN :/: Abstracts/NNS of/IN trials/NNS were/VBD reviewed/VBN independently/RB by/IN 2/CD members/NNS of/IN the/DT study/NN team/NN ./.
P10682170A01
Insulin/NN resistance/NN syndrome/NN (/( IRS/NN )/) ,/, also/RB termed/VBN syndrome/NN X/NN ,/, is/VBZ a/DT distinctive/JJ constellation/NN of/IN risk/NN factors/NNS for/IN the/DT development/NN of/IN type/NN 2/CD diabetes/NN mellitus/NN and/CC cardiovascular/JJ disease/NN ./.
P10689260A04
Patients/NNS were/VBD randomly/RB assigned/VBN to/TO receive/VB a/DT bolus/NN and/CC infusion/NN of/IN either/CC eptifibatide/NN or/CC placebo/NN in/IN addition/NN to/TO standard/JJ therapy/NN ./.
P10695704A08
Inpatient/NN medical/JJ records/NNS from/IN a/DT 254-bed/NN Brown/NNP University-affiliated/JJ teaching/JJ hospital/NN were/VBD also/RB evaluated/VBN for/IN lipid/NN profile/NN ,/, achievement/NN of/IN NCEP/NN II/CD goal/NN ,/, and/CC use/NN of/IN lipid-lowering/JJ medication/NN on/IN admission/NN and/CC discharge/NN ./.
P10699540A02
Controversy/NN also/RB exists/VBZ concerning/VBG its/PRP$ effectiveness/NN in/IN the/DT chronically/RB ill/NN ./.
P10711239A12
Tamoxifen/NN also/RB reduced/VBD the/DT incidence/NN of/IN contralateral/JJ breast/NN cancer/NN ,/, as/RB well/RB as/IN tumour/NN in/IN the/DT ipsilateral/JJ breast/NN following/VBG lumpectomy/NN ./.
P10715310A06
The/DT panel/NN addressed/VBD which/DT patients/NNS to/TO treat/VB and/CC when/WRB in/IN their/PRP$ course/NN of/IN disease/NN ,/, specific/JJ drug/NN delivery/NN issues/NNS ,/, duration/NN of/IN therapy/NN ,/, management/NN of/IN bony/JJ metastases/NNS with/IN other/JJ therapies/NNS ,/, and/CC the/DT public/JJ policy/NN implications/NNS ./.
P10727363A05
RESULTS/NNS :/: a/DT total/NN of/IN 34/CD articles/NNS were/VBD found/VBN ,/, but/CC only/RB 10/CD were/VBD reports/NNS of/IN randomised/JJ controlled/JJ trials/NNS ./.
P10731376A14
It/PRP should/MD be/VBP used/VBN early/RB after/IN symptom/NN onset/NN and/CC in/IN conjunction/NN with/IN a/DT more/RB specific/JJ marker/NN of/IN myocardial/JJ damage/NN ./.
P10733260A02
CHF/NN is/VBZ thought/VBN to/TO progress/VB as/IN a/DT result/NN of/IN activation/NN of/IN endogenous/JJ neurohormonal/JJ systems/NNS which/WDT are/VBP activated/VBN by/IN the/DT initial/JJ myocardial/JJ injury/NN ./.
P10744594A07
DATA/NNS EXTRACTION/NN :/: Two/CD independent/JJ reviewers/NNS abstracted/VBD each/DT article/NN by/IN following/NN a/DT prospectively/RB designed/JJ protocol/NN ./.
P10750936A03
Meta-analysis/NN of/IN randomized/JJ ,/, placebo/NN controlled/JJ trials/NNS ./.
P10755326A12
While/IN waiting/VBG for/IN a/DT donor/NN ,/, patients/NNS have/VBP been/VBN bridged/VBN with/IN various/JJ intravenous/JJ agents/NNS ,/, most/RBS often/RB inotropes/NNS ,/, but/CC symptom/NN relief/NN is/VBZ associated/VBN with/IN risk/NN of/IN increased/JJ mortality/NN due/JJ to/TO these/DT drugs/NNS ./.
P10767115A09
There/EX may/MD be/VBP a/DT role/NN for/IN IV/NN IgG/NN and/CC steroids/NNS ,/, especially/RB for/IN cases/NNS of/IN thrombocytopenia/NN that/WDT are/VBP immune-mediated/VBN ;/: however/WRB ,/, further/JJ investigations/NNS are/VBP necessary/JJ ./.
P10772302A07
DATA/NNS SYNTHESIS/NN :/: Six/CD randomized/JJ controlled/JJ trials/NNS were/VBD included/VBN in/IN the/DT review/NN ,/, 4/CD of/IN which/WDT used/VBD crossover/NN design/NN ./.
P10783421A08
A/DT recent/JJ meta-analysis/NN analyzed/VBD 10/CD prospective/JJ studies/NNS comparing/VBG primary/JJ angioplasty/NN with/IN intravenous/JJ fibrinolytic/JJ therapy/NN and/CC found/VBD that/IN the/DT mortality/NN rate/NN for/IN 30/CD days/NNS or/CC less/PRP was/VBD 4.4/CD %/SYM for/IN 1,290/CD patients/NNS treated/VBN with/IN primary/JJ angioplasty/NN compared/VBN with/IN 6.5/CD %/SYM for/IN 1,316/CD patients/NNS treated/VBN with/IN fibrinolytic/JJ agents/NNS (/( 95/CD %/SYM confidence/NN intervals/NNS 0.46/CD to/TO 0.49/CD ,/, P/NN =.02/CD )/) ./.
P10789664A04
OBJECTIVE/NN :/: To/TO compare/VB the/DT effect/NN of/IN doxazosin/NN ,/, an/DT alpha-blocker/NN ,/, with/IN chlorthalidone/NN ,/, a/DT diuretic/NN ,/, on/IN incidence/NN of/IN CVD/NN in/IN patients/NNS with/IN hypertension/NN as/IN part/NN of/IN a/DT study/NN of/IN 4/CD types/NNS of/IN antihypertensive/JJ drugs/NNS :/: chlorthalidone/NN ,/, doxazosin/NN ,/, amlodipine/NN ,/, and/CC lisinopril/NN ./.
P10792162A04
RESULTS/NNS :/: In/IN all/PRP ,/, 444/CD men/NNS were/VBD enrolled/VBN in/IN two/CD placebo-controlled/JJ and/CC two/CD comparative/JJ trials/NNS lasting/VBG 12-24/CD weeks/NNS ./.
P10796129A07
Expert/NN informant/NN 's/POS search/NN in/IN the/DT Japanese/JJ language/NN was/VBD made/VBN by/IN Prof./NN Y/NN ./.
P10796197A13
Further/JJ research/NN should/MD evaluate/VBP the/DT practice/NN of/IN supplementation/NN of/IN human/NN milk/NN with/IN fat/NN ./.
P10796208A12
Data/NNS were/VBD entered/VBN into/IN the/DT Review/NN Manager/NN software/NN and/CC double/RB checked/VBN ./.
P10796252A17
There/EX is/VBZ a/DT compelling/JJ need/NN for/IN the/DT long/JJ term/NN follow-up/NN and/CC reporting/NN of/IN late/JJ outcomes/NNS ,/, especially/RB neurologic/JJ and/CC developmental/JJ outcomes/NNS ,/, among/IN surviving/JJ infants/NNS who/WP participated/VBD in/IN all/DT randomized/JJ trials/NNS of/IN early/JJ postnatal/JJ corticosteroid/NN treatment/NN ./.
P10796264A19
Chronic/JJ administration/NN of/IN furosemide/NN improves/VBZ both/CC oxygenation/NN and/CC lung/NN compliance/NN ./.
P10796274A21
Large/JJ studies/NNS are/VBP needed/VBN to/TO assess/VB (/( 1/CD )/) whether/IN chronic/JJ diuretic/NN administration/NN improves/VBZ mortality/NN ,/, duration/NN of/IN oxygen/NN dependency/NN ,/, ventilator/NN dependency/NN ,/, length/NN of/IN hospital/NN stay/NN and/CC long-term/NN outcome/NN in/IN patients/NNS without/IN long-term/NN toxicity/NN and/CC (/( 2/CD )/) whether/IN adding/NN spironolactone/NN to/TO thiazides/NNS or/CC adding/NN metolazone/NN to/TO furosemide/NN has/VBZ any/DT beneficial/JJ effect/NN ./.
P10796282A11
MAIN/JJ RESULTS/NNS :/: Five/CD randomised/JJ trials/NNS with/IN data/NNS for/IN 3954/CD participants/NNS were/VBD included/VBN ./.
P10796300A12
The/DT five/CD included/JJ trials/NNS involved/VBD 1068/CD patients/NNS ./.
P10796306A30
The/DT significance/NN of/IN these/DT results/NNS is/VBZ therefore/RB questionable/JJ ./.
P10796329A14
Two/CD trials/NNS used/VBD intra-arterial/JJ administration/NN but/CC the/DT rest/NN used/VBD the/DT intravenous/JJ route/NN ./.
P10796337A10
The/DT drugs/NNS analyzed/VBN were/VBD :/: nimodipine/NN (/( eight/CD trials/NNS ,/, 1574/CD patients/NNS )/) ,/, nicardipine/NN (/( two/CD trials/NNS ,/, 954/CD patients/NNS )/) ,/, and/CC AT877/NN (/( one/CD trial/NN ,/, 276/CD patients/NNS )/) ./.
P10796343A06
SELECTION/NN CRITERIA/NNS :/: Unconfounded/JJ truly/RB or/CC quasi/RB randomised/JJ controlled/JJ trials/NNS in/IN dysphagic/JJ patients/NNS with/IN acute/JJ //SYM subacute/JJ (/( within/IN 3/CD months/NNS )/) stroke/NN ./.
P10796350A16
REVIEWER/NN 'S/POS CONCLUSIONS/NNS :/: Data/NNS in/IN this/DT review/NN are/VBP too/RB inconclusive/JJ to/TO guide/VB those/PRP wishing/VBG to/TO uphold/VB or/CC refute/VB the/DT effect/NN of/IN intercessory/JJ prayer/NN on/IN health/NN care/NN outcomes/NNS ./.
P10796364A18
REVIEWER/NN 'S/POS CONCLUSIONS/NNS :/: There/EX is/VBZ insufficient/JJ information/NN on/IN the/DT use/NN of/IN rescue/NN HFOV/NN to/TO make/VB recommendations/NNS for/IN practice/NN ./.
P10796390A01
BACKGROUND/NN :/: Although/IN medication/NN is/VBZ the/DT mainstay/NN of/IN treatment/NN for/IN schizophrenia/NN ,/, always/RB ,/, some/DT sort/NN of/IN informal/JJ or/CC formal/JJ talking/JJ therapy/NN is/VBZ indicated/VBN ./.
P10796398A11
DATA/NNS COLLECTION/NN AND/CC ANALYSIS/NN :/: All/DT data/NNS were/VBD abstracted/VBN by/IN two/CD independent/JJ and/CC trained/JJ reviewers/NNS (/( DF/NNP ,/, AT/NNP )/) ,/, and/CC verified/VBN by/IN a/DT third/JJ reviewer/NN (/( JP/NNP )/) ./.
P10796404A01
BACKGROUND/NN :/: Hallux/NN valgus/NN is/VBZ classified/VBN as/IN an/DT abnormal/JJ deviation/NN of/IN the/DT great/JJ toe/NN (/( hallux/NN )/) towards/IN the/DT midline/NN of/IN the/DT foot/NN ./.
P10796407A03
Non-nutritive/JJ sucking/NN has/VBZ been/VBN considered/VBN to/TO be/VB a/DT benign/JJ intervention/NN ,/, although/IN it/PRP has/VBZ the/DT potential/JJ to/TO have/VB a/DT negative/JJ effect/NN on/IN breastfeeding/NN or/CC on/IN the/DT incidence/NN of/IN later/RB oral/JJ aversion/NN ./.
P10796414A11
For/IN continuous/JJ data/NNS Weighted/JJ Mean/NN Differences/NNS (/( WMD/NN )/) were/VBD calculated/VBN ./.
P10796420A08
Specifically/RB ,/, we/PRP required/VBD that/IN trials/NNS be/VBP randomized/VBN or/CC cross-over/NN and/CC report/VBP at/IN least/JJS one/CD of/IN the/DT following/JJ outcome/NN measures/NNS in/IN a/DT quantitative/JJ manner/NN :/: joint/NN tenderness/NN ,/, joint/NN swelling/NN ,/, grip/NN strength/NN ,/, or/CC erythrocyte/NN sedimentation/NN rate/NN (/( ESR/NN )/) ./.
P10796428A05
Date/NN of/IN the/DT most/RBS recent/JJ search/NN :/: April/NN 1999/CD ./.
P10796432A07
For/IN practical/JJ reasons/NNS only/RB those/PRP in/IN English/NN were/VBD included/VBN ,/, but/CC all/DT languages/NNS will/MD be/VBP retrieved/VBN and/CC translated/VBN for/IN future/JJ updates/NNS ./.
P10796439A06
All/PRP randomized/JJ controlled/JJ trials/NNS which/WDT compared/VBD pain/NN response/NN to/TO venepuncture/NN vs./CC heel/NN lance/NN were/VBD searched/VBN using/VBG MEDLINE/NN ,/, Embase/NN ,/, CINAHL/NN ,/, the/DT Cochrane/NNP Library/NN ,/, reference/NN lists/NNS of/IN identified/JJ trials/NNS and/CC personal/JJ files/NNS ./.
P10796442A16
There/EX were/VBD no/DT clear/JJ differences/NNS between/IN the/DT two/CD preparations/NNS ./.
P10796457A03
It/PRP has/VBZ been/VBN shown/VBN that/IN bone/NN mineral/NN loss/NN at/IN the/DT hip/NN averages/VBZ 14/CD %/SYM in/IN the/DT first/JJ year/NN after/IN starting/NN corticosteroid/NN therapy/NN ./.
P10796461A07
The/DT pooled/JJ analysis/NN was/VBD performed/VBN using/VBG standardized/JJ mean/NN differences/NNS (/( SMDs/NNS )/) for/IN joint/NN counts/NNS ,/, pain/NN and/CC global/JJ assessments/NNS ./.
P10796480A03
OBJECTIVES/NNS :/: The/DT objective/NN of/IN this/DT review/NN was/VBD to/TO assess/VB the/DT effects/NNS of/IN adding/NN inhaled/JJ anti-cholinergics/NNS to/TO beta2-agonists/NNS in/IN acute/JJ paediatric/JJ asthma/NN ./.
P10796491A09
Six/CD of/IN seven/CD trials/NNS that/WDT measured/VBD health/NN professional/JJ practice/NN demonstrated/VBD some/DT improvement/NN for/IN at/IN least/JJS one/CD outcome/NN variable/NN ,/, and/CC in/IN two/CD trials/NNS ,/, the/DT results/NNS were/VBD statistically/RB significant/JJ and/CC clinically/RB important/JJ ./.
P10796506A11
Methodological/JJ quality/NN was/VBD assessed/VBN independently/RB by/IN two/CD reviewers/NNS ./.
P10796515A21
REVIEWER/NN 'S/POS CONCLUSIONS/NNS :/: For/IN acute/JJ maxillary/JJ sinusitis/NN confirmed/VBN radiographically/RB or/CC by/IN aspiration/NN ,/, current/JJ evidence/NN is/VBZ limited/VBN but/CC supports/VBZ penicillin/NN or/CC amoxicillin/NN for/IN 7/CD to/TO 14/CD days/NNS ./.
P10796525A05
The/DT Cochrane/NNP Controlled/JJ Trials/NNS Register/NN and/CC the/DT Inflammatory/JJ Bowel/NN Disease/NN Review/NN Group/NN Trials/NNS Register/NN were/VBD also/RB searched/VBN ./.
P10796528A16
Outcomes/NNS analysed/VBN included/VBD improvement/NN in/IN menstrual/JJ blood/NN loss/NN ,/, satisfaction/NN ,/, change/NN in/IN quality/NN of/IN life/NN ,/, duration/NN of/IN surgery/NN and/CC hospital/NN stay/NN ,/, time/NN to/TO return/VB to/TO work/NN ,/, adverse/JJ events/NNS and/CC requirement/NN for/IN repeat/NN surgery/NN because/IN of/IN failure/NN of/IN the/DT initial/JJ surgical/JJ treatment/NN ./.
P10796534A12
DATA/NNS COLLECTION/NN AND/CC ANALYSIS/NN :/: Data/NNS were/VBD extracted/VBN independently/RB by/IN the/DT reviewers/NNS ,/, pooled/VBN where/WRB appropriate/JJ and/CC possible/JJ ,/, and/CC the/DT pooled/JJ odds/NNS ratios/NNS (/( 95/CD %/SYM CI/NN )/) or/CC the/DT average/JJ differences/NNS (/( 95/CD %/SYM CI/NN )/) were/VBD estimated/VBN ./.
P10796541A09
Other/JJ sources/NNS including/VBG personal/JJ communications/NNS ,/, ongoing/JJ trials/NNS ,/, conference/NN proceedings/NNS ,/, handsearching/NN and/CC reference/NN lists/NNS of/IN published/JJ papers/NNS and/CC books/NNS were/VBD all/PRP searched/VBN for/IN relevant/JJ randomized/JJ controlled/JJ trials/NNS ./.
P10796544A21
The/DT individual/JJ patient/NN data/NNS review/NN will/MD yield/VBP further/JJ evidence/NN on/IN the/DT effects/NNS of/IN selegiline/NN compared/VBN to/TO control/NN as/IN would/MD additional/JJ studies/NNS evaluating/VBG the/DT use/NN of/IN selegiline/NN for/IN the/DT endpoints/NNS of/IN standardised/JJ cognitive/JJ scales/NNS ,/, clinician/NN impression/NN of/IN global/JJ change/NN ,/, dependency/NN and/CC caregiver/NN quality/NN of/IN life/NN ./.
P10796550A06
DATA/NNS COLLECTION/NN AND/CC ANALYSIS/NN :/: Two/CD reviewers/NNS independently/RB assessed/VBD trial/NN quality/NN and/CC extracted/VBD data/NNS ./.
P10796567A08
Specialist/NN advice/NN was/VBD sought/VBN to/TO categorise/VB interventions/NNS ./.
P10796576A07
The/DT main/JJ outcome/NN was/VBD the/DT rate/NN of/IN tracheal/JJ re-intubation/NN after/IN extubation/NN ./.
P10796587A01
BACKGROUND/NN :/: Excessively/RB heavy/JJ menstrual/JJ bleeding/NN (/( HMB/NN )/) or/CC menorrhagia/NN is/VBZ an/DT important/JJ cause/NN of/IN ill/JJ health/NN in/IN women/NNS ./.
P10796594A27
REVIEWER/NN 'S/POS CONCLUSIONS/NNS :/: Treatment/NN of/IN patients/NNS with/IN COPD/NN with/IN long/RB acting/JJ beta2-agonists/NNS produces/VBZ only/RB small/JJ increases/NNS in/IN FEV1/NN ./.
P10796603A10
The/DT objective/NN of/IN the/DT review/NN is/VBZ to/TO assess/VB the/DT effects/NNS of/IN RT/NN for/IN dementia/NN ./.
P10796607A18
For/IN the/DT risk/NN of/IN leaving/NN the/DT study/NN early/RB ,/, there/EX was/VBD also/RB a/DT trend/NN for/IN benefit/NN to/TO those/PRP allocated/VBN to/TO zuclopenthixol/NN decanoate/NN ./.
P10796617A02
Although/IN beneficial/JJ effects/NNS upon/IN clinically/RB relevant/JJ outcomes/NNS have/VBP been/VBN demonstrated/VBN in/IN randomised/JJ controlled/JJ trials/NNS ,/, there/RB remains/VBZ a/DT risk/NN of/IN severe/JJ and/CC sometimes/NNS fatal/JJ anaphylaxis/NN ./.
P10796622A05
To/TO evaluate/VB the/DT relative/JJ efficacy/NN of/IN different/JJ types/NNS of/IN fatty/JJ acid/NN supplementation/NN ./.
P10796639A16
Change/NN in/IN cognitive/JJ outcome/NN was/VBD towards/IN being/NN in/IN favour/NN of/IN treatment/NN ./.
P10796650A09
Studies/NNS were/VBD included/VBN if/IN patients/NNS presented/VBD with/IN acute/JJ asthma/NN and/CC were/VBD treated/VBN with/IN IV/NN magnesium/NN sulfate/NN vs/CC placebo/NN ./.
P10796661A05
We/PRP hand/NN searched/VBD relevant/JJ journals/NNS and/CC conference/NN proceedings/NNS ,/, and/CC contacted/VBD Hoechst/NNP (/( the/DT manufacturer/NN of/IN the/DT drug/NN )/) and/CC experts/NNS in/IN the/DT field/NN ./.
P10796671A04
SEARCH/NN STRATEGY/NN :/: Electronic/JJ searches/NNS of/IN Biological/JJ Abstracts/NNS (/( 1980-1999/CD )/) ,/, CINAHL/NN (/( 1982-1999/CD )/) ,/, The/DT Cochrane/NNP Library/NN (/( Issue/NN 1/CD ,/, 1999/CD )/) ,/, The/DT Cochrane/NNP Schizophrenia/NN Group/NN 's/POS Register/NN (/( January/NN 1999/CD )/) ,/, EMBASE/NN (/( 1980-1999/CD )/) ,/, Dialog/NN Corporation/NN Datastar/NN service/NN (/( 1999/CD )/) ,/, MEDLINE/NN (/( 1966-1999/CD )/) ,/, and/CC PsycLIT/NN (/( 1974-1999/CD )/) were/VBD undertaken/VBN ./.
P10796678A02
From/IN its/PRP$ beginnings/NNS telemedicine/NN has/VBZ been/VBN used/VBN in/IN a/DT variety/NN of/IN health/NN care/NN fields/NNS ,/, although/IN widespread/JJ interest/NN among/IN healthcare/NN providers/NNS has/VBZ only/RB now/RB become/VBP apparent/JJ with/IN the/DT development/NN of/IN more/RB sophisticated/JJ technology/NN ./.
P10796688A13
Cardiovascular/JJ mortality/NN was/VBD reduced/VBN from/IN 69/CD to/TO 50/CD deaths/NNS (/( 95/CD %/SYM CI/NN of/IN the/DT difference/NN 9/CD to/TO 31/CD )/) ./.
P10796704A14
Levodopa/NN dose/NN was/VBD reduced/VBN more/RB in/IN those/PRP receiving/VBG pergolide/NN (/( 235/CD mg/NN v/CC 51/CD mg/NN ;/: p/NN </SYM 0./CD 001/CD )/) ./.
P10796711A20
Trial/NN design/NN characteristics/NNS ./.
P10796715A21
No/DT increase/NN in/IN endometrial/JJ cancer/NN was/VBD seen/VBN in/IN any/PRP of/IN the/DT treatment/NN groups/NNS during/IN the/DT limited/JJ duration/NN (/( maximum/NN of/IN 3/CD years/NNS )/) of/IN these/DT trials/NNS ./.
P10796723A15
Subgroup/NN analysis/NN was/VBD performed/VBN according/VBG to/TO type/NN of/IN control/NN group/NN ,/, no/DT pre-treatment/NN or/CC placebo/NN ,/, and/CC for/IN some/DT outcomes/NNS there/EX were/VBD additional/JJ subgroup/NN analyses/NNS according/VBG to/TO size/NN of/IN the/DT uterus/NN in/IN gestational/JJ weeks/NNS ./.
P10796730A20
MAIN/JJ RESULTS/NNS :/: Outcomes/NNS were/VBD evaluated/VBN separately/RB for/IN unopposed/JJ oestrogen/NN and/CC oestrogen/NN //SYM progestogen/NN regimens/NNS ./.
P10796739A23
Additional/JJ randomized/JJ placebo/NN and/CC active-controlled/JJ trials/NNS are/VBP needed/VBN to/TO evaluate/VB the/DT long-term/NN clinical/JJ effectiveness/NN and/CC safety/NN of/IN Cernilton/NN ./.
P10796750A10
Studies/NNS where/WRB less/RB than/IN 50/CD %/SYM of/IN patients/NNS had/VBD a/DT spinal/JJ cord/NN injury/NN were/VBD excluded/VBN ./.
P10796754A20
In/IN order/NN to/TO detect/VB a/DT realistic/JJ treatment/NN advantage/NN ,/, larger/JJR trials/NNS will/MD have/VBP to/TO be/VB conducted/VBN ./.
P10796760A02
In/IN Australia/NNP ,/, the/DT United/JJ Kingdom/NN and/CC the/DT United/JJ States/NNS ,/, it/PRP is/VBZ the/DT second/JJ commonest/JJS cancer/NN for/IN women/NNS after/IN breast/NN cancer/NN (/( age-standardised/JJ incidence/NN 22-33/CD per/IN 100,000/CD )/) ,/, and/CC men/NNS after/IN prostate/NN or/CC lung/NN cancer/NN (/( age-standardised/JJ incidence/NN 31-47/CD per/IN 100,000/CD )/) (/( Jeffs/NNP et/CC al/NN ,/, 1996/CD ;/: Parkin/NNP et/CC al/NN ,/, 1992/CD )/) ./.
P10796766A17
REVIEWER/NN 'S/POS CONCLUSIONS/NNS :/: The/DT results/NNS of/IN non-randomised/JJ studies/NNS have/VBP concluded/VBN that/IN a/DT phenylalanine/NN restricted/JJ diet/NN is/VBZ effective/JJ in/IN reducing/NN blood/NN phenylalanine/NN levels/NNS and/CC improving/NN intelligence/NN quotient/NN and/CC neuropsychological/JJ outcome/NN ./.
P10796777A09
SELECTION/NN CRITERIA/NNS :/: We/PRP included/VBD randomized/JJ controlled/JJ trials/NNS using/VBG any/DT antibiotic/NN compared/VBN with/IN a/DT placebo/NN ./.
P10796785A17
REVIEWER/NN 'S/POS CONCLUSIONS/NNS :/: Gabapentin/NN has/VBZ efficacy/NN as/IN an/DT add-on/NN treatment/NN in/IN patients/NNS with/IN drug-resistant/JJ partial/JJ epilepsy/NN ./.
P10796793A05
Additional/JJ studies/NNS were/VBD identified/VBN from/IN the/DT reference/NN lists/NNS of/IN retrieved/JJ reports/NNS ./.
P10796799A16
No/DT significant/JJ differences/NNS were/VBD found/VBN between/IN any/PRP of/IN the/DT other/JJ outcomes/NNS measured/VBN ./.
P10796805A08
Information/NN was/VBD collected/VBN on/IN death/NN ,/, disability/NN ,/, and/CC incidence/NN of/IN infection/NN ./.
P10796814A05
SELECTION/NN CRITERIA/NNS :/: All/DT randomised/JJ and/CC pseudorandomised/JJ trials/NNS (/( published/VBN or/CC unpublished/VBN )/) comparing/VBG any/DT influenza/NN vaccine/NN with/IN a/DT placebo/NN or/CC with/IN another/DT type/NN of/IN influenza/NN vaccine/NN ./.
P10796818A17
REVIEWER/NN 'S/POS CONCLUSIONS/NNS :/: There/EX still/RB remains/VBZ considerable/JJ uncertainty/NN about/IN which/WDT forms/NNS of/IN psychosocial/JJ and/CC physical/JJ treatments/NNS of/IN self-harm/NN patients/NNS are/VBP most/RBS effective/JJ ,/, inclusion/NN of/IN insufficient/JJ numbers/NNS of/IN patients/NNS in/IN trials/NNS being/VBG the/DT main/JJ limiting/JJ factor/NN ./.
P10796830A20
However/WRB ,/, there/EX are/VBP only/RB limited/JJ data/NNS examining/VBG a/DT more-important/JJ longer-term/NN effect/NN on/IN the/DT prevention/NN of/IN unplanned/JJ pregnancies/NNS ./.
P10796838A14
Differences/NNS were/VBD resolved/VBN by/IN discussion/NN ./.
P10796845A04
OBJECTIVES/NNS :/: The/DT aim/NN of/IN this/DT review/NN is/VBZ to/TO examine/VB the/DT evidence/NN for/IN the/DT safety/NN and/CC effectiveness/NN of/IN photodynamic/JJ therapy/NN in/IN the/DT treatment/NN of/IN neovascular/JJ age-related/JJ macular/JJ degeneration/NN ./.
P10796856A05
As/IN most/DT acne/NN prescribing/NN is/VBZ undertaken/VBN by/IN general/JJ practitioners/NNS ,/, it/PRP is/VBZ important/JJ that/IN guidelines/NNS issued/VBN to/TO them/PRP are/VBP based/VBN on/IN the/DT best/RBS available/JJ evidence/NN rather/RB than/IN personal/JJ judgements/NNS ./.
P10796860A04
SEARCH/NN STRATEGY/NN :/: The/DT following/JJ electronic/JJ databases/NNS were/VBD searched/VBN :/: MEDLINE/NN to/TO June/NN 1997/CD ;/: AMED/NN ;/: ASSIA/NN ;/: BIDS/NN ;/: BIOSIS/NN Previews/NNS (/( 1985-1996/CD )/) ;/: CINAHL/NN ;/: DHSS/NN Data/NNS ;/: EMBASE/NN (/( 1974/CD to/TO June/NN 1997/CD )/) ;/: PsycLIT/NN and/CC SIGLE/NN ./.
P10796862A31
Some/DT women/NNS treated/VBN with/IN cones/NNS stop/VBP treatment/NN early/RB so/IN cones/NNS may/MD only/RB be/VBP useful/JJ for/IN those/PRP who/WP find/VBP them/PRP acceptable/JJ ./.
P10799082A02
While/IN the/DT need/NN for/IN randomized/JJ trials/NNS is/VBZ evident/JJ ,/, conducting/NN these/DT trials/NNS is/VBZ becoming/VBG increasingly/RB difficult/JJ and/CC complex/NN ./.
P10804811A08
Traditional/JJ laboratories/NNS which/WDT are/VBP unwilling/VBN to/TO adapt/VB themselves/PRP to/TO the/DT new/JJ environment/NN will/MD not/RB survive/VBP in/IN this/DT country/NN ./.
P10815085A01
OBJECTIVE/NN :/: Assays/NNS for/IN drug/NN resistance/NN testing/NN in/IN human/NN immunodeficiency/NN virus/NN type/NN 1/CD (/( HIV-1/NN )/) infection/NN are/VBP now/RB available/JJ and/CC clinical/JJ studies/NNS suggest/VBP that/IN viral/JJ drug/NN resistance/NN is/VBZ correlated/VBN with/IN poor/JJ virologic/JJ response/NN to/TO new/JJ therapy/NN ./.
P10819705A06
No/DT studies/NNS of/IN computerized/JJ screening/NN were/VBD included/VBN ./.
P10824405A14
An/DT "/`` Optimal/JJ Volume/NN Strategy/NN "/'' with/IN HFOV/NN was/VBD utilized/VBN to/TO recruit/VB alveoli/NNS and/CC optimize/VB lung/NN volume/NN ./.
P10828751A02
Resistance/NN is/VBZ an/DT ongoing/JJ problem/NN with/IN antimicrobial/JJ therapy/NN but/CC considerable/JJ progress/NN has/VBZ now/RB been/VBN made/VBN into/IN understanding/NN the/DT underlying/JJ genetic/JJ mechanisms/NNS of/IN this/DT process/NN ./.
P10849468A02
Despite/IN this/PRP ,/, asthma/NN morbidity/NN and/CC mortality/NN rates/NNS are/VBP rising/VBG ./.
P10853406A23
The/DT guideline/NN is/VBZ endorsed/VBN by/IN the/DT South/NN African/JJ Medical/JJ Association/NN ./.
P10858490A01
Cardiovascular/JJ disease/NN mortality-rate/NN reductions/NNS have/VBP slowed/VBN in/IN the/DT United/JJ States/NNS in/IN the/DT last/JJ decade/NN ,/, suggesting/VBG that/IN additional/JJ strategies/NNS are/VBP needed/VBN to/TO reduce/VB rates/NNS further/RB ./.
P10860137A09
Leflunomide/NN has/VBZ been/VBN shown/VBN to/TO be/VB equal/JJ to/TO or/CC less/RB efficacious/JJ than/IN methotrexate/NN ,/, and/CC may/MD be/VBP beneficial/JJ as/IN a/DT second-line/NN disease-modifying/JJ antirheumatic/JJ drug/NN (/( DMARD/NN )/) ./.
P10863884A19
CONCLUSIONS/NNS :/: There/EX is/VBZ evidence/NN to/TO support/VB the/DT role/NN of/IN citalopram/NN as/IN a/DT well-tolerated/JJ and/CC effective/JJ SSRI/NN antidepressant/NN ./.
P10872016A11
Smaller/JJR estrogen/NN dosages/NNS were/VBD associated/VBN with/IN lower/JJR risk/NN (/( P=.01/NN for/IN trend/NN )/) ,/, but/CC risk/NN was/VBD significantly/RB elevated/VBN for/IN all/DT dosages/NNS ./.
P10874909A17
CONCLUSIONS/NNS :/: Traumatic/JJ Brain/NN Injury/NN (/( TBI/NN )/) results/VBZ principally/RB from/IN vehicular/JJ incidents/NNS ,/, falls/NNS ,/, acts/NNS of/IN violence/NN ,/, and/CC sports/NNS injuries/NNS ,/, and/CC is/VBZ more/RB than/IN twice/RB as/RB likely/JJ in/IN males/NNS as/IN in/IN females/NNS ./.
P10890271A05
The/DT evidence/NN that/IN diet/NN alone/JJ improves/VBZ survival/NN is/VBZ poor/JJ ,/, although/IN specifically/RB increasing/NN intake/NN of/IN polyunsaturated/JJ fatty/JJ acid/NN (/( including/VBG n-3/NN fatty/JJ acids/NNS )/) relative/JJ to/TO saturated/JJ fatty/JJ acid/NN intake/NN may/MD provide/VBP some/DT clinical/JJ benefit/NN in/IN the/DT secondary/JJ prevention/NN of/IN coronary/JJ heart/NN disease/NN ./.
P10901828A07
OUTCOMES/NNS :/: The/DT main/JJ potential/JJ outcomes/NNS considered/VBN were/VBD :/: to/TO reduce/VB morbidity/NN and/CC mortality/NN by/IN correct/JJ diagnosis/NN of/IN asthma/NN ,/, to/TO achieve/VB the/DT best/JJS quality/NN of/IN life/NN for/IN the/DT child/NN with/IN asthma/NN ,/, to/TO minimise/VB side-effects/NNS from/IN medication/NN and/CC to/TO prevent/VB development/NN of/IN permanently/RB abnormal/JJ lung/NN function/NN ./.
P10908464A08
These/PRP include/VBP acute/JJ phase/NN reactants/NNS ,/, disability/NN ,/, pain/NN ,/, patient/NN global/JJ assessment/NN ,/, physician/NN global/JJ assessment/NN ,/, swollen/JJ joint/NN count/NN ,/, tender/NN joint/NN count/NN and/CC radiographic/JJ changes/NNS of/IN joints/NNS in/IN any/DT trial/NN of/IN one/CD year/NN or/CC longer/JJR [/( Tugwell/NNP 1993/CD ]/) ,/, and/CC the/DT change/NN in/IN pooled/JJ disease/NN index/NN (/( DI/NN )/) ./.
P10908475A02
Although/IN payment/NN systems/NNS may/MD be/VBP used/VBN to/TO achieve/VB policy/NN objectives/NNS (/( e.g./IN improving/NN quality/NN of/IN care/NN ,/, cost/NN containment/NN and/CC recruitment/NN to/TO under-served/JJ areas/NNS )/) ,/, little/PRP is/VBZ known/VBN about/IN the/DT effects/NNS of/IN different/JJ payment/NN systems/NNS in/IN achieving/NN these/DT objectives/NNS ./.
P10908485A02
The/DT condition/NN usually/RB results/VBZ in/IN an/DT increase/NN in/IN symptoms/NNS ,/, a/DT greater/JJR reliance/NN on/IN corticosteroids/NNS to/TO control/VB the/DT disease/NN process/NN and/CC may/MD lead/VBP to/TO a/DT progressive/JJ decline/NN in/IN lung/NN function/NN ./.
P10908489A16
One/CD large/JJ study/NN (/( 106/CD patients/NNS )/) showed/VBD an/DT improvement/NN in/IN PEFR/NN and/CC reduction/NN in/IN rescue/NN bronchodilator/NN use/NN ./.
P10908496A18
Dose-response/NN studies/NNS examining/VBG survival/NN for/IN either/DT agent/NN could/MD not/RB be/VBP identified/VBN ./.
P10908505A01
BACKGROUND/NN :/: Stress/NN is/VBZ considered/VBN an/DT important/JJ precipitating/JJ factor/NN for/IN seizures/NNS ./.
P10908512A12
Overall/RB the/DT methodological/JJ quality/NN of/IN the/DT studies/NNS included/VBN in/IN our/PRP$ review/NN was/VBD rather/RB low/JJ ./.
P10908517A33
Its/PRP$ adverse/JJ events/NNS profile/NN is/VBZ similar/JJ to/TO that/PRP of/IN other/JJ drugs/NNS ,/, but/CC it/PRP may/MD have/VBP a/DT lower/JJR level/NN of/IN extrapyramidal/JJ problems/NNS ./.
P10908521A18
All/PRP found/VBD withdrawal/NN to/TO be/VB less/RB severe/JJ in/IN the/DT buprenorphine/JJ treatment/NN group/NN ./.
P10908538A10
The/DT majority/NN of/IN the/DT studies/NNS lacked/VBD sample/NN size/NN calculations/NNS and/CC randomization/NN procedure/NN remained/VBD unclear/JJ in/IN three/CD trials/NNS ./.
P10908543A08
Interventions/NNS were/VBD continuous/JJ distending/JJ airway/NN pressure/NN including/VBG continuous/JJ positive/JJ airway/NN pressure/NN (/( CPAP/NN )/) by/IN mask/NN ,/, nasal/JJ prong/NN ,/, nasopharnygeal/JJ tube/NN ,/, or/CC endotracheal/JJ tube/NN ,/, or/CC continuous/JJ negative/JJ pressure/NN (/( CNDP/NN )/) via/IN a/DT chamber/NN enclosing/VBG the/DT thorax/NN and/CC lower/JJR body/NN ,/, compared/VBN with/IN standard/JJ care/NN ./.
P10908549A17
The/DT odds/NNS ratio/NN for/IN '/`` same/JJ or/CC worse/JJ '/'' vs/CC '/`` improved/JJ symptoms/NNS '/'' at/IN the/DT end/NN of/IN treatment/NN was/VBD 0.34/CD (/( 95/CD %/SYM CI/NN 0.10/CD ,/, 1.19/CD )/) ,/, thus/RB showing/VBG no/DT statistically/RB significant/JJ difference/NN between/IN the/DT two/CD interventions/NNS ./.
P10908555A03
OBJECTIVES/NNS :/: The/DT aims/NNS of/IN this/DT review/NN study/NN are/VBP to/TO compare/VB the/DT safety/NN and/CC efficacy/NN of/IN anti-leukotriene/NN agents/NNS with/IN inhaled/JJ glucocorticoids/NNS and/CC to/TO determine/VB the/DT dose-equivalence/NN of/IN anti-leukotrienes/NNS in/IN mcg/NN of/IN inhaled/JJ corticosteroids/NNS in/IN the/DT management/NN of/IN chronic/JJ asthma/NN ./.
P10912869A20
Our/PRP$ results/NNS cast/VBP serious/JJ doubt/NN on/IN the/DT existing/JJ policies/NNS on/IN VT/NN prophylaxis/NN ,/, and/CC we/PRP call/VBP for/IN a/DT large/JJ ,/, high-quality/NN ,/, multicenter/NN trial/NN that/WDT can/MD provide/VBP definitive/JJ answers/NNS ./.
P10920183A07
Whether/IN cases/NNS existed/VBD in/IN Japan/NNP before/RB that/DT time/NN is/VBZ currently/RB under/IN study/NN ./.
P10928402A04
STUDY/NN SELECTION/NN :/: Prospective/JJ ,/, randomized/JJ ,/, controlled/JJ studies/NNS ;/: prospective/JJ ,/, nonrandomized/JJ ,/, controlled/JJ studies/NNS ;/: prospective/JJ ,/, nonrandomized/JJ ,/, uncontrolled/JJ studies/NNS ;/: retrospective/JJ studies/NNS ;/: clinical/JJ experience/NN reports/NNS ;/: case/NN reports/NNS ;/: in/FW vitro/FW studies/NNS ;/: and/CC letters/NNS were/VBD evaluated/VBN for/IN relevant/JJ information/NN ./.
P10934310A01
OBJECTIVE/NN :/: To/TO review/VB the/DT development/NN of/IN intracoronary/JJ ultrasound/NN ,/, its/PRP$ current/JJ utility/NN and/CC the/DT impetus/NN for/IN its/PRP$ continued/JJ development/NN as/IN a/DT coronary/JJ imaging/JJ modality/NN ./.
P10939145A19
The/DT expert/NN group/NN identified/VBD 16/CD key/JJ topics/NNS for/IN a/DT national/JJ hypertension/NN guideline/NN ./.
P10949779A16
Results/NNS of/IN trials/NNS with/IN CIN3/NN as/IN an/DT endpoint/NN are/VBP arguably/RB more/RB persuasive/JJ than/IN those/PRP from/IN intervention/NN studies/NNS with/IN HPV/NN infection/NN endpoints/NNS ./.
P10966006A08
Later/JJR reports/NNS have/VBP not/RB noted/VBN increased/JJ bleeding/NN when/WRB incorporating/NN these/DT modifications/NNS plus/IN early/JJ platelet/NN transfusion/NN ,/, if/IN required/VBN ./.
P10977460A06
The/DT angiotensin/NN II/CD receptor/NN blockers/NNS (/( ARBs/NNS )/) share/VBP many/PRP of/IN the/DT organ-protective/JJ effects/NNS of/IN ACE/NN inhibitors/NNS when/WRB studied/VBN in/IN animal/NN models/NNS ./.
P10982214A02
DATA/NNS SOURCES/NNS :/: All/DT English/JJ language/NN MEDLINE/NN articles/NNS that/WDT cross-referenced/VBD allergy/NN ,/, fungal/JJ ,/, and/CC sinusitis/NN from/IN 1983-present/NN ./.
P11000650A04
DATA/NNS SOURCES/NNS :/: A/DT MEDLINE/NN search/NN was/VBD performed/VBN to/TO identify/VB all/DT English-language/NN articles/NNS regarding/VBG use/NN of/IN Gp/NN IIb/NN //SYM IIIa/NN inhibitors/NNS in/IN ACSs/NNS published/VBN between/IN 1966/CD and/CC June/NN 2000/CD ./.
P11005773A09
All/DT economic/JJ evaluations/NNS comprised/VBD analytical/JJ studies/NNS containing/VBG a/DT decision/NN tree/NN ./.
P11016488A07
Some/DT patients/NNS ,/, however/WRB ,/, have/VBP symptomatic/JJ and/CC hemodynamic/JJ rebound/NN to/TO worsened/JJ heart/NN failure/NN states/NNS during/IN or/CC shortly/RB after/IN inotrope/NN weaning/NN ./.
P11025346A05
The/DT recent/JJ introduction/NN of/IN direct/JJ thrombin/NN inhibitors/NNS ,/, platelet/NN fibrinogen/NN receptor/NN antagonists/NNS and/CC low-molecular-weight/NN heparins/NNS (/( LMWHs/NNS )/) has/VBZ offered/VBN an/DT opportunity/NN to/TO develop/VB more/RB aggressive/JJ antithrombotic/JJ regimens/NNS ./.
P11030020A09
Clinical/JJ trial/NN results/NNS provide/VBP evidence/NN that/IN some/DT ACE/NN inhibitors/NNS have/VBP renoprotective/JJ and/CC vasculoprotective/JJ effects/NNS and/CC improve/VBP outcomes/NNS of/IN patients/NNS with/IN a/DT variety/NN of/IN cardiovascular/JJ disorders/NNS ;/: differences/NNS among/IN the/DT ACE/NN inhibitors/NNS should/MD be/VBP considered/VBN in/IN formulary/JJ decision-making/NN ./.
P11034667A06
We/PRP also/RB contacted/VBD investigators/NNS in/IN the/DT field/NN ./.
P11034678A09
MAIN/JJ RESULTS/NNS :/: Nine/CD trials/NNS involving/VBG over/IN 750/CD patients/NNS aged/VBN eight/CD to/TO over/RB 65/CD and/CC including/VBG smokers/NNS and/CC non-smokers/NNS were/VBD included/VBN ./.
P11034682A16
There/EX is/VBZ some/DT evidence/NN that/IN discharge/NN planning/NN may/MD lead/VBP to/TO reduced/JJ hospital/NN length/NN of/IN stay/NN ,/, and/CC in/IN some/DT cases/NNS reduced/JJ readmission/NN to/TO hospital/NN ./.
P11034686A17
Progestogen/NN (/( Medroxyprogesterone/NN acetate/NN )/) was/VBD associated/VBN with/IN a/DT reduction/NN of/IN pain/NN during/IN treatment/NN ./.
P11034695A04
SEARCH/NN STRATEGY/NN :/: The/DT Cochrane/NNP Dementia/NN and/CC Cognitive/JJ Impairment/NN Group/NN Register/NN of/IN Clinical/JJ Trials/NNS has/VBZ been/VBN searched/VBN ,/, as/IN have/VBP the/DT electronic/JJ databases/NNS MEDLINE/NN ,/, EMBASE/NN ,/, Psychlit/NN ,/, ISI/NN and/CC Current/JJ Contents/NNS ./.
P11034699A06
Subsequently/RB ,/, guidelines/NNS for/IN their/PRP$ use/NN can/MD be/VBP made/VBN on/IN a/DT sound/JJ evidence/NN base/NN ./.
P11034705A04
Several/JJ other/JJ cholinesterase/NN inhibitors/NNS ,/, including/VBG rivastigmine/NN ,/, with/IN superior/JJ properties/NNS in/IN terms/NNS of/IN specificity/NN of/IN action/NN and/CC low/JJ risk/NN of/IN adverse/JJ effects/NNS ,/, have/VBP now/RB been/VBN introduced/VBN ./.
P11034709A15
In/IN cross-over/NN studies/NNS ,/, evening/NN peak/JJ flow/NN was/VBD better/JJR with/IN regular/JJ treatment/NN ,/, weighted/JJ mean/NN difference/NN (/( WMD/NN )/) 13.1/CD l/NN //SYM min/NN (/( 95/CD %/SYM confidence/NN interval/NN 24.3/CD ,/, 1.9/CD )/) ./.
P11034713A03
OBJECTIVES/NNS :/: The/DT object/NN of/IN this/DT review/NN was/VBD to/TO determine/VB the/DT efficacy/NN and/CC safety/NN of/IN corticosteroids/NNS or/CC ACTH/NN in/IN reducing/NN the/DT short/JJ and/CC long/JJ term/NN morbidity/NN from/IN MS/NN ./.
P11034719A10
Toxicity/NN was/VBD evaluated/VBN with/IN pooled/JJ odds/NNS ratios/NNS for/IN withdrawals/NNS and/CC adverse/JJ reactions/NNS ./.
P11034725A03
OBJECTIVES/NNS :/: The/DT objective/NN of/IN this/DT review/NN was/VBD to/TO determine/VB the/DT efficacy/NN of/IN any/DT form/NN of/IN surface/NN ES/NN in/IN the/DT prevention/NN and/or/CC treatment/NN of/IN pain/NN around/IN the/DT shoulder/NN at/IN any/DT time/NN after/IN stroke/NN ./.
P11034730A01
BACKGROUND/NN :/: Preterm/NN infants/NNS experience/VBP a/DT range/NN of/IN morbidity/NN related/VBN to/TO the/DT immaturity/NN of/IN their/PRP$ organ/NN systems/NNS and/CC to/TO concurrent/JJ disease/NN states/NNS ./.
P11034734A11
MAIN/JJ RESULTS/NNS :/: Four/CD randomized/JJ controlled/JJ trials/NNS met/VBD the/DT inclusion/NN criteria/NNS ./.
P11034739A05
OBJECTIVES/NNS :/: The/DT objective/NN of/IN this/DT review/NN was/VBD to/TO evaluate/VB the/DT efficacy/NN and/CC safety/NN of/IN long-term/NN treatment/NN of/IN symptomatic/JJ venous/JJ thromboembolism/NN with/IN low-molecular-weight/NN heparins/NNS compared/VBN with/IN vitamin/NN K/NN antagonists/NNS ./.
P11034748A13
A/DT dose/NN response/NN relationship/NN was/VBD not/RB seen/VBN with/IN duodenal/JJ ulcers/NNS ./.
P11034753A16
The/DT doses/NNS of/IN aminophylline/NN and/CC other/JJ medications/NNS and/CC the/DT severity/NN of/IN asthma/NN varied/VBD between/IN studies/NNS ./.
P11034757A18
There/EX needs/VBZ to/TO be/VB a/DT greater/JJR standardisation/NN of/IN management/NN so/IN that/IN comparisons/NNS between/IN different/JJ series/NN can/MD be/VBP made/VBN ./.
P11034764A02
It/PRP is/VBZ important/JJ to/TO quantify/VB the/DT drop-out/NN rates/NNS of/IN different/JJ antidepressant/NN drugs/NNS in/IN order/NN to/TO have/VB a/DT better/JJR understanding/NN of/IN the/DT relative/JJ tolerability/NN of/IN these/DT drugs/NNS ./.
P11034770A15
Patients/NNS reported/VBD that/IN they/PRP preferred/VBD heat/NN therapy/NN to/TO no/DT therapy/NN (/( 94/CD %/SYM like/VBP heat/NN therapy/NN better/JJR than/IN no/DT therapy/NN )/) ./.
P11034777A07
Date/NN of/IN last/JJ search/NN :/: June/NN 2000/CD ./.
P11041454A12
A/DT multicenter/NN international/JJ study/NN has/VBZ shown/VBN that/IN serum/NN Tg/NN measurements/NNS alone/JJ are/VBP not/RB as/RB sensitive/JJ in/IN the/DT identification/NN of/IN patients/NNS with/IN persistent/JJ or/CC recurrent/JJ tumor/NN as/IN are/VBP rhTSH-stimulated/JJ serum/NN Tg/NN determinations/NNS ./.
P11048901A13
The/DT target/NN hemoglobin/NN level/NN is/VBZ 12/CD g/NN //SYM dL/NN for/IN men/NNS and/CC 11/CD g/NN //SYM dL/NN for/IN women/NNS ./.
P11051137A17
The/DT nail/NN lacquer/NN is/VBZ a/DT cost/NN effective/JJ agent/NN compared/VBN with/IN the/DT oral/JJ antifungal/JJ therapies/NNS ,/, terbinafine/NN ,/, itraconazole/NN ,/, fluconazole/NN ,/, and/CC griseofulvin/NN ./.
P11059357A16
The/DT best/NN would/MD be/VBP records/NNS of/IN the/DT progression/NN of/IN a/DT disease-state/NN in/IN untreated/JJ patients/NNS ./.
P11060248A14
Moreover/RB ,/, the/DT notion/NN that/IN coronary/JJ artery/NN disease/NN can/MD be/VBP considered/VBN to/TO be/VB an/DT inflammatory/JJ condition/NN in/IN its/PRP$ own/JJ right/NN has/VBZ opened/VBN new/JJ and/CC challenging/JJ avenues/NNS for/IN research/NN ./.
P11062301A10
Investigators/NNS should/MD also/RB be/VBP encouraged/VBN to/TO combine/VB their/PRP$ individual/JJ patient/NN data/NNS in/IN meta-analyses/NNS to/TO obtain/VB a/DT more/RB robust/JJ assessment/NN of/IN the/DT value/NN of/IN DWI/NN and/CC PI/NN from/IN larger/JJR sample/NN sizes/NNS ./.
P11073480A02
The/DT administration/NN of/IN thrombolytic/JJ therapy/NN for/IN acute/JJ myocardial/JJ infarction/NN is/VBZ a/DT particularly/RB high-risk/NN situation/NN for/IN emergency/NN physicians/NNS ./.
P11074393A21
Manufacturers/NNS '/POS submissions/NNS to/TO the/DT National/JJ Institute/NN for/IN Clinical/JJ Excellence/NN were/VBD searched/VBN ./.
P11074396A17
(/( 4/CD )/) Caregiver/NN 's/POS and/CC child/NN 's/POS QoL/NN ./.
P11076126A11
Patients/NNS who/WP were/VBD discharged/VBN on/IN a/DT statin/NN showed/VBD a/DT 50/CD %/SYM reduction/NN in/IN mortality/NN over/IN those/PRP who/WP did/VBD not/RB receive/VBP statin/NN therapy/NN independent/JJ of/IN lipid/NN level/NN ./.
P11083694A01
STUDY/NN OBJECTIVES/NNS :/: Tracheostomy/NN is/VBZ one/CD of/IN the/DT most/RBS commonly/RB performed/JJ procedures/NNS in/IN the/DT patient/NN receiving/VBG long-term/NN mechanical/JJ ventilation/NN ./.
P11086757A01
OBJECTIVE/NN :/: To/TO critically/RB review/VB the/DT current/JJ data/NNS concerning/VBG the/DT efficacy/NN of/IN preventive/JJ measures/NNS described/VBN in/IN the/DT literature/NN ,/, on/IN the/DT incidence/NN of/IN lateral/JJ ankle/NN ligament/NN injuries/NNS ./.
P11095158A13
In/IN the/DT early/JJ 21st/JJ century/NN ,/, the/DT patient/NN with/IN type/NN 2/CD diabetes/NN will/MD need/VBP to/TO be/VB the/DT specific/JJ focus/NN for/IN use/NN of/IN these/DT preventive/JJ treatment/NN modalities/NNS due/JJ to/TO the/DT geometric/JJ risk/NN in/IN the/DT international/JJ incidence/NN of/IN this/DT disease/NN ./.
P11096522A15
This/PRP has/VBZ significant/JJ clinical/JJ relevance/NN because/IN the/DT presence/NN of/IN these/DT disorders/NNS guides/VBZ treatment/NN specific/JJ to/TO the/DT disorder/NN (/( s/NN )/) ./.
P11098244A20
Meta-analysis/NN of/IN the/DT limited/JJ data/NNS available/JJ shows/VBZ a/DT statistically/RB significant/JJ difference/NN in/IN survival/NN at/IN 5/CD years/NNS that/WDT favors/VBZ combined/JJ androgen/NN blockade/NN ./.
P11100995A02
In/IN the/DT last/JJ two/CD decades/NNS ,/, the/DT rediscovery/NN of/IN H./NN pylori/NN ,/, development/NN of/IN potent/JJ ulcer-healing/JJ drugs/NNS and/CC specific/JJ Cox-II/NN inhibitors/NNS have/VBP opened/VBN new/JJ horizons/NNS in/IN the/DT management/NN of/IN NSAID/NN toxicity/NN ./.
P11105180A07
Mortality/NN and/CC morbidity/NN from/IN CHD/NN were/VBD derived/VBN from/IN published/JJ meta-analyses/NNS and/CC recent/JJ studies/NNS ./.
P11109039A06
Evidence/NN for/IN risk/NN stratification/NN of/IN patients/NNS with/IN non-ST/NN segment/NN acute/JJ coronary/JJ syndromes/NNS and/CC the/DT results/NNS of/IN clinical/JJ trials/NNS for/IN the/DT individual/JJ antithrombotic/JJ and/CC antiplatelet/NN agents/NNS were/VBD reviewed/VBN ./.
P11115025A04
Seven/CD trials/NNS (/( 286/CD children/NNS in/IN total/NN )/) compared/VBD cisapride/NN with/IN placebo/NN ./.
P11122746A01
The/DT advent/NN of/IN statin/NN therapy/NN has/VBZ revolutionized/VBN the/DT ability/NN of/IN the/DT clinician/NN to/TO manage/VB patients/NNS at/IN risk/NN for/IN the/DT development/NN of/IN an/DT ischemic/JJ event/NN due/JJ to/TO dyslipidemia/NN ./.
P11129126A04
Recent/JJ evidence/NN indicates/VBZ that/IN budesonide/NN inhalation/NN suspension/NN is/VBZ significantly/RB more/RB effective/JJ than/IN nebulised/JJ sodium/NN cromoglycate/NN in/IN improving/NN control/NN of/IN asthma/NN in/IN young/JJ children/NNS with/IN persistent/JJ asthma/NN ./.
P11130523A01
BACKGROUND/NN :/: This/DT programme/NN of/IN overviews/NNS of/IN randomised/JJ trials/NNS was/VBD established/VBN to/TO investigate/VB the/DT effects/NNS of/IN angiotensin-converting-enzyme/NN (/( ACE/NN )/) inhibitors/NNS ,/, calcium/NN antagonists/NNS ,/, and/CC other/JJ blood-pressure-lowering/JJ drugs/NNS on/IN mortality/NN and/CC major/JJ cardiovascular/JJ morbidity/NN in/IN several/JJ populations/NNS of/IN patients/NNS ./.
P11134919A10
OBJECTIVES/NNS :/: The/DT objectives/NNS of/IN this/DT scoping/JJ review/NN are/VBP two-fold/NN ./.
P11138871A02
The/DT purpose/NN of/IN this/DT study/NN was/VBD to/TO observe/VB potential/JJ risk/NN factors/NNS and/CC diagnostic/JJ tests/NNS for/IN VTE/NN ,/, and/CC prophylaxis/NN against/IN VTE/NN in/IN medical-surgical/JJ ICU/NN patients/NNS ./.
P11141646A03
There/EX is/VBZ large/JJ evidence/NN from/IN observational/JJ studies/NNS that/IN HRT/NN reduces/VBZ the/DT risk/NN of/IN cardiovascular/JJ mortality/NN and/CC morbidity/NN in/IN postmenopausal/JJ women/NNS ./.
P11145762A06
These/DT studies/NNS ,/, however/WRB ,/, were/VBD either/CC uncontrolled/VBN or/CC poorly/RB controlled/VBN ,/, unblinded/VBN or/CC only/RB single-blinded/VBN ,/, and/CC enrolled/VBD small/JJ numbers/NNS of/IN patients/NNS ./.
P11152019A04
After/IN 50/CD weeks/NNS '/POS treatment/NN ,/, plasma/NN HIV/NN RNA/NN levels/NNS were/VBD below/IN the/DT limit/NN of/IN detection/NN (/( LOD/NN ;/: </SYM 50/CD copies/NNS //SYM ml/NN )/) for/IN 40/CD %/SYM of/IN patients/NNS receiving/VBG triple/JJ therapy/NN but/CC for/IN only/RB 6/CD %/SYM of/IN those/PRP receiving/VBG dual/JJ NRTI/NN therapy/NN ./.
P11153637A07
SETTING/NN :/: A/DT ten-bed/NN surgical/JJ ICU/NN in/IN an/DT academic-affiliated/JJ community/NN hospital/NN ./.
P11159653A07
There/EX were/VBD five/CD randomised/JJ controlled/JJ trials/NNS published/VBN between/IN 1989-99/CD ./.
P11174359A01
BACKGROUND/NN :/: In/IN the/DT context/NN of/IN a/DT comprehensive/JJ population/NN strategy/NN to/TO reduce/VB tobacco/NN use/NN ,/, encourage/VB healthy/JJ food/NN choices/NNS ,/, and/CC increase/VB physical/JJ activity/NN for/IN the/DT whole/JJ population/NN ,/, the/DT medical/JJ priority/NN is/VBZ to/TO focus/VB on/IN those/PRP who/WP have/VBP developed/VBN symptoms/NNS of/IN coronary/JJ heart/NN disease/NN (/( CHD/NN )/) or/CC other/JJ major/JJ atherosclerotic/JJ disease/NN ,/, and/CC those/PRP who/WP are/VBP at/IN high/JJ risk/NN of/IN developing/NN such/DT diseases/NNS in/IN the/DT future/NN ./.
P11179262A07
The/DT risk/NN of/IN major/JJ bleeding/NN balanced/VBD the/DT reduction/NN in/IN cardiovascular/JJ events/NNS when/WRB cardiovascular/JJ event/NN risk/NN was/VBD 0.22/CD %/SYM //SYM year/NN ./.
P11190039A05
Methods/NNS of/IN epithelial/JJ cauterization/NN and/CC curettage/NN were/VBD grouped/VBN as/IN relatively/RB equivalent/JJ physicochemical/JJ therapy/NN ,/, and/CC solution/NN and/CC ointment/NN formulations/NNS of/IN a/DT given/JJ topical/JJ antiviral/JJ agent/NN were/VBD combined/VBN ./.
P11192359A05
This/DT was/VBD so/RB prevalent/JJ as/IN to/TO allow/VB the/DT conduct/NN of/IN a/DT substantial/JJ study/NN ,/, the/DT ATLAS/NN trial/NN ,/, to/TO compare/VB high/JJ and/CC low/JJ dose/NN ACE/NN inhibition/NN ./.
P11195408A01
These/DT guidelines/NNS propose/VBP a/DT treatment/NN algorithm/NN in/IN which/WDT patients/NNS are/VBP evaluated/VBN regularly/RB for/IN fatigue/NN ,/, using/VBG a/DT brief/JJ screening/JJ instrument/NN ,/, and/CC are/VBP treated/VBN as/IN indicated/VBN by/IN their/PRP$ fatigue/NN level/NN ./.
P11199101A10
In/IN patients/NNS with/IN severe/JJ disease/NN ,/, reduction/NN in/IN operating/JJ lung/NN volumes/NNS is/VBZ more/RB important/JJ than/IN '/`` bronchodilitation/NN '/'' and/CC is/VBZ better/JJR sustained/VBN by/IN long/JJ acting/JJ beta/NN agonists/NNS and/CC anticholinergics/NNS ./.
P11206593A01
BACKGROUND/NN :/: This/DT review/NN summarizes/VBZ and/CC evaluates/VBZ clinical/JJ experience/NN with/IN citalopram/NN ,/, the/DT latest/JJS selective/JJ serotonin/NN reuptake/NN inhibitor/NN (/( SSRI/NN )/) to/TO be/VB approved/VBN for/IN the/DT treatment/NN of/IN depression/NN in/IN the/DT United/JJ States/NNS ./.
P11220287A09
Other/JJ novel/JJ antidiabetic/JJ agents/NNS are/VBP currently/RB under/IN development/NN ,/, including/VBG pramlintide/NN (/( an/DT amylin/NN analogue/NN )/) and/CC glucagon-like/JJ peptide/NN ./.
P11224885A01
STUDY/NN DESIGN/NN :/: A/DT systematic/JJ review/NN of/IN randomized/JJ and/CC nonrandomized/JJ controlled/JJ trials/NNS ./.
P11230834A10
The/DT use/NN of/IN eptifibatide/NN independently/RB predicted/VBD a/DT lower/JJR risk/NN of/IN events/NNS (/( adjusted/JJ RR/NN 0.31/CD ,/, 95/CD %/SYM CI/NN 0.10/CD to/TO 0.93/CD ,/, p/NN =/SYM 0.04/CD )/) ./.
P11232362A29
Only/RB in/IN this/DT way/NN can/MD the/DT challenges/NNS of/IN the/DT present/NN and/CC the/DT future/NN be/VBP met/VBN ./.
P11236168A11
Likewise/RB ,/, TEE/NN also/RB may/MD prove/VBP to/TO be/VB useful/JJ in/IN identifying/NN patients/NNS with/IN a/DT low-clinical/JJ risk/NN profile/NN who/WP may/MD be/VBP treated/VBN with/IN aspirin/NN alone/JJ and/CC patients/NNS in/IN whom/WP warfarin/NN may/MD be/VBP superior/JJ ./.
P11242429A03
OBJECTIVE/NN :/: To/TO explore/VB disagreement/NN for/IN serious/JJ adverse/JJ safety/NN (/( intracranial/JJ hemorrhage/NN [/( ICH/NN ]/) )/) and/CC efficacy/NN outcomes/NNS between/IN meta-analysis/NN of/IN phase/NN 2/CD (/( small/JJ )/) vs/CC meta-analysis/NN of/IN phase/NN 3/CD (/( large/JJ )/) randomized/JJ controlled/JJ trials/NNS comparing/VBG the/DT efficacy/NN of/IN bolus/NN thrombolytic/JJ therapy/NN with/IN infusion/NN for/IN acute/JJ myocardial/JJ infarction/NN (/( AMI/NN )/) ./.
P11249510A12
Fewer/JJR studies/NNS have/VBP investigated/VBN statins/NNS '/POS effects/NNS on/IN the/DT quality/NN of/IN lipoprotein/NN particles/NNS ,/, the/DT activities/NNS of/IN cholesteryl/NN ester/NN transfer/NN protein/NN and/CC lecithin/NN :/: cholesterol/NN acyltransferase/NN as/RB well/RB as/IN their/PRP$ possible/JJ synergistic/JJ effects/NNS with/IN n-3/NN fatty/JJ acids/NNS ,/, anti-oxidants/NNS and/CC aspirin/NN in/IN reducing/NN cardiovascular/JJ events/NNS ./.
P11255426A03
DATA/NNS SOURCES/NNS :/: Studies/NNS with/IN English-language/NN abstracts/NNS identified/VBN in/IN MEDLINE/NN (/( 1966-August/NN 2000/CD )/) ,/, HealthSTAR/NN (/( 1975-August/NN 2000/CD ,/, PsychINFO/NN (/( 1984-August/NN 2000/CD )/) ;/: Cochrane/NNP Library/NN databases/NNS ;/: and/CC articles/NNS listed/VBN in/IN reference/NN lists/NNS of/IN key/JJ articles/NNS ./.
P11255880A19
For/IN this/DT reason/NN ,/, guidelines/NNS for/IN such/DT patients/NNS are/VBP aimed/VBN at/IN keeping/NN the/DT other/JJ risk/NN factors/NNS under/IN strict/JJ control/NN in/IN order/NN to/TO significantly/RB reduce/VB their/PRP$ effect/NN ./.
P11261530A05
STUDY/NN SELECTION/NN AND/CC DATA/NNS EXTRACTION/NN :/: Prospective/JJ ,/, randomized/JJ ,/, double-blind/JJ ,/, placebo-controlled/JJ ,/, human/NN trials/NNS were/VBD selected/VBN for/IN review/NN and/CC discussion/NN ./.
P11262422A02
Policy/NN documents/NNS have/VBP advocated/VBN the/DT importance/NN of/IN public/JJ views/NNS as/IN one/CD such/DT criterion/NN ./.
P11270126A05
The/DT anticoagulation/NN target/NN for/IN AF/NN is/VBZ INR/NN 2/CD to/TO 3/CD with/IN INR/NN 2.5/CD as/IN the/DT specific/JJ goal/NN ./.
P11276294A08
A/DT total/NN of/IN 18/CD trials/NNS involving/VBG 2939/CD men/NNS were/VBD reviewed/VBN ./.
P11279681A08
Additional/JJ information/NN was/VBD sought/VBN from/IN all/DT trialists/NNS ./.
P11279687A04
SEARCH/NN STRATEGY/NN :/: We/PRP searched/VBD the/DT The/DT Cochrane/NNP Library/NN ,/, Issue/NN 32000/CD ;/: MEDLINE/NN ,/, EMBASE/NN ,/, LILACS/NN ,/, Current/JJ Contents/NNS ,/, Dissertation/NN Abstracts/NNS ,/, and/CC Index/NN to/TO UK/NNP Theses/NNS to/TO August/NN 2000/CD ./.
P11279691A04
SEARCH/NN STRATEGY/NN :/: We/PRP searched/VBD the/DT Cochrane/NNP Musculoskeletal/JJ Injuries/NNS Group/NN trials/NNS register/NN ,/, MEDLINE/NN ,/, PubMed/NN ,/, the/DT Cochrane/NNP Controlled/JJ Trials/NNS Register/NN ,/, CINAHL/NN ,/, the/DT National/JJ Research/NN Register/NN and/CC bibliographies/NNS of/IN trial/NN reports/NNS ./.
P11279699A02
When/WRB it/PRP affects/VBZ one/CD side/NN of/IN the/DT mouth/NN the/DT lower/JJR jaw/NN may/MD have/VBP to/TO move/VB to/TO one/CD side/NN to/TO allow/VB the/DT back/IN teeth/NN to/TO meet/VB together/RB ./.
P11279702A14
The/DT effect/NN remained/VBD statistically/RB significant/JJ when/WRB the/DT results/NNS from/IN studies/NNS with/IN less/RB rigorous/JJ methodology/NN were/VBD excluded/VBN in/IN a/DT sensitivity/NN analysis/NN ./.
P11279713A01
BACKGROUND/NN :/: Asthma/NN is/VBZ one/CD of/IN the/DT most/RBS common/JJ reasons/NNS for/IN paediatric/JJ admissions/NNS to/TO hospital/NN ,/, with/IN substantial/JJ cost/NN to/TO the/DT community/NN ./.
P11279716A25
PFMT/NN may/MD be/VBP more/RB effective/JJ than/IN some/DT types/NNS of/IN electrical/JJ stimulation/NN but/CC there/EX were/VBD problems/NNS in/IN combining/NN the/DT data/NNS from/IN these/DT trials/NNS ./.
P11279720A01
BACKGROUND/NN :/: Long/JJ term/NN levodopa/NN therapy/NN in/IN Parkinson/NN 's/POS disease/NN is/VBZ associated/VBN with/IN the/DT development/NN of/IN motor/NN complications/NNS including/VBG abnormal/JJ involuntary/JJ movements/NNS and/CC a/DT shortening/JJ response/NN to/TO each/DT dose/NN (/( wearing/VBG off/IN phenomenon/NN )/) ./.
P11279723A14
The/DT clinical/JJ trial/NN registers/NNS of/IN the/DT National/JJ Cancer/NN Institute/NN and/CC the/DT Radiation/NN Therapy/NN Oncology/NN Group/NN were/VBD consulted/VBN for/IN ongoing/JJ trials/NNS ./.
P11279726A23
Low/JJ dose/NN corticosteroids/NNS (/( </SYM or/CC =/SYM 80/CD mg/NN //SYM day/NN of/IN methylprednisolone/NN or/CC </SYM or/CC =/SYM 400/CD mg/NN //SYM day/NN of/IN hydrocortisone/NN )/) appear/VBP to/TO be/VB adequate/JJ in/IN the/DT initial/JJ management/NN of/IN these/DT adult/NN patients/NNS ./.
P11279735A01
BACKGROUND/NN :/: Concerns/NNS regarding/VBG the/DT safety/NN of/IN transfused/JJ blood/NN have/VBP prompted/VBN re-consideration/NN of/IN the/DT use/NN of/IN allogeneic/JJ (/( blood/NN from/IN an/DT unrelated/JJ donor/NN )/) blood/NN transfusion/NN ./.
P11279739A08
DATA/NNS COLLECTION/NN AND/CC ANALYSIS/NN :/: No/DT controlled/JJ trials/NNS of/IN suitable/JJ quality/NN were/VBD identified/VBN for/IN inclusion/NN in/IN the/DT review/NN ./.
P11279745A18
These/DT results/NNS should/MD be/VBP interpreted/VBN with/IN caution/NN ./.
P11279752A01
BACKGROUND/NN :/: Coronary/JJ artery/NN bypass/NN surgery/NN (/( CABG/NN )/) may/MD be/VBP life/NN saving/NN ,/, but/CC known/JJ side/NN effects/NNS include/VBP neurological/JJ damage/NN and/CC cognitive/JJ impairment/NN ./.
P11279758A01
BACKGROUND/NN :/: Prevalence/NN studies/NNS show/VBP that/IN behaviour/NN problems/NNS in/IN children/NNS are/VBP quite/RB common/JJ (/( 10-15/CD %/SYM in/IN preschoolers/NNS )/) ./.
P11279762A08
Data/NNS were/VBD excluded/VBN where/WRB more/RB than/IN 50/CD %/SYM of/IN participants/NNS in/IN any/DT group/NN were/VBD lost/VBN to/TO follow/NN up/RP ./.
P11279766A16
Suitable/JJ outcome/NN measures/NNS should/MD be/VBP chosen/VBN so/IN that/IN the/DT efficacy/NN and/CC effectiveness/NN of/IN non-pharmacological/JJ swallowing/JJ therapy/NN can/MD be/VBP assessed/VBN and/CC an/DT economic/JJ analysis/NN performed/VBN ./.
P11279772A04
OBJECTIVES/NNS :/: To/TO assess/VB whether/IN computer/NN support/NN for/IN drug/NN dosage/NN benefits/VBZ patients/NNS and/CC hence/RB whether/IN it/PRP should/MD be/VBP more/RB widely/RB available/JJ ./.
P11279781A19
Further/JJ reviews/NNS comparing/VBG the/DT effective/JJ interventions/NNS and/CC studies/NNS that/WDT include/VBP cost-effectiveness/NN ,/, women/NNS 's/POS satisfaction/NN and/CC equity/NN issues/NNS are/VBP needed/VBN ./.
P11279789A16
More/DT research/NN is/VBZ needed/VBN to/TO investigate/VB the/DT effects/NNS of/IN these/DT and/CC other/JJ related/JJ interventions/NNS ./.
P11281087A04
Risk/NN is/VBZ highest/JJS in/IN smokers/NNS with/IN chronic/JJ obstructive/JJ pulmonary/JJ disease/NN ./.
P11286095A05
Our/PRP$ current/JJ quality/NN improvement/NN initiative/NN ,/, developed/VBN through/IN the/DT Occupational/JJ Health/NN Services/NNS Project/NN ,/, synthesizes/VBZ what/WP was/VBD learned/VBN from/IN the/DT MCP/NN and/CC other/JJ pilot/NN studies/NNS to/TO make/VB delivery/NN system/NN improvements/NNS ./.
P11288383A16
The/DT guideline/NN was/VBD developed/VBN by/IN the/DT Executive/NN Committee/NN of/IN the/DT Southern/JJ African/JJ Hypertension/NN Society/NN with/IN consensus/NN meeting/JJ endorsement/NN ,/, and/CC is/VBZ endorsed/VBN by/IN the/DT South/NN African/JJ Medical/JJ Association/NN Guideline/NN Commitee/NN ./.
P11293649A02
Nocturnal/JJ and/CC early/JJ morning/NN symptoms/NNS are/VBP quite/RB common/JJ among/IN patients/NNS with/IN asthma/NN ./.
P11296189A01
STUDY/NN OBJECTIVES/NNS :/: To/TO critically/RB review/VB the/DT available/JJ data/NNS on/IN the/DT diagnostic/JJ evaluation/NN ,/, risk/NN stratification/NN ,/, and/CC therapeutic/JJ management/NN of/IN patients/NNS with/IN acute/JJ exacerbations/NNS of/IN COPD/NN ./.
P11302109A09
Mainly/RB because/IN of/IN the/DT on-course/NN modification/NN of/IN the/DT study/NN protocol/NN ,/, 402/CD //SYM 2133/CD (/( 18.8/CD %/SYM )/) patients/NNS in/IN the/DT control/NN group/NN started/VBD a/DT cholesterol-lowering/JJ treatment/NN during/IN follow-up/NN ./.
P11303413A02
The/DT total/JJ economic/JJ cost/NN of/IN COPD/NN in/IN the/DT US/NNP in/IN 1993/CD was/VBD estimated/VBN to/TO be/VB over/RB $/SYM US15.5/NN billion/CD ,/, with/IN $/SYM US6.1/NN billion/CD for/IN hospitalisation/NN ,/, $/SYM US4.4/NN billion/CD for/IN physician/NN and/CC other/JJ fees/NNS ,/, $/SYM US2.5/NN billion/CD for/IN drugs/NNS ,/, $/SYM US1.5/NN billion/CD for/IN nursing/JJ home/NN care/NN and/CC $/SYM US1.0/NN billion/CD for/IN home/NN care/NN ./.
P11306234A15
Four/CD high-risk/NN studies/NNS reported/VBD results/NNS for/IN preterm/NN delivery/NN less/RB than/IN 34/CD weeks/NNS ./.
P11308231A14
There/EX was/VBD no/DT difference/NN in/IN studies/NNS that/WDT provided/VBD lipids/NNS as/IN a/DT component/NN of/IN TPN/NN when/WRB compared/VBN with/IN studies/NNS that/WDT did/VBD not/RB ./.
P11315826A04
This/DT study/NN will/MD help/VBP clarify/VB the/DT treatment/NN of/IN HTN/NN in/IN the/DT setting/NN of/IN diabetes/NN ./.
P11318073A04
OBJECTIVE/NN :/: This/DT article/NN reviews/VBZ the/DT pharmacologic/JJ properties/NNS and/CC clinical/JJ usefulness/NN of/IN linezolid/NN ./.
P11319991A09
METHODS/NNS -/: DATA/NNS EXTRACTION/NN (/( NON-HEALTH/NN TECHNOLOGY/NN ASSESSMENT/NN LITERATURE/NN SEARCH/NN )/) :/: The/DT new/JJ statistical/JJ techniques/NNS identified/VBN were/VBD categorised/VBN into/IN four/CD subgroups/NNS of/IN increasing/JJ complexity/NN :/: exploratory/JJ data/NNS analysis/NN ;/: simple/JJ series/NN data/NNS analysis/NN ;/: complex/JJ data/NNS structure/NN analysis/NN ,/, generic/JJ techniques/NNS ./.
P11331734A30
Continued/JJ scientific/JJ efforts/NNS need/VBP to/TO be/VB directed/VBN to/TO the/DT identification/NN of/IN the/DT causes/NNS of/IN ASD/NN ./.
P11346064A05
STUDY/NN SELECTION/NN :/: Clinical/JJ efficacy/NN data/NNS were/VBD extracted/VBN from/IN clinical/JJ trials/NNS ,/, case/NN reports/NNS ,/, and/CC abstracts/NNS that/WDT mentioned/VBD linezolid/NN ./.
P11349622A03
Moreover/RB ,/, the/DT mechanisms/NNS leading/VBG to/TO the/DT instability/NN of/IN an/DT atherosclerotic/JJ plaque/NN are/VBP complex/JJ themselves/PRP ./.
P11359552A12
Actual/JJ patient/NN harm/NN from/IN serious/JJ errors/NNS was/VBD rarely/RB recorded/VBN ./.
P11373981A04
The/DT total/JJ CK/NN level/NN is/VBZ far/RB too/RB insensitive/JJ and/CC nonspecific/JJ a/DT test/NN to/TO be/VB used/VBN to/TO diagnose/VB AMI/NN ./.
P11376301A09
CONCLUSIONS/NNS :/: The/DT potential/JJ clinical/JJ impact/NN of/IN the/DT PRINCE/NN trial/NN is/VBZ substantial/JJ because/IN nearly/RB 50/CD %/SYM of/IN myocardial/JJ infarctions/NNS in/IN the/DT United/JJ States/NNS occur/VBP in/IN persons/NNS with/IN normal/JJ cholesterol/NN levels/NNS ,/, and/CC inflammatory/JJ markers/NNS such/JJ as/IN hs-CRP/NN may/MD provide/VBP a/DT means/NNS to/TO detect/VB such/DT individuals/NNS at/IN high/JJ risk/NN who/WP do/VBP not/RB currently/RB qualify/VBP for/IN statin/NN therapy/NN ./.
P11381277A07
Reference/NN lists/NNS were/VBD scanned/VBN ,/, experts/NNS were/VBD polled/VBN ,/, and/CC the/DT personal/JJ files/NNS of/IN the/DT subgroup/NN members/NNS and/CC authors/NNS were/VBD used/VBN to/TO identify/VB other/JJ studies/NNS ./.
P11394560A08
However/WRB ,/, the/DT discriminating/JJ power/NN of/IN specific/JJ variables/NNS from/IN the/DT medical/JJ history/NN and/CC exercise/NN test/NN remains/VBZ unclear/JJ because/IN of/IN inadequate/JJ study/NN design/NN and/CC differences/NNS in/IN study/NN populations/NNS ./.
P11399237A21
Quality/NN assessment/NN was/VBD conducted/VBN independently/RB by/IN two/CD reviewers/NNS ./.
P11401736A02
STUDY/NN DESIGN/NN :/: A/DT systematic/JJ review/NN was/VBD performed/VBN with/IN meta-analysis/NN where/WRB appropriate/JJ ./.
P11405951A11
The/DT meta-analysis/NN shows/VBZ that/IN the/DT use/NN of/IN natural/JJ surfactant/NN rather/RB than/IN synthetic/JJ surfactant/NN results/VBZ in/IN a/DT significant/JJ reduction/NN in/IN the/DT risk/NN of/IN pneumothorax/NN (/( typical/JJ relative/JJ risk/NN 0.63/CD ,/, 95/CD %/SYM CI/NN 0.53/CD ,/, 0.75/CD ;/: typical/JJ risk/NN difference/NN -0.04/CD ,/, 95/CD %/SYM CI/NN -0.06/CD ,/, -0.03/CD )/) and/CC the/DT risk/NN of/IN mortality/NN (/( typical/JJ relative/JJ risk/NN 0.87/CD ,/, 95/CD %/SYM CI/NN 0.76/CD ,/, 0.98/CD ;/: typical/JJ risk/NN difference/NN -0.02/CD ,/, 95/CD %/SYM CI/NN -0.05/CD ,/, 0.00/CD )/) ./.
P11405961A13
Where/WRB possible/JJ ,/, intention-to-treat/NN data/NNS were/VBD used/VBN ./.
P11405964A11
To/TO avoid/VB duplication/NN of/IN data/NNS in/IN the/DT reviews/NNS ,/, the/DT labour/NN induction/NN methods/NNS have/VBP been/VBN listed/VBN in/IN a/DT specific/JJ order/NN ,/, from/IN one/CD to/TO 25/CD ./.
P11405971A01
OBJECTIVES/NNS :/: To/TO determine/VB the/DT clinical/JJ efficacy/NN of/IN piracetam/NN for/IN the/DT features/NNS of/IN dementia/NN or/CC cognitive/JJ impairment/NN ,/, classified/VBN according/VBG to/TO the/DT major/JJ subtypes/NNS of/IN dementia/NN :/: vascular/JJ ,/, Alzheimer/NNP 's/POS disease/NN or/CC mixed/JJ vascular/JJ and/CC Alzheimer/NNP 's/POS disease/NN ,/, or/CC unclassified/JJ dementia/NN ,/, or/CC cognitive/JJ impairment/NN not/RB fulfilling/VBG the/DT criteria/NNS for/IN dementia/NN ./.
P11405980A21
Frequency/NN of/IN STIs/NNS :/: In/IN both/CC Mwanza/NNP and/CC Rakai/NNP ,/, there/EX was/VBD no/DT significant/JJ reduction/NN in/IN gonorrhoea/NN ,/, chlamydia/NN ,/, urethritis/NN ,/, or/CC reported/JJ STI/NN symptoms/NNS among/IN intervention/NN communities/NNS ./.
P11405986A05
OBJECTIVES/NNS :/: To/TO assess/VB the/DT effectiveness/NN of/IN prophylactic/JJ antibiotic/JJ administration/NN before/IN IUD/NN insertion/NN in/IN reducing/NN IUD-related/JJ complications/NNS and/CC discontinuations/NNS within/IN three/CD months/NNS of/IN insertion/NN ./.
P11405990A23
For/IN this/DT outcome/NN there/EX was/VBD statistically/RB significant/JJ between/IN study/NN heterogeneity/NN (/( for/IN RR/NN ,/, p=0.02/NN ;/: for/IN RD/NN ,/, p=0.0001/NN )/) ./.
P11405998A15
Any/DT disagreement/NN was/VBD resolved/VBN by/IN discussion/NN ./.
P11406004A03
OBJECTIVES/NNS :/: To/TO review/VB evidence/NN for/IN the/DT efficacy/NN of/IN speleotherapy/NN in/IN the/DT treatment/NN of/IN asthma/NN ./.
P11406016A11
In/IN DDAVP-treated/JJ patients/NNS the/DT relative/JJ risk/NN of/IN requiring/NN re-operation/NN due/JJ to/TO bleeding/NN was/VBD 0.56/CD (/( 95/CD %/SYM CI/NN :/: 0.18/CD to/TO 1.73/CD )/) ./.
P11406027A01
BACKGROUND/NN :/: Reduced/JJ perfusion/NN of/IN organs/NNS such/JJ as/IN the/DT brain/NN ,/, heart/NN ,/, kidneys/NNS and/CC the/DT gastrointestinal/JJ tract/NN may/MD lead/VBP to/TO acute/JJ dysfunction/NN and/CC be/VBP associated/VBN with/IN permanent/JJ injury/NN ./.
P11406033A10
SELECTION/NN CRITERIA/NNS :/: Randomized/JJ controlled/JJ trials/NNS in/IN patients/NNS with/IN localized/JJ esophageal/JJ cancer/NN ,/, with/IN one/CD arm/NN employing/NN radiotherapy/NN alone/JJ ,/, and/CC one/CD arm/NN employing/NN combination/NN radiotherapy/NN chemotherapy/NN were/VBD included/VBN ./.
P11406037A17
MAIN/JJ RESULTS/NNS :/: In/IN general/NN ,/, media-based/JJ therapies/NNS for/IN behavioural/JJ disorders/NNS in/IN children/NNS had/VBD a/DT moderate/JJ effect/NN when/WRB compared/VBN with/IN both/CC no-treatment/NN controls/NNS and/CC with/IN standard/JJ care/NN ./.
P11406045A11
These/DT methodological/JJ problems/NNS could/MD potentially/RB lead/VBN to/TO bias/NN from/IN a/DT number/NN of/IN sources/NNS ./.
P11406055A16
The/DT trials/NNS included/VBD 584/CD patients/NNS ./.
P11406061A14
Authors/NNS ,/, other/JJ experts/NNS in/IN the/DT field/NN and/CC pharmaceutical/JJ companies/NNS were/VBD contacted/VBN for/IN knowledge/NN of/IN suitable/JJ trials/NNS ,/, published/VBN or/CC unpublished/VBN ./.
P11406065A10
SELECTION/NN CRITERIA/NNS :/: Randomised/JJ or/CC quasi-randomised/JJ controlled/JJ clinical/JJ trials/NNS involving/VBG preterm/NN infants/NNS ./.
P11406071A15
An/DT adequately/RB powered/JJ randomised/JJ controlled/JJ trial/NN would/MD be/VBP useful/JJ to/TO determine/VB if/IN the/DT use/NN of/IN extra-amniotic/JJ prostaglandins/NNS would/MD lower/VBP the/DT rate/NN of/IN caesarean/NN section/NN ./.
P11419424A09
These/DT data/NNS support/VBP a/DT policy/NN involving/VBG broader/JJR use/NN of/IN the/DT early/JJ inhibition/NN of/IN glycoprotein/NN IIb/NN //SYM IIIa/NN in/IN combination/NN with/IN an/DT early/JJ invasive/JJ strategy/NN in/IN such/DT patients/NNS ./.
P11427188A08
It/PRP reports/VBZ a/DT series/NN of/IN case/NN studies/NNS ,/, each/PRP describing/VBG the/DT development/NN of/IN a/DT clinical/JJ guideline/NN ;/: each/DT case/NN study/NN illustrates/VBZ different/JJ issues/NNS in/IN incorporating/NN these/DT different/JJ types/NNS of/IN evidence/NN ./.
P11434828A06
INTERVENTIONS/NNS :/: Participants/NNS in/IN the/DT double-blind/JJ primary/JJ prevention/NN trial/NN were/VBD randomly/RB assigned/VBN to/TO receive/VB 40/CD mg/NN //SYM d/NN of/IN pravastatin/NN (/( n/NN =/SYM 865/CD )/) or/CC placebo/NN (/( n/NN =/SYM 837/CD )/) for/IN 24/CD weeks/NNS ./.
P11441927A13
These/PRP constitute/VBP about/IN 75/CD %/SYM ,/, of/IN all/DT haematological/JJ malignancies/NNS ./.
P11441935A03
This/DT synthesis/NN of/IN the/DT literature/NN on/IN chemotherapy/NN in/IN patients/NNS with/IN acute/JJ myeloid/NN leukaemia/NN (/( AML/NN )/) is/VBZ based/VBN on/IN 129/CD scientific/JJ articles/NNS :/: one/CD meta-analysis/NN ,/, 51/CD randomised/JJ trials/NNS ,/, 39/CD prospective/JJ and/CC 18/CD retrospective/JJ studies/NNS ,/, and/CC 20/CD other/JJ articles/NNS ./.
P11441937A21
High-dose/NN infusional/JJ regimens/NNS with/IN modulated/JJ fluorouracil/NN may/MD turn/VBP out/RP to/TO be/VB superior/JJ to/TO conventional/JJ bolus/NN regimens/NNS ,/, since/IN they/PRP result/VBP in/IN more/DT tumour/NN regressions/NNS ,/, longer/JJR times/NNS to/TO disease/NN progression/NN and/CC possibly/RB longer/JJR survival/NN ./.
P11441940A22
Thus/RB ,/, there/EX are/VBP preliminary/JJ data/NNS supporting/VBG the/DT substitution/NN of/IN cisplatin/NN with/IN carboplatin/NN ./.
P11445744A10
These/DT studies/NNS reported/VBD variable/JJ hospital/NN and/CC intensive/JJ care/NN unit/NN (/( ICU/NN )/) occurrence/NN rates/NNS ,/, ranging/VBG from/IN 2/CD %/SYM to/TO 11/CD %/SYM of/IN all/DT hospital/NN or/CC ICU/NN admissions/NNS ./.
P11449817A12
Although/IN many/PRP of/IN these/DT studies/NNS can/MD be/VBP cited/VBN for/IN various/JJ methodologic/JJ flaws/NNS ,/, the/DT most/RBS consistent/JJ problem/NN is/VBZ that/IN sample/NN sizes/NNS are/VBP too/RB small/JJ to/TO detect/VB difference/NN between/IN two/CD or/CC more/DT active/JJ treatments/NNS ./.
P11455747A08
Incidence/NN is/VBZ 5/CD %/SYM to/TO 40/CD %/SYM in/IN high-risk/NN surgical/JJ patients/NNS ./.
P11464448A13
However/WRB ,/, recent/JJ retrospective/JJ real-life/NN clinical/JJ studies/NNS show/VBP that/IN only/RB 38/CD %/SYM of/IN patients/NNS receiving/VBG some/DT form/NN of/IN lipid-lowering/JJ therapy/NN achieved/VBD NCEP-defined/JJ LDL-C/NN target/NN levels/NNS ,/, demonstrating/VBG the/DT need/NN for/IN the/DT use/NN of/IN more/RB aggressive/JJ treatment/NN ./.
P11469927A01
The/DT continued/JJ widespread/JJ prevalence/NN of/IN breast/NN cancer/NN supports/VBZ placing/NN a/DT high/JJ priority/NN on/IN research/NN aimed/VBN at/IN its/PRP$ primary/JJ prevention/NN ,/, particularly/RB among/IN women/NNS who/WP are/VBP at/IN increased/JJ risk/NN for/IN developing/NN this/DT disease/NN ./.
P11478189A12
4./CD Work/VBP at/IN building/NN a/DT reputation/NN for/IN general/JJ objectivity/NN ,/, reliance/NN on/IN multiple/JJ data/NNS sources/NNS ,/, reaching/NN opinions/NNS only/RB after/IN reviewing/NN complete/JJ information/NN from/IN both/CC sides/NNS ,/, and/CC completing/NN the/DT evaluation/NN ./.
P11483848A16
The/DT presumed/JJ efficacy/NN is/VBZ based/VBN on/IN a/DT collection/NN of/IN animal/NN and/CC human/NN data/NNS concerning/VBG occupational/JJ ,/, perinatal/JJ ,/, and/CC nonoccupational/JJ exposures/NNS to/TO HIV/NN ./.
P11495374A06
Mammograms/NNS miss/VBP approximately/RB 12/CD %/SYM to/TO 37/CD %/SYM of/IN cancers/NNS ,/, generate/VBP false-positive/JJ results/NNS ,/, and/CC cause/VBP anxiety/NN while/IN abnormal/JJ results/NNS are/VBP evaluated/VBN ./.
P11501601A06
Subgroup/NN analyses/NNS have/VBP demonstrated/VBN that/IN the/DT efficacy/NN of/IN statins/NNS extends/VBZ to/TO specific/JJ subgroups/NNS of/IN patients/NNS ,/, including/VBG women/NNS ,/, people/NNS with/IN diabetes/NN ,/, and/CC older/JJR individuals/NNS ./.
P11509058A04
DESIGN/NN AND/CC SETTING/NN :/: Cost-effectiveness/NN analysis/NN using/VBG the/DT Coronary/JJ Heart/NN Disease/NN Policy/NN Model/NN ,/, a/DT validated/JJ ,/, state-transition/NN model/NN of/IN CHD/NN events/NNS in/IN adults/NNS aged/VBN 35/CD through/CC 84/CD years/NNS ./.
P11512506A07
The/DT panel/NN composed/VBD a/DT draft/JJ statement/NN that/WDT was/VBD read/VBN in/IN its/PRP$ entirety/NN and/CC circulated/VBN to/TO the/DT experts/NNS and/CC the/DT audience/NN for/IN comment/NN ./.
P11520256A09
There/EX are/VBP no/DT clearcut/NN advantages/NNS to/TO distinguish/VB these/DT antihistamines/NNS ,/, although/IN for/IN children/NNS under/IN 5/CD years/NNS of/IN age/NN ,/, only/RB cetirizine/NN and/CC loratadine/NN are/VBP approved/VBN ./.
P11524642A04
Antiplatelet/NN ,/, antithrombin/NN ,/, and/CC fibrinolytic/JJ agents/NNS unknown/VBN in/IN clinical/JJ practice/NN as/RB recently/RB as/IN 5/CD years/NNS ago/RB have/VBP secured/VBN places/NNS in/IN the/DT emergency/NN physician/NN 's/POS armamentarium/NN for/IN treating/NN acute/JJ coronary/JJ syndrome/NN ./.
P11529246A05
This/DT pathology/NN results/VBZ in/IN focal/JJ changes/NNS in/IN the/DT function/NN of/IN several/JJ deep/JJ brain/NN nuclei/NNS ,/, which/WDT have/VBP been/VBN well-characterized/VBN in/IN humans/NNS and/CC animal/NN models/NNS and/CC which/WDT account/VBP for/IN many/PRP of/IN the/DT motor/NN symptoms/NNS of/IN PD/NN ./.
P11530420A04
Whether/IN or/CC not/RB individuals/NNS with/IN TS/NN have/VBP significant/JJ discrepancies/NNS between/IN their/PRP$ verbal/JJ and/CC nonverbal/JJ abilities/NNS remains/VBZ unclear/JJ ./.
P11532236A23
This/PRP was/VBD not/RB a/DT cohesive/JJ group/NN ,/, however/WRB ./.
P11532238A38
METHODS/NNS -/: DATA/NNS SYNTHESIS/NN :/: For/IN all/DT comparisons/NNS ,/, the/DT primary/JJ outcome/NN was/VBD the/DT number/NN of/IN clients/NNS who/WP were/VBD in/IN competitive/JJ employment/NN at/IN various/JJ time/NN points/NNS ./.
P11532240A03
In/IN addition/NN ,/, the/DT research/NN :/: (/( 1/CD )/) explored/VBD the/DT '/`` diagnostic/JJ accuracy/NN '/'' of/IN initial/JJ clinical/JJ investigation/NN of/IN the/DT knee/NN by/IN an/DT orthopaedic/JJ trainee/NN ,/, consultant/NN knee/NN specialist/NN and/CC consultant/NN radiologist/NN ;/: (/( 2/CD )/) considered/VBD the/DT variability/NN and/CC diagnostic/JJ accuracy/NN of/IN interpretations/NNS of/IN knee/NN MRI/NN investigations/NNS between/IN radiologists/NNS ;/: (/( 3/CD )/) measured/VBD the/DT strength/NN of/IN preference/NN for/IN the/DT potential/JJ diagnostic/JJ //SYM therapeutic/JJ impact/NN of/IN knee/NN MRI/NN (/( i.e./IN the/DT avoidance/NN of/IN surgery/NN )/) ./.
P11533360A28
Policy-level/NN changes/NNS at/IN the/DT state/NN and/CC community/NN led/VBD to/TO lasting/JJ changes/NNS in/IN the/DT organization/NN and/CC financing/NN of/IN care/NN ,/, which/WDT enabled/VBD changes/NNS in/IN clinical/JJ services/NNS to/TO take/VB place/NN ./.
P11535983A08
The/DT results/NNS of/IN ICON3/NN ,/, in/IN accordance/NN with/IN GOG132/NN study/NN ,/, appear/VBP to/TO contradict/VB the/DT earlier/JJR positive/JJ results/NNS seen/VBN for/IN PTX/NN and/CC CP/NN in/IN the/DT GOG-111/NN and/CC OV10/NN trials/NNS and/CC suggested/VBD that/IN single/JJ agent/NN carboplatin/NN ,/, CY-adriamycin-CP/NN are/VBP safe/JJ and/CC effective/JJ first-line/NN treatments/NNS for/IN women/NNS requiring/VBG chemotherapy/NN for/IN ovarian/JJ cancer/NN ./.
P11550833A02
The/DT objective/NN of/IN this/DT review/NN was/VBD to/TO assess/VB the/DT effectiveness/NN of/IN the/DT various/JJ methods/NNS of/IN immobilisation/NN for/IN acute/JJ ankle/NN sprain/NN ./.
P11557249A01
Patients/NNS admitted/VBN with/IN suspicion/NN of/IN an/DT acute/JJ coronary/JJ syndrome/NN (/( ACS/NN )/) still/RB constitute/VBP a/DT diagnostic/JJ ,/, prognostic/JJ and/CC therapeutic/JJ challenge/NN for/IN the/DT treating/JJ physician/NN ./.
P11561607A05
Specialized/JJ centers/NNS have/VBP reported/VBN improved/JJ hospital/NN morbidity/NN ,/, mortality/NN and/CC survival/NN after/IN pancreaticoduodenectomy/NN ;/: however/WRB ,/, disease-specific/JJ survival/NN after/IN surgical/JJ resection/NN remains/VBZ dismal/JJ ./.
P11567728A09
The/DT continuing/JJ elucidation/NN of/IN pathophysiological/JJ pathways/NNS relevant/JJ in/IN rheumatoid/JJ arthritis/NN ,/, coupled/VBN with/IN continuing/JJ advances/NNS in/IN biotechnology/NN and/CC rational/JJ drug/NN design/NN ,/, offer/VBP substantial/JJ hope/NN for/IN the/DT continued/JJ development/NN of/IN increasingly/RB potent/JJ and/CC specific/JJ pharmacotherapy/NN for/IN treatment/NN of/IN rheumatoid/JJ arthritis/NN ./.
P11570305A01
OBJECTIVE/NN :/: To/TO help/VB family/NN physicians/NNS who/WP care/VBP for/IN patients/NNS with/IN acute/JJ stroke/NN or/CC who/WP are/VBP involved/VBN in/IN planning/NN service/NN delivery/NN or/CC resource/NN allocation/NN to/TO understand/VB recent/JJ developments/NNS in/IN acute/JJ stroke/NN care/NN ./.
P11575024A05
Scientific/JJ evidence/NN was/VBD given/VBN precedence/NN over/IN clinical/JJ anecdotal/JJ experience/NN ./.
P11581453A18
Ethically/RB sound/JJ ,/, specific/JJ policies/NNS for/IN storage/NN ,/, ownership/NN ,/, and/CC use/NN in/IN future/JJ studies/NNS of/IN archived/JJ samples/NNS remaining/VBG from/IN PKU/NN testing/NN should/MD be/VBP established/VBN ./.
P11587008A09
CONCLUSIONS/NNS :/: Consensus/NN recommendations/NNS were/VBD used/VBN to/TO create/VB an/DT algorithm/NN for/IN evaluating/NN women/NNS with/IN postmenopausal/JJ bleeding/NN ./.
P11589256A11
Finally/RB ,/, risedronate/NN has/VBZ been/VBN associated/VBN with/IN a/DT lower/JJR incidence/NN of/IN gastric/JJ ulcers/NNS than/IN alendronate/NN ./.
P11595196A06
The/DT Beyond/IN Endorsed/JJ Lipid/NN Lowering/NN with/IN EBCT/NN Scanning/NN (/( BELLES/NN )/) trial/NN will/MD use/VBP EBCT/NN to/TO compare/VB the/DT effects/NNS of/IN 12/CD months/NNS of/IN treatment/NN with/IN aggressive/JJ or/CC moderate/JJ statin/NN therapy/NN on/IN the/DT progression/NN of/IN coronary/JJ atherosclerosis/NN ./.
P11669360A03
Prior/JJ evidence/NN has/VBZ been/VBN limited/VBN regarding/VBG effective/JJ diagnostic/JJ strategies/NNS for/IN the/DT assessment/NN of/IN symptomatic/JJ women/NNS ./.
P11680099A07
reports/NNS and/CC opinion/NN of/IN expert/NN committees/NNS and/CC working/JJ teams/NNS ./.
P11685852A02
Routine/JJ ultrasound/NN in/IN late/JJ pregnancy/NN (/( after/IN 24/CD weeks/NNS gestation/NN )/) (/( Cochrane/NNP Review/NN )/) ./.
P11686052A60
The/DT proposed/JJ treatments/NNS for/IN the/DT other/JJ disorders/NNS are/VBP conventional/JJ :/: haloperidol/NN and/CC lithium/NN for/IN bipolar/JJ disorders/NNS ,/, fluvoxamine/NN for/IN obsessive/JJ compulsive/JJ disorders/NNS and/CC neuroleptics/NNS for/IN psychotic/JJ disorders/NNS ./.
P11686949A17
No/DT completed/JJ studies/NNS of/IN interventions/NNS to/TO raise/VB blood/NN pressure/NN were/VBD identified/VBN ./.
P11686953A16
Higher/JJR doses/NNS of/IN nicotine/NN patch/NN may/MD produce/VBP small/JJ increases/NNS in/IN quit/NN rates/NNS ./.
P11686957A20
~bullet~Home/NN hazard/NN modification/NN in/IN association/NN with/IN advice/NN on/IN optimising/NN medication/NN (/( 1/CD trial/NN ,/, 658/CD participants/NNS )/) ,/, or/CC in/IN association/NN with/IN an/DT education/NN package/NN on/IN exercise/NN and/CC reducing/NN fall/NN risk/NN (/( 1/CD trial/NN ,/, 3182/CD participants/NNS )/) ./.
P11686965A09
SELECTION/NN CRITERIA/NNS :/: Two/CD reviewers/NNS independently/RB assessed/VBD citations/NNS or/CC papers/NNS and/CC selected/VBD all/DT randomised/JJ trials/NNS that/WDT included/VBD people/NNS with/IN serious/JJ mental/JJ illnesses/NNS and/CC compared/VBD zuclopenthixol/NN acetate/NN with/IN other/JJ drug/NN regimes/NNS ./.
P11686970A06
OBJECTIVES/NNS :/: To/TO determine/VB the/DT effects/NNS of/IN vaginal/JJ misoprostol/NN for/IN third/JJ trimester/NN cervical/JJ ripening/NN or/CC induction/NN of/IN labour/NN ./.
P11686975A11
Measured/VBD clinically/RB relevant/JJ outcomes/NNS ./.
P11686981A15
Further/JJ trials/NNS -/: one/CD of/IN them/PRP very/RB large/JJ -/: are/VBP currently/RB in/IN progress/NN ./.
P11686989A13
Method/NN to/TO ascertain/VB cases/NNS was/VBD similar/JJ in/IN one/CD study/NN and/CC not/RB similar/JJ in/IN the/DT other/JJ ./.
P11686996A23
Two/CD women/NNS in/IN the/DT Goretex/NN group/NN had/VBD late/JJ sling/NN erosion/NN of/IN the/DT urethra/NN requiring/VBG removal/NN of/IN the/DT Goretex/NN ,/, although/IN their/PRP$ incontinence/NN remained/VBD cured/VBN ./.
P11687000A13
MAIN/JJ RESULTS/NNS :/: Seven/CD eligible/JJ controlled/JJ trials/NNS were/VBD included/VBN in/IN the/DT analysis/NN representing/VBG 924/CD randomized/JJ pediatric/JJ patients/NNS ./.
P11687004A09
PPIs/NNS were/VBD significantly/RB more/RB effective/JJ than/IN both/CC H2RA/NN s/NNS and/CC antacids/NNS ./.
P11687013A33
JAPANESE/JJ HERBAL/JJ COMBINATION/NN :/: One/CD small/JJ trial/NN showed/VBD the/DT herbal/JJ combination/NN to/TO be/VB more/RB effective/JJ for/IN pain/NN relief/NN than/IN placebo/NN ,/, and/CC less/DT additional/JJ pain/NN medication/NN was/VBD taken/VBN by/IN the/DT treatment/NN group/NN ./.
P11687024A14
The/DT two/CD in-hospital/NN studies/NNS were/VBD very/RB different/JJ in/IN quality/NN (/( A/NN and/CC C/NN )/) and/CC size/NN (/( 773/CD and/CC 53/CD patients/NNS )/) ./.
P11687028A02
The/DT role/NN of/IN the/DT occupational/JJ therapist/NN is/VBZ to/TO support/VB the/DT patient/NN and/CC help/VBP them/PRP maintain/VB their/PRP$ usual/JJ level/NN of/IN self-care/NN ,/, work/NN and/CC leisure/NN activities/NNS for/IN as/RB long/RB as/IN possible/JJ ./.
P11687033A13
The/DT conclusions/NNS are/VBP also/RB limited/VBN by/IN some/PRP of/IN the/DT methodological/JJ deficiencies/NNS of/IN the/DT included/JJ studies/NNS ./.
P11687038A06
SELECTION/NN CRITERIA/NNS :/: All/DT randomized/JJ controlled/JJ trials/NNS (/( RCTs/NNS )/) and/CC controlled/JJ clinical/JJ trials/NNS (/( CCTs/NNS )/) comparing/VBG therapeutic/JJ ultrasound/NN against/IN placebo/NN or/CC another/DT active/JJ intervention/NN in/IN patients/NNS with/IN OA/NN were/VBD selected/VBN ./.
P11687043A01
BACKGROUND/NN :/: :/: Two/CD recent/JJ clinical/JJ reports/NNS describe/VBP an/DT association/NN between/IN statin/NN therapy/NN and/CC a/DT reduction/NN in/IN the/DT occurrence/NN of/IN Alzheimer/NNP 's/POS disease/NN by/IN as/RB much/PRP as/IN 70/CD %/SYM ./.
P11687048A19
Because/IN alternative/JJ antidepressants/NNS exist/VBP which/WDT have/VBP been/VBN proven/VBN to/TO be/VB effective/JJ and/CC safe/JJ the/DT clinical/JJ usefulness/NN of/IN 5-HTP/NN and/CC tryptophan/NN is/VBZ limited/VBN at/IN present/JJ ./.
P11687053A20
MAIN/JJ RESULTS/NNS :/: One/CD eligible/JJ study/NN was/VBD found/VBN dealing/VBG with/IN prevention/NN of/IN CLD/NN ;/: this/DT study/NN used/VBD salbutamol/NN and/CC enrolled/VBD 173/CD infants/NNS ./.
P11687058A09
SELECTION/NN CRITERIA/NNS :/: All/DT randomised/JJ or/CC quasi-randomised/JJ clinical/JJ trials/NNS comparing/VBG different/JJ haemodialysis/NN membrane/NN material/NN in/IN patients/NNS with/IN ESRD/NN ./.
P11687061A18
Amniotomy/NN and/CC intravenous/JJ oxytocin/NN resulted/VBD in/IN more/DT postpartum/NN haemorrhage/NN than/IN vaginal/JJ prostaglandins/NNS (/( RR/NN 5.5/CD ,/, CI/NN 1.26-24.07/CD )/) ./.
P11687078A12
95/CD %/SYM confidence/NN intervals/NNS were/VBD used/VBN ./.
P11687084A23
There/EX is/VBZ a/DT possible/JJ reduction/NN in/IN the/DT severity/NN of/IN chronic/JJ lung/NN disease/NN (/( shortened/JJ duration/NN of/IN assisted/JJ ventilation/NN )/) ./.
P11687092A17
van/NNP Wassenaer/NNP 1997/CD found/VBD no/DT significant/JJ differences/NNS in/IN the/DT Bayley/NNP MDI/NN and/CC PDI/NN at/IN 24/CD months/NNS ,/, incidence/NN of/IN cerebral/JJ palsy/NN (/( RR/NN 0.72/CD ,/, 95/CD %/SYM CI/NN 0.28/CD ,/, 1.84/CD )/) ,/, death/NN and/CC cerebral/JJ palsy/NN (/( RR/NN 0.70/CD ,/, 95/CD %/SYM CI/NN 0.43/CD ,/, 1.14/CD )/) or/CC the/DT RAKIT/NN IQ/NN score/NN (/( WMD/NN -2.10/CD ,/, 95/CD %/SYM CI/NN -7.91/CD ,/, 3.71/CD )/) at/IN 5.7/CD years/NNS of/IN age/NN ./.
P11687098A08
Trial/NN quality/NN was/VBD scored/VBN by/IN the/DT Cochrane/NNP assessment/NN of/IN allocation/NN concealment/NN &/CC the/DT Jadad/NNP scale/NN of/IN methodological/JJ quality/NN ./.
P11687106A17
Manual/JJ muscle/NN testing/NN was/VBD assessed/VBN in/IN three/CD studies/NNS (/( 54/CD patients/NNS )/) ,/, with/IN 29/CD patients/NNS (/( 54/CD %/SYM )/) improving/NN in/IN at/IN least/JJS one/CD muscular/JJ district/NN during/IN study/NN treatment/NN versus/CC four/CD patients/NNS (/( 7/CD %/SYM )/) during/IN placebo/NN (/( odds/NNS ratio/NN [/( OR/CC ]/) 14.5/CD ,/, 95/CD %/SYM confidence/NN interval/NN [/( CI/NN ]/) 4.7-43.7/CD )/) ./.
P11687114A05
SELECTION/NN CRITERIA/NNS :/: Prospective/JJ randomised/JJ controlled/JJ trials/NNS (/( RCTs/NNS )/) which/WDT evaluated/VBD educational/JJ programmes/NNS for/IN the/DT prevention/NN of/IN foot/NN ulcers/NNS in/IN people/NNS with/IN diabetes/NN mellitus/NN ./.
P11687118A03
The/DT present/JJ reviews/NNS addresses/VBZ to/TO the/DT use/NN of/IN hot/JJ ,/, humid/NN air/NN in/IN common/JJ cold/NN ./.
P11687120A24
The/DT GnRH/NN antagonist/NN flexible/JJ regimen/NN should/MD be/VBP the/DT area/NN of/IN research/NN in/IN the/DT near/JJ future/NN ./.
P11687130A08
MAIN/JJ RESULTS/NNS :/: Three/CD trials/NNS were/VBD included/VBN ,/, two/CD based/VBN in/IN general/JJ practice/NN and/CC one/CD in/IN a/DT neurology/NN centre/NN ./.
P11687134A08
MAIN/JJ RESULTS/NNS :/: We/PRP found/VBD three/CD small/JJ trials/NNS (/( 50/CD patients/NNS )/) of/IN relaxation/NN therapy/NN ./.
P11687139A02
Treatment/NN is/VBZ readily/RB available/JJ and/CC puts/VBZ a/DT large/JJ demand/NN on/IN healthcare/NN budgets/NNS ./.
P11687142A13
Of/IN these/DT nine/CD trials/NNS ,/, four/CD were/VBD excluded/VBN ,/, two/CD at/IN further/JJ investigation/NN revealed/VBD a/DT lack/NN of/IN randomisation/NN and/CC two/CD included/VBD combined/JJ oral/JJ contraceptives/NNS that/WDT are/VBP now/RB discontinued/VBN due/JJ to/TO very/RB high/JJ oestrogen/NN content/NN ./.
P11687152A20
Details/NNS of/IN late/JJ morbidity/NN were/VBD sparse/JJ ./.
P11687159A18
The/DT results/NNS should/MD be/VBP viewed/VBN with/IN caution/NN as/IN patient/NN numbers/NNS are/VBP small/JJ ./.
P11687164A18
REVIEWER/NN 'S/POS CONCLUSIONS/NNS :/: There/EX is/VBZ a/DT need/NN for/IN evaluations/NNS of/IN interventions/NNS combining/VBG provider/NN training/NN and/CC patient/NN education/NN ,/, and/CC for/IN evaluations/NNS conducted/VBN in/IN developing/JJ countries/NNS ./.
P11687168A14
Positive/JJ urine/NN sample/NN for/IN cocaine/NN metabolites/NNS was/VBD the/DT main/JJ efficacy/NN outcome/NN ,/, with/IN no/DT significant/JJ results/NNS obtained/VBN regardless/RB the/DT type/NN of/IN antidepressant/NN ./.
P11687174A02
In/IN RA/NN this/PRP resulted/VBD in/IN the/DT development/NN of/IN the/DT Outcome/NN Measures/NNS in/IN Arthritis/NN Clinical/JJ Trials/NNS (/( OMERACT/NN )/) ,/, and/CC in/IN juvenile/JJ arthritis/NN the/DT Pediatric/JJ Rheumatology/NN International/JJ Trials/NNS Organization/NN (/( PRINTO/NN )/) core/NN set/NN ./.
P11687176A13
REVIEWER/NN 'S/POS CONCLUSIONS/NNS :/: :/: There/EX is/VBZ no/DT good/JJ evidence/NN to/TO recommend/VB statins/NNS for/IN reducing/NN the/DT risk/NN of/IN Alzheimer/NNP 's/POS disease/NN ./.
P11687180A29
Thus/RB there/EX is/VBZ insufficient/JJ evidence/NN on/IN the/DT total/JJ costs/NNS and/CC benefits/NNS of/IN treating/NN pre-dialysis/NN patients/NNS with/IN rHu/NN EPO/NN ./.
P11687187A12
MAIN/JJ RESULTS/NNS :/: Four/CD studies/NNS were/VBD included/VBN ./.
P11687193A20
There/EX were/VBD no/DT significant/JJ differences/NNS in/IN trials/NNS where/WRB participants/NNS had/VBD primary/JJ cocaine/NN dependence/NN or/CC had/VBD additional/JJ diagnosis/NN of/IN opioid/NN dependence/NN and/or/CC were/VBD in/IN methadone/NN maintenance/NN treatment/NN ./.
P11687198A12
The/DT pooled/JJ RR/NN for/IN remission/NN of/IN binge/NN episodes/NNS was/VBD 0.88/CD (/( 95/CD %/SYM CI/NN 0.83-0.93/CD ;/: p/NN </SYM 0,001/CD )/) favoring/VBG drugs/NNS ./.
P11695246A01
The/DT cyclooxygenase/NN (/( COX/NN )/) -2/CD selective/JJ inhibitors/NNS celecoxib/NN and/CC rofecoxib/NN have/VBP been/VBN found/VBN to/TO be/VB more/RB effective/JJ than/IN placebo/NN and/CC comparably/RB effective/JJ to/TO nonselective/JJ nonsteroidal/JJ anti-inflammatory/JJ drugs/NNS (/( NSAIDs/NNS )/) in/IN the/DT treatment/NN of/IN patients/NNS with/IN osteoarthritis/NN and/CC rheumatoid/JJ arthritis/NN ./.
P11699634A27
None/CD of/IN these/DT anticipated/JJ advances/NNS will/MD be/VBP achieved/VBN ,/, however/WRB ,/, in/IN the/DT absence/NN of/IN a/DT progressive/JJ ,/, third-party/NN payment/NN system/NN that/WDT acknowledges/VBZ its/PRP$ responsibility/NN to/TO compensate/VB providers/NNS adequately/RB to/TO ensure/VB that/IN the/DT next/JJ generation/NN of/IN conservative/JJ therapy/NN can/MD be/VBP enjoyed/VBN by/IN the/DT American/JJ people/NNS ./.
P11701099A48
Trials/NNS should/MD be/VBP undertaken/VBN in/IN community/NN settings/NNS to/TO ensure/VB the/DT generalisability/NN of/IN results/NNS ./.
P11701102A23
However/WRB ,/, power/NN was/VBD considerably/RB reduced/VBN for/IN smaller/JJR interactions/NNS ,/, which/WDT are/VBP much/RB more/RB likely/JJ in/IN practice/NN ./.
P11701786A05
Computer/NN database/NN searches/NNS were/VBD performed/VBN independently/RB by/IN two/CD investigators/NNS to/TO identify/VB all/DT potentially/RB relevant/JJ study/NN titles/NNS ./.
P11702861A16
Methods/NNS used/VBN to/TO determine/VB the/DT extent/NN of/IN resection/NN were/VBD subjective/JJ and/CC qualitative/JJ in/IN almost/RB all/DT studies/NNS ./.
P11708038A04
METHODOLOGY/NN :/: The/DT MEDLINE/NN ,/, EMBASE/NN ,/, Best/JJS Evidence/NN ,/, and/CC Cochrane/NNP Systematic/JJ Review/NN databases/NNS and/CC Internet/NN Web/NN sites/NNS were/VBD searched/VBN for/IN articles/NNS and/CC guidelines/NNS published/VBN between/IN January/NN 1980/CD and/CC May/NN 2001/CD to/TO identify/VB quality/NN indicators/NNS for/IN CAP/NN and/CC relevant/JJ evidence/NN ./.
P11711010A09
CONCLUSIONS/NNS :/: There/EX is/VBZ no/DT evidence/NN to/TO support/VB using/NN beta2-agonists/NNS in/IN children/NNS with/IN acute/JJ cough/NN and/CC no/DT evidence/NN of/IN airflow/NN obstruction/NN ./.
P11713849A02
Blood/NN pressure/NN management/NN remains/VBZ one/CD of/IN the/DT most/RBS cost-effective/JJ methods/NNS of/IN cardiovascular/JJ risk/NN factor/NN reduction/NN ./.
P11715181A21
The/DT current/JJ multicenter/NN prospective/JJ trials/NNS will/MD provide/VBP much/DT needed/JJ guidance/NN on/IN this/DT subject/NN ./.
P11720920A15
More/DT research/NN is/VBZ needed/VBN to/TO establish/VB more/DT evidence/NN regarding/VBG situations/NNS in/IN which/WDT teleadvice/NN is/VBZ beneficial/JJ and/CC efficient/JJ ./.
P11724098A06
Treatment/NN of/IN these/DT underlying/JJ etiologies/NNS should/MD be/VBP considered/VBN ./.
P11727406A09
The/DT patients/NNS for/IN whom/WP combination/NN therapy/NN is/VBZ most/RBS commonly/RB successful/JJ are/VBP those/PRP who/WP do/VBP not/RB achieve/VBP adequate/JJ glycemic/JJ control/NN using/VBG daytime/NN oral/JJ agents/NNS but/CC who/WP still/RB show/VBP some/DT evidence/NN of/IN responsiveness/NN to/TO the/DT medications/NNS ./.
P11728541A05
We/PRP calculated/VBD summary/NN estimates/NNS across/IN studies/NNS for/IN important/JJ efficacy/NN and/CC tolerability/NN parameters/NNS ,/, and/CC separately/RB summarised/VBD direct/JJ comparator/NN trials/NNS ./.
P11735631A11
Wide/JJ variability/NN in/IN ACE/NN inhibitor/NN use/NN is/VBZ noted/VBN ,/, with/IN higher/JJR rates/NNS consistently/RB reported/VBN among/IN patients/NNS having/VBG systolic/JJ dysfunction/NN confirmed/VBN by/IN an/DT objective/JJ assessment/NN --/: an/DT apparent/JJ minority/NN of/IN the/DT those/PRP having/VBG CHF/NN ./.
P11735713A10
For/IN diagnostic/JJ accuracy/NN ,/, sensitivity/NN was/VBD 0.81/CD to/TO 1.00/CD for/IN dermatologists/NNS and/CC 0.42/CD to/TO 1.00/CD for/IN PCPs/NNS ./.
P11747684A05
Medications/NNS analyzed/VBN include/VBP alendronate/NN ,/, either/CC 5/CD mg/NN //SYM day/NN or/CC 5/CD mg/NN //SYM day/NN ,/, followed/VBN by/IN 10/CD mg/NN //SYM day/NN ;/: raloxifene/NN ,/, 60/CD or/CC 120/CD mg/NN //SYM day/NN ;/: and/CC combination/NN hormone/NN replacement/NN therapy/NN (/( HRT/NN )/) of/IN four/CD different/JJ regimen/NN types/NNS ./.
P11756209A02
Thus/RB diabetes/NN not/RB only/RB increases/VBZ the/DT risk/NN of/IN coronary/JJ heart/NN disease/NN but/CC also/RB increases/VBZ the/DT case/NN fatality/NN rate/NN ,/, ensuring/VBG that/IN the/DT majority/NN of/IN patients/NNS die/VBP of/IN cardiovascular/JJ causes/NNS ,/, often/RB before/IN the/DT age/NN of/IN 50/CD years/NNS ./.
P11761209A07
All/DT randomised/JJ controlled/JJ trials/NNS (/( RCTs/NNS )/) descrbiing/VBG individuals/NNS with/IN diagnosed/JJ lateral/JJ epicondylitis/NN and/CC assessing/VBG the/DT use/NN of/IN an/DT orthotic/JJ device/NN as/IN a/DT treatment/NN strategy/NN were/VBD evaluatedfor/VBN inclusion/NN ./.
P11768834A10
Full/JJ reports/NNS were/VBD available/JJ for/IN only/RB 6/CD of/IN the/DT 11/CD studies/NNS ./.
P11772158A17
CONCLUSIONS/NNS :/: Paclitaxel/NN used/VBN in/IN combination/NN with/IN cisplatin/NN offers/VBZ survival/NN and/CC utility/NN gains/NNS versus/CC cyclophosphamide/NN plus/CC cisplatin/NN ,/, when/WRB used/VBN as/IN first-line/NN treatment/NN in/IN patients/NNS with/IN stage/NN III/CD or/CC IV/CD ovarian/JJ cancer/NN ./.
P11773571A24
Comparison/NN of/IN final/JJ videotape/NN interpretation/NN to/TO initial/JJ telemedicine/NN diagnosis/NN resulted/VBD in/IN 1/CD minor/JJ diagnostic/JJ change/NN (/( membranous/JJ versus/CC inlet/RB ventricular/JJ septal/JJ defect/NN )/) ./.
P11780589A03
In/IN the/DT United/JJ States/NNS alone/JJ ,/, the/DT uncontrolled/JJ epilepsy/NN represents/VBZ more/RB than/IN 500,000/CD people/NNS ./.
P11784221A05
Patients/NNS with/IN 2/CD or/CC more/DT cardiac/JJ risk/NN factors/NNS or/CC with/IN documented/JJ coronary/JJ artery/NN disease/NN were/VBD classified/VBN as/IN high/JJ risk/NN and/CC were/VBD considered/VBN eligible/JJ for/IN treatment/NN with/IN a/DT beta-blocker/NN if/IN they/PRP had/VBD no/DT obvious/JJ contraindications/NNS to/TO its/PRP$ use/NN ./.
P11789467A04
The/DT Dietary/JJ Supplement/NN and/CC Health/NN Education/NN Act/NN signed/VBN into/IN law/NN in/IN October/NN 1994/CD ,/, requires/VBZ no/DT proof/NN of/IN efficacy/NN ,/, no/DT demonstration/NN of/IN safety/NN ,/, and/CC sets/VBZ no/DT standards/NNS for/IN quality/NN control/NN for/IN the/DT products/NNS labeled/VBN as/IN "/`` supplements/NNS "/'' thereby/RB increasing/VBG the/DT risk/NN of/IN adverse/JJ effects/NNS of/IN these/DT herbs/NNS ./.
P11791816A03
To/TO investigate/VB the/DT effects/NNS of/IN exercise/NN training/NN upon/IN CHF/NN patients/NNS ,/, a/DT systematic/JJ literature/NN review/NN was/VBD carried/VBN out/RP of/IN trials/NNS (/( from/IN 1966/CD to/TO December/NN 2000/CD )/) which/WDT used/VBD as/IN their/PRP$ main/JJ outcome/NN measures/NNS the/DT effects/NNS of/IN exercise/NN training/NN upon/IN :/: (/( a/NN )/) physical/JJ performance/NN ;/: or/CC (/( b/NN )/) quality/NN of/IN life/NN ;/: or/CC (/( c/NN )/) morbidity/NN //SYM mortality/NN ./.
P11793629A03
STUDY/NN SELECTION/NN AND/CC DATA/NNS EXTRACTION/NN :/: All/PRP of/IN the/DT articles/NNS identified/VBN from/IN the/DT data/NNS sources/NNS were/VBD evaluated/VBN ./.
P11802753A13
Continued/JJ efforts/NNS should/MD be/VBP made/VBN in/IN all/DT settings/NNS to/TO optimize/VB the/DT use/NN of/IN antithrombotic/JJ therapy/NN among/IN persons/NNS at/IN an/DT elevated/JJ risk/NN of/IN atherothrombotic/JJ events/NNS ./.
P11809427A06
Total/JJ cholesterol/NN and/CC apolipoprotein/NN B/NN reductions/NNS and/CC apolipoprotein/NN A-I/NN increases/NNS were/VBD also/RB greater/JJR with/IN rosuvastatin/NN ;/: triglyceride/NN reductions/NNS were/VBD similar/JJ ./.
P11813503A28
Despite/IN a/DT poor/JJ virologic/JJ response/NN for/IN some/PRP of/IN them/PRP ,/, a/DT rise/NN in/IN CD4/NN cell/NN count/NN was/VBD observed/VBN for/IN all/DT patients/NNS during/IN the/DT study/NN period/NN ./.
P11817979A04
In/IN general/NN ,/, quinapril/NN provided/VBD similar/JJ blood/NN pressure/NN control/NN to/TO other/JJ standard/JJ antihypertensive/JJ therapies/NNS including/VBG other/JJ ACE/NN inhibitors/NNS ,/, calcium/NN antagonists/NNS and/CC beta-adrenoceptor/NN antagonists/NNS in/IN comparative/JJ clinical/JJ trials/NNS ./.
P11820489A06
First/RB ,/, the/DT topic/NN should/MD be/VBP of/IN common/JJ interest/NN and/CC relevance/NN to/TO family/NN practice/NN ./.
P11827558A06
Quinupristin/NN //SYM dalfopristin/NN is/VBZ a/DT streptogramin/NN ,/, which/WDT impairs/VBZ bacterial/JJ protein/NN synthesis/NN at/IN both/CC early/JJ peptide/NN chain/NN elongation/NN and/CC late/JJ peptide/NN chain/NN extrusion/NN steps/NNS ./.
P11832671A11
A/DT hybrid/NN strategy/NN using/VBG greater-than-or-equal15/NN %/SYM risk/NN ,/, or/CC 10/CD %/SYM to/TO 14/CD %/SYM risk/NN with/IN a/DT parental/JJ history/NN of/IN premature/JJ coronary/JJ heart/NN disease/NN or/CC treated/JJ ,/, controlled/JJ hypertension/NN ,/, identified/VBD 20/CD %/SYM for/IN treatment/NN :/: n=2646/NN ;/: events/NNS expected/VBN to/TO be/VB prevented=97/NN ;/: number/NN needed/VBN to/TO treat=27/NN ;/: sensitivity=0.44/NN (/( 0.40-0.47/CD )/) ;/: sensitivity/NN when/WRB LDL-C/NN was/VBD greater-than-or-equal130/NN mg/NN //SYM dL=0.66/NN ./.
P11837527A01
BACKGROUND/NN :/: Dysarthria/NN is/VBZ a/DT common/JJ sequel/NN of/IN nonprogressive/JJ brain/NN damage/NN (/( typically/RB stroke/NN and/CC traumatic/JJ brain/NN damage/NN )/) ./.
P11840109A03
SUMMARY/NN OF/IN BACKGROUND/NN DATA/NNS :/: Whiplash/NN constitutes/VBZ a/DT considerable/JJ problem/NN in/IN health/NN care/NN ./.
P11845635A02
They/PRP are/VBP not/RB absolute/JJ care/NN directives/NNS ,/, but/CC are/VBP intended/VBN to/TO facilitate/VB individualized/JJ decision/NN making/NN related/VBN to/TO patient/NN care/NN situations/NNS ./.
P11850611A14
For/IN chronic/JJ treatment/NN of/IN VTE/NN ,/, warfarin/NN is/VBZ the/DT treatment/NN of/IN choice/NN (/( INR/NN 2.0-3.0/CD )/) ,/, also/RB in/IN the/DT elderly/NN ./.
P11858225A03
High/JJ incidence/NN of/IN alcohol-impaired/JJ driving/NN ./.
P11862245A14
Future/JJ trials/NNS comparing/VBG efficacy/NN of/IN agents/NNS in/IN high/JJ risk/NN patients/NNS and/CC rigorously/RB evaluating/VBG thromboembolic/JJ events/NNS will/MD allow/VBP unconditional/JJ recommendations/NNS ./.
P11865567A58
DISCUSSION/NN :/: The/DT diversity/NN of/IN psychiatric/JJ morbidity/NN in/IN SLE/NN and/CC SS/NN may/MD be/VBP due/JJ to/TO differences/NNS in/IN patient/NN selection/NN and/CC a/DT lack/NN of/IN uniform/JJ clinical/JJ criteria/NNS ./.
P11869563A24
Given/VBN the/DT lower/JJR complication/NN rate/NN of/IN the/DT SHS/NN in/IN comparison/NN with/IN intramedullary/JJ nails/NNS ,/, it/PRP appears/VBZ that/IN for/IN trochanteric/NN fractures/NNS the/DT SHS/NN is/VBZ superior/JJ ./.
P11869578A04
It/PRP is/VBZ also/RB recommended/VBN for/IN neonates/NNS with/IN post-extubation/NN tracheal/JJ obstruction/NN and/CC stridor/NN in/IN neonatal/JJ and/CC respiratory/JJ textbooks/NNS and/CC reviews/NNS ./.
P11869583A13
Continuous/JJ measures/NNS of/IN outcome/NN were/VBD combined/VBN using/VBG standardised/JJ mean/NN differences/NNS ./.
P11869591A05
SELECTION/NN CRITERIA/NNS :/: Randomised/JJ trials/NNS comparing/VBG intravenous/JJ immunoglobulin/NN (/( monoclonal/JJ or/CC polyclonal/JJ )/) with/IN placebo/NN or/CC no/DT intervention/NN ,/, in/IN patients/NNS with/IN bacterial/JJ sepsis/NN or/CC septic/JJ shock/NN ./.
P11869600A08
Eligible/JJ studies/NNS needed/VBD to/TO assess/VB at/IN least/JJS one/CD of/IN the/DT outcome/NN variables/NNS defined/VBN a/FW priori/FW for/IN this/DT systematic/JJ review/NN ./.
P11869609A01
BACKGROUND/NN :/: Lateral/JJ epicondylitis/NN (/( tennis/NN elbow/NN )/) is/VBZ a/DT frequently/RB reported/JJ condition/NN ./.
P11869615A16
REVIEWER/NN 'S/POS CONCLUSIONS/NNS :/: There/EX is/VBZ weak/JJ and/CC unreliable/JJ evidence/NN that/IN the/DT absorbed/JJ drug/NN ,/, ketoconazole/NN ,/, may/MD eradicate/VBP oral/JJ candidiasis/NN and/CC that/IN a/DT higher/JJR dose/NN of/IN the/DT partially/RB absorbed/JJ drug/NN ,/, clotrimazole/NN ,/, may/MD give/VBP greater/JJR benefit/NN than/IN a/DT lower/JJR 10mg/NN dose/NN ,/, however/WRB ,/, researchers/NNS may/MD wish/VBP to/TO prevent/VB rather/RB than/IN treat/VB oral/JJ candidiasis/NN ./.
P11869624A15
In/IN most/DT cases/NNS ,/, the/DT first/PRP or/CC corresponding/JJ author/NN of/IN each/DT included/JJ trial/NN was/VBD contacted/VBN for/IN additional/JJ information/NN ./.
P11869629A17
Large/JJ clinical/JJ trials/NNS underway/VBP or/CC about/RB to/TO commence/VB are/VBP likely/RB to/TO contribute/VB valuable/JJ further/JJ information/NN to/TO clarify/VB these/DT areas/NNS of/IN clinical/JJ uncertainty/NN ./.
P11869636A05
SELECTION/NN CRITERIA/NNS :/: Randomised/JJ trials/NNS in/IN children/NNS and/CC adults/NNS comparing/VBG Fluticasone/NN to/TO either/CC Beclomethasone/NN or/CC Budesonide/NN in/IN the/DT treatment/NN of/IN chronic/JJ asthma/NN ./.
P11869641A07
DATA/NNS COLLECTION/NN AND/CC ANALYSIS/NN :/: Two/CD reviewers/NNS independently/RB selected/VBD trials/NNS for/IN inclusion/NN and/CC extracted/VBD data/NNS ./.
P11869648A11
MAIN/JJ RESULTS/NNS :/: The/DT initial/JJ search/NN retrieved/VBD 95/CD studies/NNS ./.
P11869655A16
~bullet~There/EX is/VBZ no/DT good/JJ evidence/NN comparing/VBG the/DT Epley/NNP manoeuvre/NN with/IN other/JJ physical/JJ ,/, medical/JJ or/CC surgical/JJ therapy/NN for/IN posterior/JJ canal/NN BPPV/NN ./.
P11869662A04
SEARCH/NN STRATEGY/NN :/: We/PRP searched/VBD the/DT Cochrane/NNP Controlled/JJ Trials/NNS Register/NN ,/, issue/NN 1/CD ,/, 2001/CD ,/, MEDLINE/NN 1966/CD to/TO 2001/CD ,/, EMBASE/NN 1980/CD to/TO 2001/CD ,/, CANCERCD/NN 1980/CD to/TO 2001/CD ,/, Science/NN Citation/NN Index/NN 1991/CD to/TO 2001/CD ,/, CINAHL/NN 1982/CD to/TO 2001/CD ,/, as/RB well/RB as/IN sources/NNS of/IN grey/JJ literature/NN ./.
P11869665A15
The/DT percent/NN overall/JJ survival/NN at/IN 1/CD ,/, 2/CD ,/, 5/CD ,/, and/CC 10/CD years/NNS for/IN the/DT early/JJ treatment/NN group/NN was/VBD 88/CD %/SYM ,/, 73/CD %/SYM ,/, 44/CD %/SYM ,/, and/CC 18/CD %/SYM ./.
P11869669A02
Lateral/JJ elbow/NN pain/NN ,/, or/CC tennis/NN elbow/NN ,/, is/VBZ a/DT common/JJ condition/NN causing/VBG pain/NN in/IN the/DT elbow/NN and/CC forearm/NN and/CC lack/NN of/IN strength/NN and/CC function/NN of/IN the/DT elbow/NN and/CC wrist/NN ./.
P11869676A03
SEARCH/NN STRATEGY/NN :/: We/PRP searched/VBD the/DT Cochrane/NNP Airways/NNS Group/NN trials/NNS register/NN ,/, electronic/JJ reference/NN databases/NNS ,/, UK/NNP National/JJ Research/NN Register/NN ,/, bibliographies/NNS of/IN included/JJ studies/NNS ,/, and/CC contacted/VBD pharmaceutical/JJ companies/NNS ./.
P11872916A02
The/DT realization/NN that/IN atherosclerosis/NN is/VBZ an/DT inflammatory/JJ disease/NN has/VBZ led/VBN to/TO a/DT search/NN for/IN new/JJ stroke/NN and/CC cardiovascular/JJ disease/NN risk/NN factors/NNS and/CC treatments/NNS ./.
P11884907A10
A/DT fixed/JJ effects/NNS model/NN was/VBD used/VBN throughout/RB for/IN continuous/JJ variables/NNS ,/, except/IN where/WRB heterogeneity/NN existed/VBD ,/, in/IN which/DT case/NN ,/, a/DT random/JJ effects/NNS model/NN was/VBD used/VBN ./.
P11888339A06
Various/JJ migraine/NN surveys/NNS have/VBP indicated/VBN that/IN a/DT rapid/JJ onset/NN of/IN therapeutic/JJ effect/NN is/VBZ a/DT highly/RB desirable/JJ attribute/NN of/IN an/DT antimigraine/JJ drug/NN ./.
P11899566A04
Owing/JJ to/TO their/PRP$ age/NN ,/, the/DT elderly/NN are/VBP more/RB afflicted/VBN with/IN chronic/JJ diseases/NNS ,/, including/VBG coronary/JJ artery/NN disease/NN ./.
P11907914A04
DATA/NNS EXTRACTION/NN :/: Data/NNS extraction/NN and/CC quality/NN assessment/NN were/VBD performed/VBN in/IN duplicate/NN ,/, with/IN assistance/NN of/IN a/DT manual/NN ./.
P11918516A04
Abstracts/NNS presented/VBN at/IN infectious/JJ diseases/NNS and/CC critical/JJ care/NN meetings/NNS were/VBD also/RB reviewed/VBN ./.
P11923602A03
The/DT past/JJ decade/NN has/VBZ witnessed/VBN the/DT development/NN of/IN a/DT variety/NN of/IN locoregional/JJ therapies/NNS for/IN HCC/NN ./.
P11925374A14
However/WRB ,/, this/DT study/NN failed/VBD to/TO recruit/VB the/DT planned/JJ number/NN of/IN participants/NNS and/CC was/VBD consequently/RB underpowered/VBN ./.
P11929334A05
Among/IN patients/NNS with/IN acute/JJ ST/NN elevation/NN MI/NN ,/, randomised/JJ trials/NNS have/VBP demonstrated/VBN bivalirudin/NN to/TO be/VB significantly/RB more/RB effective/JJ than/IN heparin/NN in/IN improving/NN early/JJ patency/NN in/IN patients/NNS receiving/VBG thrombolytic/JJ therapy/NN with/IN streptokinase/NN ./.
P11939601A04
IVIG/NN is/VBZ U.S/NN ./.
P11959890A08
Nevertheless/RB ,/, by/IN exploring/NN the/DT relative/JJ effectiveness/NN of/IN the/DT different/JJ intervention/NN strategies/NNS for/IN each/DT outcome/NN and/CC follow-up/NN period/NN ,/, we/PRP suggest/VBP the/DT specific/JJ therapies/NNS that/WDT should/MD be/VBP considered/VBN for/IN further/JJ investigation/NN ./.
P11967397A06
RESULTS/NNS :/: Major/JJ deficiencies/NNS in/IN treatment/NN that/WDT were/VBD identified/VBN include/VBP inappropriate/JJ dosing/NN with/IN antipsychotic/JJ agents/NNS ,/, underutilization/NN of/IN adjunctive/JJ antidepressant/NN therapy/NN ,/, very/RB low/JJ rates/NNS of/IN prescription/NN of/IN psychosocial/JJ interventions/NNS and/CC lack/NN of/IN continuity/NN between/IN inpatient/NN and/CC outpatient/JJ settings/NNS ./.
P11967417A01
BACKGROUND/NN :/: "/`` Systematic/JJ reviews/NNS "/'' have/VBP come/VBP to/TO be/VB recognized/VBN as/IN the/DT most/RBS rigorous/JJ method/NN of/IN summarizing/NN confusing/JJ and/CC often/RB contradictory/JJ primary/JJ research/NN in/IN a/DT transparent/JJ and/CC reproducible/JJ manner/NN ./.
P11967432A03
AIMS/NNS OF/IN THE/DT STUDY/NN :/: The/DT scope/NN of/IN this/DT review/NN was/VBD to/TO examine/VB studies/NNS published/VBN in/IN the/DT international/JJ literature/NN to/TO describe/VB and/CC compare/VB the/DT social/JJ costs/NNS of/IN depression/NN in/IN various/JJ countries/NNS ./.
P11967455A22
IMPLICATIONS/NNS FOR/IN FURTHER/JJ RESEARCH/NN :/: Further/RB research/NN that/WDT improves/VBZ our/PRP$ understanding/NN of/IN how/WRB decisions/NNS regarding/VBG provider/NN choice/NN ,/, concurrent/JJ psychotherapy/NN ,/, and/CC drug/NN choice/NN are/VBP made/VBN will/MD improve/VBP our/PRP$ understanding/NN of/IN the/DT effects/NNS treatment/NN choices/NNS on/IN the/DT cost-effectiveness/NN of/IN depression/NN care/NN ./.
P11978164A06
Clinical/JJ investigations/NNS were/VBD evaluated/VBN for/IN design/NN ,/, sample/NN size/NN ,/, diagnosis/NN ,/, duration/NN ,/, and/CC outcome/NN ./.
P11982721A25
The/DT response/NN is/VBZ durable/JJ in/IN approximately/RB 80/CD %/SYM of/IN responders/NNS ./.
P11991548A01
OBJECTIVE/NN :/: This/DT article/NN reviews/VBZ the/DT recommendations/NNS by/IN the/DT World/NN Health/NN Organization/NN 's/POS new/JJ guidelines/NNS ,/, "/`` Allergic/JJ Rhinitis/NN and/CC Its/PRP$ Impact/NN on/IN Asthma/NN "/'' (/( ARIA/NN )/) ,/, and/CC the/DT paradigm/NN for/IN treating/NN allergic/JJ rhinitis/NN based/VBN on/IN disease/NN classification/NN ./.
P11993293A32
Few/JJ schools/NNS screen/VBP for/IN processing/JJ problems/NNS ,/, including/VBG auditory/JJ and/CC visual/JJ motor/NN processing/JJ problems/NNS ,/, processing/JJ speed/NN ,/, comprehension/NN ,/, and/CC short-term/NN and/CC long-term/NN memory/NN problems/NNS ./.
P12004249A04
DATA/NNS SUMMARY/NN :/: Taken/VBN en/FW toto/FW ,/, the/DT data/NNS suggest/VBP that/IN NE/NN could/MD contribute/VBP to/TO ALI/NN and/CC endothelial/JJ cell/NN injury/NN that/WDT is/VBZ relevant/JJ to/TO ALI/NN ./.
P12011590A01
Although/IN the/DT manifestations/NNS of/IN sickle/JJ cell/NN disease/NN (/( SCD/NN )/) do/VBP not/RB typically/RB necessitate/VBP critical/JJ care/NN management/NN ,/, several/JJ life-threatening/JJ complications/NNS may/MD require/VBP admission/NN to/TO the/DT pediatric/JJ intensive/JJ care/NN unit/NN ./.
P12017503A04
DATA/NNS EXTRACTION/NN :/: All/DT titles/NNS (/( 4397/CD )/) ,/, articles/NNS ,/, and/or/CC abstracts/NNS (/( 1362/CD )/) were/VBD evaluated/VBN by/IN 2/CD independent/JJ reviewers/NNS who/WP extracted/VBD data/NNS on/IN study/NN design/NN and/CC quality/NN ,/, sample/NN size/NN ,/, type/NN of/IN intervention/NN ,/, and/CC outcomes/NNS ./.
P12020339A01
CONTEXT/NN :/: Complications/NNS of/IN atherosclerosis/NN cause/VBP most/DT morbidity/NN and/CC mortality/NN in/IN patients/NNS with/IN diabetes/NN mellitus/NN ./.
P12022907A12
Bivalirudin/NN has/VBZ also/RB induced/VBN early/JJ patency/NN in/IN patients/NNS with/IN myocardial/JJ infarction/NN in/IN combination/NN with/IN streptokinase/NN ,/, but/CC its/PRP$ use/NN with/IN newer/JJR thrombolytics/NNS needs/VBZ to/TO be/VB studied/VBN ./.
P12027776A16
Treatment/NN should/MD be/VBP individualised/VBN for/IN each/DT patient/NN ./.
P12034414A04
Two/CD reviewers/NNS independently/RB extracted/VBD data/NNS from/IN the/DT studies/NNS ./.
P12040543A09
CONCLUSIONS/NNS :/: Further/JJ work/NN is/VBZ needed/VBN to/TO create/VB operational/JJ definitions/NNS and/CC to/TO pilot/NN test/VB the/DT selected/JJ measures/NNS ./.
P12045080A02
METHODS/NNS :/: The/DT review/NN followed/VBD the/DT methodology/NN of/IN systematic/JJ reviews/NNS and/CC was/VBD facilitated/VBN through/IN the/DT use/NN of/IN a/DT structured/JJ template/NN ,/, a/DT companion/NN explanatory/JJ piece/NN ,/, and/CC a/DT grading/JJ and/CC methodological/JJ scoring/JJ system/NN based/VBN on/IN published/JJ criteria/NNS for/IN critical/JJ appraisal/NN ./.
P12049028A32
NATIONAL/JJ IMPLEMENTATION/NN OF/IN THE/DT PRIMARY/JJ CARE/NN RESEARCH/NN TEAM/NN ASSESSMENT/NN :/: The/DT pilot/NN project/NN has/VBZ been/VBN very/RB successful/JJ and/CC recommendations/NNS have/VBP been/VBN made/VBN to/TO progress/VB to/TO a/DT UK/NNP scheme/NN ./.
P12053714A05
The/DT motion/NN studies/NNS afforded/VBN by/IN cineangiography/NN also/RB permitted/VBD dynamic/JJ visualization/NN of/IN the/DT contracting/JJ ventricle/NN which/WDT led/VBD to/TO the/DT concept/NN of/IN regional/JJ wall/NN motion/NN abnormalities/NNS being/NN characteristic/JJ of/IN CAD/NN and/CC provided/VBD some/PRP of/IN our/PRP$ earliest/JJS understanding/NN of/IN left/JJ ventricular/JJ dysfunction/NN ./.
P12057986A04
At/IN the/DT time/NN of/IN enrollment/NN ,/, patients/NNS were/VBD stratified/VBN according/VBG to/TO diabetes/NN status/NN ./.
P12064194A14
The/DT findings/NNS of/IN both/CC the/DT SPEED/NN and/CC TIMI/NN 14/CD trials/NNS were/VBD incorporated/VBN into/IN the/DT design/NN of/IN the/DT large/JJ (/( approximately/RB 17,000/CD patients/NNS )/) GUSTO/NN V/CD mortality/NN trial/NN ,/, which/WDT compared/VBD standard/JJ reteplase/NN therapy/NN with/IN abciximab/NN plus/CC low-dose/NN reteplase/NN ./.
P12065798A03
Data/NNS from/IN recently/RB completed/JJ phase/NN III/CD adjuvant/NN trials/NNS and/CC worldwide/JJ consensus/NN conferences/NNS document/VBP the/DT benefits/NNS of/IN adjuvant/NN therapy/NN in/IN improving/NN disease-free/JJ survival/NN and/CC overall/JJ survival/NN for/IN patients/NNS diagnosed/VBN with/IN invasive/JJ breast/NN cancer/NN >/SYM 1.0/CD cm/NN in/IN size/NN ./.
P12072654A14
SUMMARY/NN :/: Among/IN the/DT multitude/NN of/IN oral/JJ ,/, intravesical/JJ ,/, interventional/JJ and/CC complementary/JJ treatments/NNS suggested/VBN few/JJ studies/NNS have/VBP high/JJ levels/NNS of/IN evidence/NN ./.
P12075559A04
We/PRP assess/VBP the/DT evidence/NN for/IN the/DT use/NN of/IN apheresis/NN ,/, the/DT optimal/JJ schedules/NNS for/IN apheresis/NN ,/, and/CC the/DT replacement/NN solutions/NNS used/VBN ,/, based/VBN on/IN randomized/JJ controlled/JJ trials/NNS ./.
P12076380A01
BACKGROUND/NN :/: Electroconvulsive/NN therapy/NN (/( ECT/NN )/) involves/VBZ the/DT induction/NN of/IN a/DT seizure/NN (/( fit/NN )/) for/IN therapeutic/JJ purposes/NNS by/IN the/DT administration/NN of/IN a/DT variable/JJ frequency/NN electrical/JJ stimulus/NN shock/NN via/IN electrodes/NNS applied/VBN to/TO the/DT scalp/NN ./.
P12076389A07
Due/JJ to/TO the/DT variable/JJ methods/NNS of/IN collecting/NN and/CC presenting/NN outcome/NN data/NNS ,/, no/DT statistical/JJ summary/NN measure/NN was/VBD calculated/VBN ./.
P12076395A06
This/PRP included/VBD searches/NNS of/IN the/DT Oxford/NNP Database/NN of/IN Perinatal/JJ trials/NNS ,/, Cochrane/NNP Controlled/JJ Trials/NNS Register/NN (/( Cochrane/NNP Library/NN ,/, Issue/NN 4/CD ,/, 2001/CD )/) ,/, MEDLINE/NN (/( 1966-January/NN 2002/CD )/) ,/, EMBASE/NN ,/, CINAHL/NN (/( 1982-January/NN 2002/CD )/) ,/, previous/JJ reviews/NNS including/VBG cross/NN references/NNS ,/, abstracts/NNS ,/, conferences/NNS and/CC symposia/NN proceedings/NNS ,/, expert/NN informants/NNS ,/, journal/NN hand/NN searching/NN mainly/RB in/IN the/DT English/JJ language/NN ./.
P12076403A06
(/( 2/CD )/) Women/NNS defined/VBN as/IN high/JJ risk/NN of/IN hypertensive/JJ disorders/NNS of/IN pregnancy/NN ./.
P12076407A08
DATA/NNS COLLECTION/NN AND/CC ANALYSIS/NN :/: All/DT trials/NNS ,/, judged/VBN as/IN fitting/NN the/DT selection/NN criteria/NNS by/IN two/CD reviewers/NNS ,/, were/VBD independently/RB assessed/VBN by/IN two/CD reviewers/NNS for/IN methodological/JJ quality/NN by/IN use/NN of/IN an/DT 11/CD item/NN checklist/NN ./.
P12076411A11
We/PRP performed/VBD meta-analyses/NNS with/IN Review/NN Manager/NN 4.1/CD software/NN using/VBG a/DT fixed/JJ effects/NNS model/NN ./.
P12076414A27
The/DT pharmacology/NN and/CC toxicology/NN of/IN melatonin/NN needs/VBZ systematic/JJ study/NN ,/, and/CC routine/JJ pharmaceutical/JJ quality/NN control/NN of/IN melatonin/NN products/NNS must/MD be/VBP established/VBN ./.
P12076418A22
There/EX is/VBZ also/RB insufficient/JJ evidence/NN to/TO determine/VB the/DT effects/NNS of/IN early/JJ weight/NN bearing/NN after/IN the/DT internal/JJ fixation/NN of/IN an/DT intracapsular/JJ proximal/JJ femoral/JJ fracture/NN ./.
P12076423A22
Also/RB ,/, no/DT difference/NN in/IN mean/NN improvement/NN on/IN the/DT disability/NN scale/NN was/VBD found/VBN at/IN two/CD weeks/NNS (/( effect/NN size/NN -0.12/CD ,/, 95/CD %/SYM confidence/NN interval/NN -0.68/CD to/TO 0.45/CD )/) or/CC six/CD weeks/NNS (/( effect/NN size/NN -0.07/CD ,/, 95/CD %/SYM confidence/NN interval/NN -0.63/CD to/TO 0.50/CD )/) between/IN prednisolone/NN and/CC intravenous/JJ immunoglobulin/NN ./.
P12076426A05
SEARCH/NN STRATEGY/NN :/: The/DT following/JJ databases/NNS were/VBD searched/VBN :/: MEDLINE/NN ,/, Psyclit/NN ,/, EMBASE/NN ,/, Science/NN Citation/NN Index/NN ,/, Social/JJ Science/NN Citation/NN Index/NN ,/, CINAHL/NN ,/, Cochrane/NNP Controlled/JJ Trials/NNS Register/NN (/( CCTR/NN )/) and/CC the/DT Cochrane/NNP Heart/NN Group/NN 's/POS specialised/JJ register/NN from/IN 1985/CD to/TO July/NN 2001/CD ./.
P12076431A07
DATA/NNS COLLECTION/NN AND/CC ANALYSIS/NN :/: One/CD reviewer/NN assessed/VBD potentially/RB relevant/JJ studies/NNS for/IN inclusion/NN and/CC undertook/VBD data/NNS extraction/NN ./.
P12076435A10
Endolaryngeal/JJ resection/NN of/IN early/JJ glottic/JJ tumours/NNS is/VBZ becoming/VBG more/RB common/JJ and/CC a/DT well/RB designed/JJ multicentre/NN RCT/NN is/VBZ warranted/VBN ./.
P12076440A14
In/IN the/DT two/CD trials/NNS with/IN adequate/JJ allocation/NN concealment/NN ,/, death/NN was/VBD more/RB common/JJ in/IN the/DT anticonvulsant/JJ group/NN (/( Relative/JJ Risk/NN 2.0/CD ;/: 95/CD %/SYM confidence/NN interval/NN 1.20/CD to/TO 3.33/CD ;/: fixed/JJ effect/NN model/NN )/) ./.
P12076445A03
The/DT major/JJ difficulty/NN with/IN IPPV/NN is/VBZ that/IN it/PRP is/VBZ invasive/JJ ,/, resulting/VBG in/IN airway/NN and/CC lung/NN injury/NN and/CC contributing/VBG to/TO the/DT development/NN of/IN chronic/JJ lung/NN disease/NN ./.
P12076453A05
The/DT hallmark/NN of/IN this/DT condition/NN ,/, is/VBZ a/DT massive/JJ shift/NN of/IN fluid/NN from/IN the/DT intra-vascular/JJ compartment/NN to/TO the/DT third/JJ space/NN resulting/VBG in/IN profound/JJ intra-vascular/JJ depletion/NN and/CC hemoconcentration/NN ./.
P12076456A13
Analysis/NN included/VBD haloperidol/NN treated/JJ patients/NNS ,/, compared/VBN with/IN placebo/NN MAIN/JJ RESULTS/NNS :/: The/DT five/CD included/JJ trials/NNS led/VBD to/TO the/DT following/JJ results/NNS :/: 1/CD ./.
P12076461A03
Metformin/NN ,/, however/WRB ,/, is/VBZ thought/VBN to/TO increase/VB the/DT risk/NN of/IN lactic/JJ acidosis/NN ,/, and/CC is/VBZ considered/VBN to/TO be/VB contraindicated/VBN in/IN many/DT chronic/JJ hypoxemic/JJ conditions/NNS that/WDT may/MD be/VBP associated/VBN with/IN lactic/JJ acidosis/NN ,/, such/JJ as/IN cardiovascular/JJ ,/, renal/JJ ,/, hepatic/JJ and/CC pulmonary/JJ disease/NN ,/, and/CC advancing/JJ age/NN ./.
P12076468A04
Evidence/NN is/VBZ required/VBN as/IN to/TO the/DT safest/JJS and/CC most/RBS effective/JJ means/NNS of/IN preventing/NN chest/NN tube/NN blockage/NN and/CC preventing/NN cardiac/JJ tamponade/NN ./.
P12076475A11
Initial/JJ treatment/NN was/VBD conservative/JJ ,/, involving/VBG plaster/NN cast/NN immobilisation/NN ,/, in/IN all/PRP but/CC 20/CD patients/NNS whose/WDT fractures/NNS were/VBD fixed/VBN surgically/RB ./.
P12076479A14
Regarding/VBG the/DT studies/NNS that/WDT compare/VBP methadone/NN with/IN other/JJ opioid/NN agonists/NNS ,/, in/IN Sorensen/NNP 1982/CD methadyl/NN acetate/NN performed/VBD similarly/RB to/TO methadone/NN on/IN most/DT process/NN and/CC outcome/NN measures/NNS ,/, while/IN in/IN Tennant/NNP 1975/CD ,/, methadone/NN reduced/VBD severity/NN of/IN withdrawal/NN and/CC had/VBD fewer/JJR drop-outs/NNS than/IN did/VBD a/DT propoxyphene/NN group/NN ./.
P12076484A14
However/WRB ,/, the/DT effectiveness/NN of/IN the/DT '/`` long-short/JJ '/'' course/NN (/( from/IN 28/CD weeks/NNS in/IN pregnancy/NN for/IN the/DT mother/NN and/CC for/IN the/DT baby/NN until/IN 3/CD days/NNS old/NN )/) and/CC the/DT '/`` short-long/JJ '/'' course/NN (/( from/IN 35/CD weeks/NNS in/IN pregnancy/NN for/IN the/DT mother/NN and/CC for/IN the/DT baby/NN until/IN 6/CD weeks/NNS old/NN )/) did/VBD not/RB differ/VBP from/IN that/PRP of/IN the/DT '/`` long-long/JJ '/'' course/NN ./.
P12076491A01
BACKGROUND/NN :/: Public/JJ concerns/NNS regarding/VBG the/DT safety/NN of/IN transfused/JJ blood/NN have/VBP prompted/VBN re-consideration/NN of/IN the/DT indications/NNS for/IN the/DT transfusion/NN of/IN allogeneic/JJ red/JJ cells/NNS (/( blood/NN from/IN an/DT unrelated/JJ donor/NN )/) ,/, and/CC a/DT range/NN of/IN techniques/NNS designed/VBN to/TO minimise/VB transfusion/NN requirements/NNS ./.
P12076498A03
Hence/RB ,/, there/EX may/MD be/VBP a/DT role/NN for/IN some/PRP of/IN these/DT drugs/NNS in/IN the/DT treatment/NN of/IN Alzheimer/NNP 's/POS disease/NN ./.
P12076503A04
SEARCH/NN STRATEGY/NN :/: We/PRP searched/VBD the/DT Musculoskeletal/JJ Review/NN Group/NN 's/POS trials/NNS register/NN database/NN ,/, the/DT Cochrane/NNP Clinical/JJ Trials/NNS Register/NN (/( Cochrane/NNP Library/NN issue/NN 2/CD ,/, 2001/CD )/) ,/, MEDLINE/NN ,/, CINAHL/NN ,/, EMBASE/NN and/CC SCISEARCH/NN up/IN to/TO June/NN 2001/CD ./.
P12082187A02
A/DT number/NN of/IN procedural/JJ and/CC patient/NN factors/NNS have/VBP been/VBN shown/VBN to/TO predict/VB the/DT occurrence/NN of/IN SAT/NN ,/, including/VBG longer/JJR stent/NN length/NN ,/, smaller/JJR minimum/NN luminal/JJ diameter/NN ,/, persistent/JJ dissection/NN ,/, multivessel/NN intervention/NN ,/, and/CC possibly/RB acute/JJ coronary/JJ syndrome/NN (/( ACS/NN )/) presentation/NN ./.
P12086276A16
While/IN 15/CD %/SYM were/VBD current/JJ smokers/NNS ,/, 56/CD %/SYM were/VBD ex-smokers/NNS ./.
P12086558A02
DATA/NNS SOURCES/NNS :/: Literature/NN search/NN strategy/NN involved/VBN using/NN MEDLINE/NN (/( 1966-July/NN 2001/CD )/) and/CC AIDSLINE/NN (/( MEDSCAPE/NN )/) databases/NNS (/( up/IN to/TO July/NN 2001/CD )/) ./.
P12092641A08
Information/NN was/VBD then/RB organized/VBN and/CC correlated/VBN in/IN order/NN to/TO provide/VB a/DT detailed/JJ description/NN of/IN the/DT key/JJ conditions/NNS and/CC their/PRP$ interrelatedness/NN ./.
P12093715A11
Limited/JJ data/NNS exist/VBP for/IN ED-based/JJ practice/NN ,/, but/CC ,/, based/VBN on/IN the/DT burden/NN of/IN disease/NN ,/, relative/JJ ease/NN of/IN intervention/NN ,/, and/CC likely/JJ efficacy/NN ,/, routine/JJ screening/NN of/IN all/DT patients/NNS for/IN tobacco/NN use/NN and/CC referral/NN of/IN smokers/NNS to/TO primary/JJ care/NN and/CC cessation/NN programs/NNS are/VBP recommended/VBN ./.
P12096151A09
No/DT meta-analyses/NNS were/VBD performed/VBN ,/, as/IN no/DT data/NNS were/VBD available/JJ from/IN randomized/JJ comparisons/NNS ./.
P12105077A09
Recognition/NN of/IN the/DT seizure/NN state/NN remains/VBZ the/DT foremost/RBS challenge/NN to/TO overcome/VB ./.
P12108581A22
Strategies/NNS to/TO protect/VB the/DT safety/NN of/IN both/CC the/DT patient/NN and/CC the/DT public/JJ safety/NN worker/NN must/MD be/VBP devised/VBN and/CC tested/VBN ./.
P12114036A15
INTERPRETATION/NN :/: Adding/NN simvastatin/NN to/TO existing/JJ treatments/NNS safely/RB produces/VBZ substantial/JJ additional/JJ benefits/NNS for/IN a/DT wide/JJ range/NN of/IN high-risk/NN patients/NNS ,/, irrespective/RB of/IN their/PRP$ initial/JJ cholesterol/NN concentrations/NNS ./.
P12114165A20
Quiz/NN scores/NNS confirmed/VBD that/IN the/DT residents/NNS achieved/VBD the/DT desired/JJ learning/JJ objectives/NNS ./.
P12116690A17
Two/CD novel/JJ serotonin/NN agonists/NNS are/VBP currently/RB under/IN development/NN for/IN constipated/JJ IBS/NN patients/NNS ,/, tegaserod/NN and/CC prucalopride/NN ./.
P12117354A07
These/DT criteria/NNS were/VBD applied/VBN in/IN a/DT blinded/JJ fashion/NN by/IN 2/CD independent/JJ investigators/NNS ./.
P12120485A12
Training/NN and/CC preparation/NN for/IN contingencies/NNS experienced/VBN in/IN an/DT attack/NN have/VBP the/DT potential/JJ to/TO enhance/VB delivery/NN of/IN care/NN ./.
P12130935A04
Resolution/NN of/IN nosocomial/JJ pneumonia/NN ,/, in/IN terms/NNS of/IN improvement/NN of/IN clinical/JJ parameters/NNS such/JJ as/IN oxygenation/NN ,/, fever/NN ,/, leukocytosis/NN and/CC bacterial/JJ eradication/NN ,/, has/VBZ been/VBN reported/VBN ,/, and/CC these/DT data/NNS can/MD lead/VBP to/TO a/DT better/JJR understanding/NN of/IN the/DT natural/JJ course/NN of/IN the/DT disease/NN ./.
P12133028A07
Bradykinin/NN ,/, a/DT potent/JJ vasodilator/NN ,/, acts/VBZ by/IN stimulating/NN formation/NN of/IN vasodilatory/JJ prostaglandins/NNS such/JJ as/IN prostacyclin/NN ,/, whereas/IN aspirin/NN or/CC acetyl/NN salicylic/JJ acid/NN inhibits/VBZ the/DT enzyme/NN cyclooxygenase/NN ,/, which/WDT in/IN turn/NN decreases/VBZ the/DT production/NN of/IN the/DT prostaglandins/NNS ./.
P12137445A06
Reasons/NNS for/IN the/DT underuse/NN may/MD include/VBP physicians/NNS '/POS and/CC patients/NNS '/POS attitudes/NNS and/CC knowledge/NN ,/, and/CC the/DT perceptions/NNS of/IN physicians/NNS and/CC healthcare/NN purchasers/NNS about/IN economic/JJ factors/NNS ./.
P12137608A07
References/NNS of/IN all/DT identified/JJ studies/NNS were/VBD searched/VBN for/IN further/JJ trial/NN citations/NNS ./.
P12137612A21
REVIEWER/NN 'S/POS CONCLUSIONS/NNS :/: There/EX is/VBZ insufficient/JJ evidence/NN available/JJ from/IN randomised/JJ controlled/JJ trials/NNS to/TO determine/VB the/DT relative/JJ effectiveness/NN of/IN surgical/JJ and/CC conservative/JJ treatment/NN for/IN acute/JJ injuries/NNS of/IN the/DT lateral/JJ ligament/NN complex/NN of/IN the/DT ankle/NN ./.
P12137619A12
They/PRP may/MD also/RB result/VBP in/IN a/DT greater/JJR improvement/NN in/IN long/JJ term/NN outcomes/NNS such/JJ as/IN menstrual/JJ loss/NN and/CC dysmenorrhoea/NN ./.
P12137624A05
Though/IN both/DT methods/NNS are/VBP widely/RB used/VBN ,/, the/DT advantages/NNS and/CC disadvantages/NNS of/IN laparoscopic/JJ sterilisation/NN compared/VBN to/TO mini-laparotomy/NN have/VBP not/RB been/VBN systematically/RB evaluated/VBN ./.
P12137627A10
MAIN/JJ RESULTS/NNS :/: The/DT timing/NN of/IN support/NN :/: early/JJ versus/CC delayed/JJ Of/IN the/DT seven/CD trials/NNS addressing/VBG the/DT timing/NN of/IN support/NN ,/, data/NNS on/IN mortality/NN were/VBD obtained/VBN for/IN all/DT seven/CD trials/NNS (/( 284/CD participants/NNS )/) ./.
P12137632A39
Longer-term/NN use/NN of/IN galantamine/NN has/VBZ not/RB been/VBN assessed/VBN in/IN a/DT controlled/JJ fashion/NN ./.
P12137636A29
Such/DT education/NN may/MD be/VBP effective/JJ in/IN increasing/NN the/DT short-term/NN use/NN of/IN contraception/NN ./.
P12137642A07
Control/NN could/MD include/VBP an/DT opiate/JJ ,/, sedative/NN or/CC non-pharmacological/JJ treatment/NN ./.
P12137653A09
Random/JJ effects/NNS meta-analyses/NNS were/VBD performed/VBN where/WRB data/NNS could/MD be/VBP pooled/VBN ./.
P12137656A17
There/EX were/VBD no/DT differences/NNS between/IN ACDR/NN CPR/NN and/CC STR/NN for/IN mortality/NN either/CC immediately/RB (/( RR/NN 0.98/CD [/( 95/CD %/SYM CI/NN 0.94/CD -/SYM 1.03/CD ]/) )/) or/CC at/IN hospital/NN discharge/NN (/( RR/NN 0.99/CD [/( 95/CD %/SYM CI/NN 0.98/CD -/SYM 1.01/CD ]/) )/) ./.
P12137667A15
Exercise/NN capacity/NN improved/VBD in/IN patients/NNS treated/VBN with/IN intravenous/JJ epoprostenol/NN (/( Standardised/JJ Mean/NN Difference/NN )/) 0.69/CD ,/, 95/CD %/SYM Confidence/NN Intervals/NNS (/( CI/NN )/) 0.40/CD ,/, 0.97/CD ./.
P12137675A18
There/EX was/VBD an/DT effect/NN on/IN some/DT verbal/JJ memory/NN functions/NNS (/( immediate/JJ recall/NN )/) ,/, on/IN a/DT test/NN of/IN abstract/JJ reasoning/NN and/CC a/DT test/NN of/IN speed/NN and/CC accuracy/NN in/IN relatively/RB young/JJ (/( 47/CD years/NNS of/IN age/NN )/) surgically/RB menopausal/JJ women/NNS who/WP had/VBD been/VBN given/VBN a/DT bolus/NN intramuscular/JJ injection/NN of/IN 10/CD mg/NN E2/NN every/DT month/NN for/IN 3/CD months/NNS ./.
P12137681A08
Studies/NNS reported/VBD mainly/RB goitre/NN rates/NNS and/CC urinary/JJ iodine/NN excretion/NN as/IN outcome/NN measures/NNS ./.
P12137687A22
The/DT protocols/NNS of/IN two/CD of/IN the/DT studies/NNS mandated/VBD the/DT use/NN of/IN early/JJ exchange/NN transfusion/NN ,/, limiting/VBG the/DT generalizability/NN of/IN the/DT results/NNS ./.
P12137691A05
SEARCH/NN STRATEGY/NN :/: We/PRP searched/VBD MEDLINE/NN ,/, Embase/NN ,/, Amed/NN ,/, Cinahl/NN ,/, CISCOM/NN and/CC the/DT Cochrane/NNP Controlled/JJ Trial/NN Register/NN ./.
P12137696A15
Seven/CD infants/NNS only/RB were/VBD randomised/VBN to/TO treatment/NN with/IN dopamine/NN and/CC seven/CD to/TO receive/VB placebo/NN ./.
P12137705A05
The/DT manufacturers/NNS of/IN rofecoxib/NN ,/, MSD/NN ,/, were/VBD also/RB approached/VBN by/IN the/DT UK/NNP National/JJ Institute/NN for/IN Clinical/JJ Excellence/NN to/TO submit/VB additional/JJ evidence/NN to/TO inform/VB it/PRP 's/POS appraisal/NN on/IN the/DT use/NN of/IN cyclo-oxygenase/NN inhibitors/NNS for/IN arthritis/NN ./.
P12137712A13
Continuous/JJ data/NNS were/VBD pooled/VBN using/VBG weighted/JJ mean/NN differences/NNS and/CC dichotomous/JJ data/NNS using/VBG relative/JJ risks/NNS ./.
P12137716A05
Additional/JJ RCTs/NNS were/VBD identified/VBN from/IN the/DT Cochrane/NNP Airways/NNS Group/NN 's/POS registry/NN of/IN COPD/NN RCTs/NNS using/VBG the/DT strategy/NN :/: [/( exp/NN ,/, lung/NN diseases/NNS ,/, obstructive/JJ ]/) and/CC [/( exp/NN ,/, rehabilitation/NN or/CC exp/NN ,/, exercise/NN therapy/NN ]/) and/CC [/( research/NN design/NN or/CC longitudinal/JJ studies/NNS or/CC evaluation/NN study/NN or/CC randomized/JJ controlled/JJ trial/NN ]/) ./.
P12140910A02
The/DT advanced/JJ practice/NN nursing/JJ model/NN at/IN Mount/NN Sinai/NN Hospital/NN is/VBZ one/CD successful/JJ care/NN delivery/NN model/NN that/WDT fills/VBZ the/DT needs/NNS of/IN both/CC CCI/NN patients/NNS and/CC the/DT nurses/NNS who/WP work/VBP with/IN them/PRP ./.
P12149041A08
In/IN primary/JJ prevention/NN ,/, the/DT data/NNS are/VBP not/RB as/RB convincing/VBG and/CC generalisations/NNS can/MD not/RB be/VBP made/VBN as/IN to/TO whether/IN ,/, and/CC in/IN which/DT subgroup/NN ,/, drug/NN therapy/NN to/TO lower/VB low/JJ density/NN lipoprotein/NN (/( LDL/NN )/) cholesterol/NN should/MD be/VBP initiated/VBN ./.
P12150693A03
In/IN both/CC ST-segment/NN elevation/NN and/CC non-ST-segment/NN elevation/NN MI/NN ,/, aspirin/NN //SYM clopidogrel/NN ,/, heparin/NN //SYM low/JJ molecular/JJ weight/NN heparin/NN //SYM direct/JJ thrombin/NN inhibitors/NNS ,/, beta-blockers/NNS and/CC angiotensin/NN converting/JJ enzyme/NN inhibitors/NNS are/VBP part/NN of/IN the/DT routine/JJ regimens/NNS ./.
P12164804A07
For/IN both/DT subsets/NNS ,/, protein/NN A/NN immunoadsorption/NN is/VBZ reportedly/RB successful/JJ ./.
P12169077A13
Publication/NN bias/NN was/VBD examined/VBN using/VBG Begg/NNP modified/JJ funnel/NN plots/NNS and/CC formally/RB tested/VBN using/VBG the/DT Egger/NNP weighted-linear/JJ regression/NN method/NN ./.
P12175274A06
A/DT booster/NN dose/NN of/IN PNCRM7/NN elicited/VBD an/DT anamnestic/JJ response/NN to/TO all/DT seven/CD serotypes/NNS ./.
P12187868A06
Amiodarone/NN has/VBZ been/VBN evaluated/VBN in/IN numerous/JJ clinical/JJ trials/NNS in/IN patients/NNS with/IN heart/NN failure/NN and/CC appears/VBZ to/TO be/VB safe/JJ and/CC effective/JJ in/IN terms/NNS of/IN conversion/NN to/TO sinus/NN rhythm/NN ,/, maintenance/NN of/IN sinus/NN rhythm/NN as/RB well/RB as/IN control/NN of/IN ventricular/JJ rate/NN ./.
P12192737A25
Dietary/JJ surveys/NNS carried/VBN out/RP in/IN the/DT US/NNP population/NN indicate/VBP that/IN less/RB than/IN 12/CD percent/NN of/IN US/NNP children/NNS and/CC adults/NNS meet/VBP this/DT recommended/JJ level/NN of/IN intake/NN (/( 104/CD )/) ./.
P12196062A06
The/DT prognosis/NN is/VBZ poor/JJ ,/, with/IN a/DT mean/NN survival/NN time/NN of/IN 2.8/CD years/NNS after/IN diagnosis/NN if/IN untreated/VBN ./.
P12196870A35
(/( III-C/NN )/) Part/NN II/CD :/: New/JJ Technologies/NNS for/IN Fetal/JJ Surveillance/NN in/IN Labour/NN ./.
P12196882A23
The/DT clinician/NN is/VBZ advised/VBN to/TO examine/VB the/DT breast/NN in/IN the/DT postpartum/NN period/NN if/IN the/DT woman/NN is/VBZ not/RB breastfeeding/VBG ./.
P12197448A10
Further/RB randomized/JJ controlled/JJ trials/NNS with/IN larger/JJR sample/NN sizes/NNS are/VBP required/VBN to/TO demonstrate/VB the/DT efficacy/NN of/IN a/DT combination/NN antidepressant/NN strategy/NN for/IN patients/NNS with/IN treatment-resistant/JJ depression/NN ./.
P12202465A08
Individual/JJ studies/NNS showed/VBD similar/JJ results/NNS ,/, reflected/VBN in/IN the/DT P/NN values/NNS of/IN the/DT test/NN of/IN heterogeneity/NN (/( P/NN =/SYM 0.99/CD for/IN vertebral/JJ and/CC 0.88/CD for/IN nonvertebral/JJ fractures/NNS )/) ./.
P12202471A10
At/IN the/DT lumbar/JJ spine/NN and/CC forearm/NN sites/NNS ,/, hydroxylated/JJ vitamin/NN D/NN doses/NNS above/IN 50/CD microg/NN yield/VBP larger/JJR effects/NNS than/IN lower/JJR doses/NNS ./.
P12207806A12
In/IN most/DT populations/NNS studied/VBN ,/, 60/CD %/SYM of/IN people/NNS who/WP develop/VBP diabetes/NN have/VBP either/CC IGT/NN or/CC IFG/NN 5/CD years/NNS or/CC so/RB before/RB ,/, with/IN the/DT other/JJ 40/CD %/SYM having/NN normal/JJ glucose/NN tolerance/NN at/IN that/DT time/NN ./.
P12215733A08
Beta-blockers/NNS have/VBP been/VBN shown/VBN to/TO significantly/RB reduce/VB sudden/JJ death/NN as/RB well/RB as/IN total/JJ mortality/NN ,/, while/IN the/DT effects/NNS of/IN amiodarone/NN have/VBP been/VBN less/RB decisive/JJ ./.
P12222079A20
Strategies/NNS need/VBP to/TO be/VB developed/VBN and/CC tested/VBN to/TO enhance/VB motivation/NN and/CC to/TO target/VB treatment/NN efforts/NNS at/IN those/DT youth/NN who/WP are/VBP most/RBS likely/RB to/TO benefit/VB from/IN services/NNS ./.
P12227125A09
One/CD study/NN involving/VBG high-risk/NN patients/NNS reported/VBD a/DT reduction/NN in/IN ulcer/NN incidence/NN (/( OR/NN 0.28/CD ,/, 95/CD %/SYM confidence/NN interval/NN [/( CI/NN ]/) 0.13-0.59/CD )/) and/CC amputation/NN rate/NN (/( OR/NN 0.32/CD ,/, 95/CD %/SYM CI/NN 0.14-0.71/CD )/) after/IN 1/CD year/NN ./.
P12229053A10
To/TO prepare/VB for/IN this/DT "/`` certainty/NN ,/, "/'' radiology/NN departments/NNS must/MD answer/VBP many/DT questions/NNS ./.
P12235735A03
Diabetic/JJ individuals/NNS with/IN hypertension/NN have/VBP a/DT greater/JJR risk/NN of/IN macrovascular/JJ and/CC microvascular/JJ disease/NN than/IN normotensive/JJ diabetic/JJ individuals/NNS ./.
P12241126A10
However/WRB ,/, all/PRP have/VBP potential/JJ serious/JJ adverse/JJ events/NNS ./.
P12269960A10
The/DT mechanism/NN of/IN any/DT anti-dyspeptic/JJ action/NN is/VBZ difficult/JJ to/TO define/VB ,/, as/IN the/DT causes/NNS of/IN non-ulcer/NN dyspepsia/NN are/VBP unclear/JJ ./.
P12350192A04
DATA/NNS SOURCES/NNS :/: Relevant/JJ articles/NNS were/VBD identified/VBN through/IN searches/NNS of/IN the/DT Cochrane/NNP Library/NN ,/, MEDLINE/NN ,/, and/CC EMBASE/NN (/( 1984-2001/CD )/) ,/, manual/JJ searches/NNS of/IN bibliographies/NNS of/IN known/JJ primary/JJ and/CC review/NN articles/NNS ,/, and/CC contact/NN with/IN manufacturers/NNS ./.
P12354487A08
Combined/JJ oestrogen/NN //SYM progestagen/NN HRT/NN was/VBD used/VBN in/IN three/CD trials/NNS and/CC oestrogen/NN alone/JJ in/IN one/CD ./.
P12360366A10
The/DT accrual/JJ of/IN breast/NN cancer/NN cases/NNS appearing/VBG during/IN the/DT fourth/JJ year/NN of/IN observation/NN is/VBZ similar/JJ to/TO that/PRP found/VBN in/IN previous/JJ studies/NNS ,/, and/CC remains/VBZ inferior/JJ to/TO the/DT increases/NNS related/VBN to/TO lifestyle/NN factors/NNS reported/VBN in/IN other/JJ studies/NNS ./.
P12369881A02
The/DT potential/NN of/IN this/DT drug/NN class/NN has/VBZ yet/RB to/TO be/VB fully/RB explored/VBN ./.
P12371014A09
Electrophysiologic/JJ studies/NNS performed/VBN during/IN the/DT antiarrhythmic/JJ surgical/JJ procedure/NN can/MD not/RB provide/VBP complete/JJ information/NN ,/, and/CC their/PRP$ use/NN is/VBZ thus/RB restricted/VBN to/TO the/DT arrhythmogenic/JJ myocardial/JJ target/NN only/RB [/( 32/CD ,/, 45/CD ]/) ./.
P12381215A07
Antihypertensive/JJ agents/NNS have/VBP been/VBN extensively/RB studied/VBN in/IN the/DT primary/JJ prevention/NN of/IN stroke/NN ;/: however/WRB ,/, relatively/RB few/JJ trials/NNS of/IN antihypertensive/JJ agents/NNS in/IN the/DT secondary/JJ prevention/NN of/IN stroke/NN are/VBP available/JJ ./.
P12383060A08
Out/IN of/IN 76/CD eligible/JJ clinical/JJ trials/NNS ,/, 53/CD (/( 12/CD not/RB yet/RB published/VBN )/) involving/VBG 24089/CD patients/NNS met/VBD the/DT criteria/NNS for/IN inclusion/NN ./.
P12386751A21
Catheter-directed/JJ thrombolysis/NN is/VBZ known/VBN to/TO improve/VB lysis/NN rates/NNS ./.
P12390557A06
The/DT dyslipidemia/NN may/MD be/VBP associated/VBN with/IN lipodystrophy/NN ,/, insulin/NN resistance/NN ,/, and/CC ,/, rarely/RB ,/, frank/JJ diabetes/NN mellitus/NN ./.
P12391943A10
Cost-effectiveness/NN base/NN case/NN estimates/NNS ranged/VBD from/IN 2,415/CD Pounds/NNS savings/NNS to/TO 49,476/CD Pounds/NNS additional/JJ cost/NN (/( 1997/CD prices/NNS )/) per/IN unit/NN of/IN effect/NN for/IN donepezil/NN and/CC a/DT small/JJ savings/NNS for/IN rivastigmine/NN ./.
P12398573A02
DATA/NNS SOURCES/NNS :/: A/DT MEDLINE/NN search/NN (/( 1966-September/NN 2001/CD )/) was/VBD conducted/VBN using/VBG the/DT following/JJ terms/NNS :/: pravastatin/NN ,/, lovastatin/NN ,/, simvastatin/NN ,/, atorvastatin/NN ,/, cerivastatin/NN ,/, fluvastatin/NN ,/, statins/NNS ,/, hydroxymethylglutaryl/NN coenzyme/NN A/NN reductase/NN inhibitor/NN ,/, acute/JJ coronary/JJ syndromes/NNS ,/, unstable/JJ angina/NN ,/, and/CC myocardial/JJ infarction/NN ./.
P12406054A04
Cigarette/NN smoking/NN appears/VBZ to/TO be/VB the/DT most/RBS significant/JJ environmental/JJ risk/NN factor/NN ./.
P12407856A06
We/PRP believe/VBP that/IN several/JJ aspects/NNS of/IN the/DT new/JJ definition/NN need/VBP to/TO be/VB discussed/VBN before/IN the/DT new/JJ criteria/NNS for/IN MI/NN are/VBP used/VBN in/IN clinical/JJ practice/NN in/IN Italy/NNP ./.
P12408744A39
In/IN November/NN 2001/CD ,/, Genentech/NN and/CC Novartis/NN stated/VBD that/IN an/DT amended/JJ BLA/NN would/MD be/VBP submitted/VBN to/TO the/DT FDA/NN in/IN the/DT fourth/JJ quarter/NN of/IN 2002/CD ./.
P12411873A05
Radionuclide/NN imaging/JJ techniques/NNS appear/VBP to/TO be/VB appropriate/JJ in/IN risk/NN assessment/NN ,/, prognosis/NN and/CC evaluation/NN of/IN therapy/NN in/IN patients/NNS after/IN acute/JJ myocardial/JJ infarction/NN ./.
P12415021A14
Increasing/VBG the/DT rate/NN of/IN follow-up/NN to/TO diagnostic/JJ evaluation/NN from/IN the/DT base-case/NN estimate/NN of/IN 77/CD %/SYM to/TO 100/CD %/SYM decreased/VBD the/DT incremental/JJ cost/NN of/IN UNHS/NN to/TO $/SYM 38000/CD per/IN additional/JJ infant/NN whose/WDT deafness/NN was/VBD diagnosed/VBN by/IN 6/CD months/NNS ./.
P12419477A03
The/DT update/NN was/VBD made/VBN possible/JJ by/IN a/DT series/NN of/IN large/JJ ,/, cholesterol-lowering/JJ clinical/JJ trials/NNS ./.
P12424170A02
To/TO assess/VB whether/IN results/NNS obtained/VBN in/IN secondary/JJ care/NN can/MD be/VBP extrapolated/VBN to/TO primary/JJ care/NN and/CC suggest/VB how/WRB future/JJ trials/NNS should/MD be/VBP designed/VBN to/TO provide/VB more/RB rigorous/JJ evidence/NN ./.
P12428993A13
In/IN elderly/JJ patients/NNS (/( arbitrarily/RB defined/VBN as/IN aged/JJ >/SYM 75/CD years/NNS )/) ,/, the/DT management/NN of/IN atrial/JJ fibrillation/NN varies/VBZ ;/: it/PRP requires/VBZ an/DT individual/JJ approach/NN ,/, which/WDT largely/RB depends/VBZ on/IN comorbid/JJ conditions/NNS ,/, underlying/VBG cardiac/JJ disease/NN ,/, and/CC patient/NN and/CC physician/NN preferences/NNS ./.
P12431942A12
Generalist/NN and/CC specialist/NN pediatricians/NNS prepared/VBD clinical/JJ cases/NNS ./.
P12434275A04
With/IN the/DT exception/NN of/IN allogeneic/JJ stem/NN cell/NN transplantation/NN ,/, no/DT treatment/NN modality/NN has/VBZ been/VBN proven/VBN to/TO be/VB of/IN benefit/NN over/IN supportive/JJ care/NN ./.
P12435257A04
PATIENTS/NNS :/: A/DT total/NN of/IN 4052/CD patients/NNS with/IN AF/NN randomly/RB assigned/VBN to/TO receive/VB therapeutic/JJ doses/NNS of/IN oral/JJ anticoagulant/NN or/CC aspirin/NN with/IN or/CC without/IN low-dose/NN oral/JJ anticoagulants/NNS ./.
P12436944A03
These/DT numbers/NNS will/MD continue/VBP to/TO climb/VB ,/, internationally/RB ,/, since/IN the/DT leading/JJ associated/JJ risk/NN for/IN diabetes/NN development/NN ,/, obesity/NN ,/, has/VBZ reached/VBN epidemic/JJ proportions/NNS ,/, globally/RB ./.
P12440233A08
The/DT low/JJ density/NN lipoprotein/NN target/NN of/IN </SYM 100/CD mg/NN was/VBD present/JJ in/IN only/RB 22/CD %/SYM of/IN patients/NNS before/IN enrollment/NN ,/, with/IN improvement/NN of/IN up/IN to/TO 57/CD %/SYM after/IN the/DT follow-up/NN period/NN ./.
P12447156A02
Despite/IN the/DT compelling/JJ scientific/JJ evidence/NN that/IN beta-blockers/NNS reduce/VBP hospitalizations/NNS and/CC mortality/NN in/IN patients/NNS with/IN heart/NN failure/NN ,/, this/DT lifesaving/JJ therapy/NN continues/VBZ to/TO be/VB underutilized/VBN ./.
P12457213A12
For/IN ulcer/NN bleedings/NNS ,/, endoscopic/JJ treatment/NN is/VBZ the/DT established/JJ first/JJ choice/NN ./.
P12472045A01
Stroke/NN is/VBZ the/DT leading/JJ cause/NN of/IN serious/JJ long-term/NN disability/NN in/IN the/DT United/JJ States/NNS ./.
P12479763A02
OBJECTIVE/NN :/: To/TO determine/VB whether/IN treatment/NN with/IN a/DT calcium/NN channel/NN blocker/NN or/CC an/DT angiotensin-converting/JJ enzyme/NN inhibitor/NN lowers/VBZ the/DT incidence/NN of/IN coronary/JJ heart/NN disease/NN (/( CHD/NN )/) or/CC other/JJ cardiovascular/JJ disease/NN (/( CVD/NN )/) events/NNS vs/CC treatment/NN with/IN a/DT diuretic/NN ./.
P12485545A12
We/PRP describe/VBP a/DT classification/NN derived/VBN from/IN these/DT studies/NNS that/WDT is/VBZ based/VBN on/IN the/DT actual/JJ practice/NN of/IN primary/JJ care/NN and/CC provides/VBZ a/DT starting/JJ point/NN for/IN future/JJ epidemiologic/JJ and/CC interventional/JJ research/NN ./.
P12489289A11
Immunofluorescence/NN assays/NNS have/VBP been/VBN well/RB characterized/VBN and/CC validated/VBN in/IN clinical/JJ trials/NNS ,/, however/WRB they/PRP are/VBP not/RB universally/RB available/JJ ./.
P12495903A14
Specific/JJ recommendations/NNS for/IN supportive/JJ therapy/NN ,/, including/VBG iron/NN chelation/NN ,/, were/VBD issued/VBN ./.
P12501499A17
Eleven/CD published/JJ trials/NNS investigating/VBG the/DT effect/NN of/IN diets/NNS in/IN ulcerative/JJ colitis/NN show/VBP only/RB for/IN elimination/NN diet/NN a/DT positive/JJ treatment/NN effect/NN ./.
P12505250A01
Little/JJ information/NN exists/VBZ to/TO quantify/VB the/DT functional/JJ status/NN and/CC economic/JJ consequences/NNS of/IN lipid-lowering/JJ therapy/NN in/IN elderly/JJ patients/NNS ./.
P12507182A04
Evidence/NN based/JJ medicine/NN is/VBZ designed/VBN to/TO discover/VB the/DT best/JJS evidence/NN available/JJ and/CC apply/VB it/PRP in/IN daily/JJ practice/NN for/IN treatment/NN of/IN the/DT individual/JJ patient/NN ./.
P12512406A14
Although/IN a/DT complete/JJ tendon/NN rupture/NN with/IN loading/NN after/IN steroid/NN injection/NN has/VBZ been/VBN reported/VBN ,/, no/DT reliable/JJ proof/NN exists/VBZ of/IN the/DT deleterious/JJ effects/NNS of/IN peritendinous/JJ injections/NNS ;/: conclusions/NNS in/IN literature/NN are/VBP based/VBN mainly/RB on/IN uncontrolled/JJ case/NN reports/NNS that/WDT fail/VBP under/IN scientific/JJ scrutiny/NN ,/, whereas/IN scientifically/RB rigorous/JJ studies/NNS have/VBP not/RB been/VBN performed/VBN ./.
P12513114A11
Most/RBS successful/JJ management/NN strategies/NNS combine/VBP pharmacological/JJ and/CC nonpharmacological/JJ (/( home/NN remedies/NNS ,/, massage/NN ,/, topical/JJ agents/NNS ,/, heat/NN and/CC cold/NN packs/NNS and/CC informal/JJ cognitive/JJ strategies/NNS )/) therapies/NNS ./.
P12518268A07
Patients/NNS should/MD be/VBP informed/VBN of/IN these/DT side/NN effects/NNS in/IN order/NN to/TO prevent/VB excessive/JJ BWG/NN ,/, and/CC their/PRP$ blood/NN glucose/NN and/CC lipids/NNS should/MD be/VBP monitored/VBN before/IN treatment/NN and/CC then/RB at/IN regular/JJ intervals/NNS ./.
P12519539A02
Its/PRP$ pathogenesis/NN has/VBZ not/RB been/VBN elucidated/VBN yet/RB ,/, but/CC may/MD be/VBP related/VBN to/TO vasospasm/NN ./.
P12519543A10
Participants/NNS '/POS ages/NNS ranged/VBD from/IN 40/CD to/TO 85/CD ,/, and/CC both/DT sexes/NNS were/VBD equally/RB represented/VBN ./.
P12519548A02
Manual/JJ therapy/NN practitioners/NNS are/VBP also/RB varied/VBN ,/, including/VBG physiotherapists/NNS ,/, respiratory/JJ therapists/NNS ,/, chiropractic/JJ and/CC osteopathic/JJ physicians/NNS ./.
P12519554A08
Where/WRB insufficient/JJ data/NNS were/VBD presented/VBN original/JJ authors/NNS were/VBD contacted/VBN for/IN further/JJ details/NNS ./.
P12519563A05
SEARCH/NN STRATEGY/NN :/: Searches/NNS were/VBD conducted/VBN in/IN January/NN 2002/CD ./.
P12519569A03
SEARCH/NN STRATEGY/NN :/: We/PRP searched/VBD the/DT following/JJ databases/NNS up/IN to/TO 2001/CD ,/, inclusive/JJ :/: Cochrane/NNP Drugs/NNS and/CC Alcohol/NN Review/NN Group/NN Register/NN ,/, the/DT Cochrane/NNP Controlled/JJ Trials/NNS Register/NN ,/, MEDLINE/NN ,/, EMBASE/NN ,/, Current/JJ Contents/NNS ,/, Psychlit/NN ,/, CORK/NN [/( www./NN state.vt.su/NN //SYM adap/NN //SYM cork/NN ]/) ,/, Alcohol/NN and/CC Drug/NN Council/NN of/IN Australia/NNP (/( ADCA/NN )/) [/( www.adca.org.au/NN ]/) ,/, Australian/JJ Drug/NN Foundation/NN (/( ADF/NN -VIC/NN )/) [/( www.adf.org.au/NN ]/) ,/, Centre/NN for/IN Education/NN and/CC Information/NN on/IN Drugs/NNS and/CC Alcohol/NN (/( CEIDA/NN )/) [/( www.ceida.net.au/NN ]/) ,/, Australian/JJ Bibliographic/JJ Network/NN (/( ABN/NN )/) ,/, and/CC Library/NN of/IN Congress/NN databases/NNS ,/, available/JJ NIDA/NN monographs/NNS and/CC the/DT College/NN on/IN Problems/NNS of/IN Drug/NN Dependence/NN Inc/NN ./.
P12519576A10
DATA/NNS COLLECTION/NN AND/CC ANALYSIS/NN :/: The/DT methodological/JJ quality/NN of/IN the/DT studies/NNS was/VBD assessed/VBN using/VBG criteria/NNS for/IN blinding/NN of/IN randomization/NN ,/, blinding/NN of/IN intervention/NN ,/, completeness/NN of/IN follow-up/NN and/CC blinding/NN of/IN outcome/NN assessment/NN ./.
P12519586A08
SELECTION/NN CRITERIA/NNS :/: All/DT relevant/JJ ,/, unconfounded/JJ ,/, randomized/JJ ,/, double-blind/JJ controlled/JJ studies/NNS ,/, in/IN which/WDT extracts/NNS of/IN Ginkgo/NN biloba/NN at/IN any/DT strength/NN and/CC over/IN any/DT period/NN were/VBD compared/VBN with/IN placebo/NN for/IN their/PRP$ effects/NNS on/IN people/NNS with/IN acquired/JJ cognitive/JJ impairment/NN ,/, including/VBG dementia/NN ,/, of/IN any/DT degree/NN of/IN severity/NN ./.
P12519590A06
All/DT searches/NNS were/VBD performed/VBN during/IN April/NN and/CC May/NN 2001/CD ./.
P12519597A01
BACKGROUND/NN :/: Sickle/JJ cell/NN disease/NN is/VBZ an/DT inherited/JJ disorder/NN of/IN haemoglobin/NN ,/, which/WDT results/VBZ in/IN abnormal/JJ red/JJ blood/NN cells/NNS ./.
P12519607A02
Research/NN suggests/VBZ that/IN parenting/NN has/VBZ an/DT important/JJ role/NN to/TO play/VB in/IN helping/NN children/NNS to/TO become/VB well/RB adjusted/JJ adults/NNS ,/, and/CC that/IN the/DT first/JJ few/JJ months/NNS and/CC years/NNS of/IN a/DT child/NN 's/POS life/NN are/VBP especially/RB important/JJ in/IN establishing/NN patterns/NNS of/IN emotional/JJ ,/, cognitive/JJ and/CC social/JJ functioning/NN which/WDT will/MD in/IN turn/NN influence/VBP the/DT child/NN 's/POS future/JJ development/NN and/CC in/IN particular/NN ,/, their/PRP$ mental/JJ health/NN ./.
P12519612A02
Tap/NN water/NN is/VBZ commonly/RB used/VBN in/IN the/DT community/NN for/IN cleansing/NN wounds/NNS because/IN it/PRP is/VBZ easily/RB accessible/JJ ,/, efficient/JJ and/CC cost/NN effective/JJ ,/, however/WRB ,/, there/EX is/VBZ an/DT unresolved/JJ debate/NN about/IN its/PRP$ use/NN ./.
P12519615A14
The/DT differences/NNS were/VBD similar/JJ among/IN the/DT studies/NNS and/CC when/WRB combined/VBN :/: Weighted/JJ Mean/NN Difference/NN (/( WMD/NN )/) 0.0/CD liters/NNS (/( 95/CD %/SYM Confidence/NN Interval/NN (/( 95/CD %/SYM CI/NN )/) -0.19/CD ,/, 0.19/CD )/) ./.
P12519624A01
BACKGROUND/NN :/: Immunization/NN rates/NNS for/IN children/NNS and/CC adults/NNS are/VBP rising/VBG ,/, but/CC coverage/NN levels/NNS have/VBP not/RB reached/VBN national/JJ goals/NNS ./.
P12520824A10
Early/JJ and/CC sustained/JJ antiplatelet/NN use/NN after/IN atherothrombotic/JJ stroke/NN reduces/VBZ stroke/NN recurrence/NN ./.
P12527564A07
There/EX is/VBZ a/DT great/JJ deal/NN of/IN evidence/NN about/IN a/DT wide/JJ variety/NN of/IN clinician-based/JJ and/CC community-based/JJ efforts/NNS at/IN smoking/JJ avoidance/NN or/CC cessation/NN ./.
P12530498A03
We/PRP sought/VBD the/DT opinion/NN of/IN pediatric/JJ cardiologists/NNS practicing/VBG in/IN U.S./NNP fellowship/NN programs/NNS on/IN the/DT subject/NN by/IN means/NNS of/IN a/DT multiple-choice/NN survey/NN ./.
P12534856A05
It/PRP is/VBZ one/CD of/IN the/DT causes/NNS of/IN frequent/JJ hospital/NN readmissions/NNS ,/, reflecting/VBG acute/JJ decompensation/NN and/CC compromised/JJ quality/NN of/IN life/NN for/IN patients/NNS and/CC increased/JJ cost/NN and/CC resource/NN use/NN for/IN the/DT healthcare/NN system/NN ./.
P12535389A09
The/DT second/JJ author/NN assessed/VBD the/DT quality/NN of/IN trials/NNS and/CC extracted/VBD data/NNS independently/RB ./.
P12535396A12
MAIN/JJ RESULTS/NNS :/: There/EX are/VBP 17/CD included/JJ trials/NNS ./.
P12535398A26
The/DT apparent/JJ increase/NN in/IN uterine/JJ hyperstimulation/NN is/VBZ of/IN concern/NN ./.
P12535405A10
We/PRP reviewed/VBD studies/NNS in/IN scope/NN for/IN criteria/NNS of/IN outcome/NN relevance/NN (/( measurement/NN of/IN at/IN least/JJS one/CD of/IN a/DT list/NN of/IN behavioral/JJ or/CC biologic/JJ outcomes/NNS ,/, e.g./IN ,/, unprotected/JJ sex/NN or/CC incidence/NN of/IN HIV/NN infections/NNS )/) and/CC methodologic/JJ rigor/NN (/( randomized/JJ controlled/JJ trials/NNS or/CC certain/JJ strong/JJ quasi-experimental/JJ designs/NNS with/IN comparison/NN groups/NNS )/) ./.
P12535410A01
BACKGROUND/NN :/: In/IN nephrotic/JJ syndrome/NN protein/NN leaks/VBZ from/IN the/DT blood/NN to/TO the/DT urine/NN through/IN the/DT glomeruli/NNS resulting/VBG in/IN hypoproteinaemia/NN and/CC generalised/JJ oedema/NN ./.
P12535413A33
The/DT data/NN suggests/VBZ less/DT persisting/JJ pain/NN and/CC numbness/NN following/VBG laparoscopic/JJ repair/NN ./.
P12535419A16
There/EX was/VBD no/DT evidence/NN from/IN these/DT studies/NNS that/IN this/DT increase/NN in/IN uptake/NN of/IN tests/NNS was/VBD related/VBN to/TO informed/JJ decision/NN making/NN by/IN consumers/NNS ./.
P12535424A21
In/IN addition/NN ,/, meta-analysis/NN of/IN available/JJ data/NNS from/IN two/CD studies/NNS (/( Jacqz-Aigrain/NNP 1994/CD ,/, Anand/NNP 1999/CD )/) showed/VBD a/DT statistically/RB significantly/RB longer/JJR duration/NN of/IN NICU/NN stay/NN in/IN the/DT midazolam/NN group/NN compared/VBN to/TO the/DT placebo/NN group/NN (/( WMD/NN 5.4/CD days/NNS ,/, 95/CD %/SYM CI/NN 0.4/CD ,/, 10.5/CD )/) ./.
P12535427A22
Both/PRP of/IN these/PRP were/VBD conducted/VBN under/IN open/JJ conditions/NNS and/CC had/VBD serious/JJ methodological/JJ problems/NNS ./.
P12535430A20
New/JJ Trials/NNS with/IN longer/JJR follow/NN up/RP are/VBP required/VBN ./.
P12535436A20
There/EX was/VBD no/DT evidence/NN of/IN any/DT publication/NN bias/NN ./.
P12535440A09
Types/NNS of/IN outcome/NN measures/NNS :/: Primary/JJ :/: improvement/NN in/IN the/DT Neuropathy/NN Disability/NN Score/NN or/CC Modified/JJ Rankin/NNP Scale/NN six/CD months/NNS after/IN randomisation/NN Secondary/JJ :/: Neuropathy/NN Disability/NN Score/NN and/or/CC the/DT Modified/JJ Rankin/NNP Score/NN 12/CD months/NNS after/IN randomisation/NN ./.
P12535443A21
REVIEWER/NN 'S/POS CONCLUSIONS/NNS :/: The/DT evidence/NN available/JJ indicates/VBZ that/IN Open/JJ retropubic/JJ colposuspension/NN is/VBZ the/DT most/RBS effective/JJ treatment/NN modality/NN for/IN stress/NN urinary/JJ incontinence/NN especially/RB in/IN the/DT long/JJ term/NN ./.
P12535453A05
Such/PDT an/DT approach/NN is/VBZ not/RB ,/, however/WRB ,/, without/IN cost/NN and/CC the/DT actual/JJ benefit/NN of/IN the/DT adoption/NN of/IN routine/JJ outcome/NN and/CC needs/NNS assessment/NN in/IN the/DT day-to-day/NN care/NN of/IN those/PRP with/IN schizophrenia/NN remains/VBZ unclear/JJ ./.
P12535460A15
The/DT final/JJ total/NN of/IN participants/NNS included/VBN in/IN the/DT meta-analysis/NN was/VBD 224/CD ./.
P12535468A13
Four/CD RCTs/NNS evaluated/VBD the/DT beta-blockers/NNS ,/, propranolol/NN and/CC pindolol/NN ,/, one/CD RCT/NN evaluated/VBD the/DT central/JJ nervous/JJ system/NN stimulant/NN ,/, methylphenidate/NN and/CC one/CD RCT/NN evaluated/VBD amantadine/NN ,/, a/DT drug/NN normally/RB used/VBN in/IN parkinsonism/NN and/CC related/JJ disorders/NNS ./.
P12535472A15
The/DT risk/NN of/IN a/DT carry-over/JJ effect/NN into/IN the/DT second/JJ arm/NN meant/VBP that/IN these/DT results/NNS were/VBD not/RB analysed/VBN ./.
P12535476A08
The/DT manufacturers/NNS of/IN amantadine/NN were/VBD contacted/VBN ./.
P12535479A20
REVIEWER/NN 'S/POS CONCLUSIONS/NNS :/: Budesonide/NN is/VBZ effective/JJ in/IN the/DT treatment/NN of/IN collagenous/JJ colitis/NN ./.
P12535486A10
Quantitative/JJ data/NNS are/VBP presented/VBN using/VBG relative/JJ risks/NNS or/CC mean/NN differences/NNS together/RB with/IN 95/CD per/IN cent/CD confidence/NN limits/NNS ./.
P12535495A15
Quality/NN of/IN life/NN was/VBD not/RB adequately/RB evaluated/VBN in/IN the/DT studies/NNS ./.
P12535501A07
DATA/NNS COLLECTION/NN AND/CC ANALYSIS/NN :/: Trial/NN inclusion/NN and/CC methodological/JJ quality/NN was/VBD assessed/VBN by/IN two/CD independent/JJ reviewers/NNS according/VBG to/TO predetermined/JJ criteria/NNS ./.
P12535505A18
There/EX was/VBD no/DT significant/JJ difference/NN in/IN readmission/NN rates/NNS between/IN day/NN hospital/NN patients/NNS and/CC controls/NNS (/( n=667/NN ,/, 5/CD RCTs/NNS ,/, RR/NN 0.91/CD CI/NN 0.72/CD to/TO 1.15/CD )/) ./.
P12535509A08
NPPV/NN resulted/VBD in/IN decreased/JJ mortality/NN (/( Relative/JJ Risk/NN [/( RR/NN ]/) 0.41/CD ;/: 95/CD %/SYM Confidence/NN Intervals/NNS [/( CI/NN ]/) 0.26/CD ,/, 0.64/CD )/) ,/, decreased/JJ need/NN for/IN intubation/NN (/( RR/NN 0.42/CD ;/: 95/CD %/SYM CI/NN 0.31/CD ,/, 0.59/CD )/) ,/, reduction/NN in/IN treatment/NN failure/NN (/( RR/NN 0.51/CD ;/: 95/CD %/SYM CI/NN 0.39/CD ,/, 0.67/CD )/) ,/, rapid/JJ improvement/NN within/IN the/DT first/JJ hour/NN in/IN pH/NN (/( Weight/NN Mean/NN Difference/NN [/( WMD/NN ]/) 0.03/CD ;/: 95/CD %/SYM CI/NN 0.02/CD ,/, 0.04/CD )/) ,/, PaCO2/NN (/( WMD/NN -0.40/CD kPa/NN ;/: 95/CD %/SYM CI/NN -0.78/CD ,/, -0.03/CD )/) and/CC respiratory/JJ rate/NN (/( WMD/NN -3.08/CD bpm/NN ;/: 95/CD %/SYM CI/NN -4.26/CD ,/, -1.89/CD )/) ./.
P12540330A04
OUTCOMES/NNS MEASURED/VBN :/: To/TO prepare/VB the/DT data/NNS ,/, systematic/JJ reviews/NNS were/VBD performed/VBN for/IN low/JJ back/NN ,/, knee/NN ,/, neck/NN ,/, and/CC shoulder/NN pain/NN ./.
P12544987A10
Both/CC univariate/JJ and/CC multivariable/JJ regression/NN analyses/NNS showed/VBD a/DT consistent/JJ relative/JJ risk/NN reduction/NN in/IN 28-day/NN mortality/NN rates/NNS for/IN drotrecogin/NN alfa/NN (/( activated/JJ )/) ./.
P12552027A05
Studies/NNS of/IN side/NN effects/NNS of/IN anticonvulsants/NNS commonly/RB used/VBN to/TO treat/VB seizures/NNS in/IN children/NNS are/VBP also/RB reviewed/VBN ./.
P12554124A04
Osteoarthritis/NN (/( OA/NN )/) is/VBZ one/CD of/IN the/DT chronic/JJ conditions/NNS for/IN which/WDT HRT/NN has/VBZ been/VBN suggested/VBN to/TO provide/VB beneficial/JJ outcomes/NNS ./.
P12563091A04
Therefore/RB ,/, a/DT predictive/JJ marker/NN of/IN PE/NN emergence/NN is/VBZ critical/JJ ./.
P12570125A11
Therapeutic/JJ modalities/NNS such/JJ as/IN new/JJ drugs/NNS ,/, e.g./IN epoprostenol/NN ,/, treprostinil/NN and/CC bosentan/NN ,/, and/CC surgical/JJ interventions/NNS ,/, e.g./IN transplantation/NN and/CC blade/NN septostomy/NN ,/, which/WDT were/VBD unavailable/JJ several/JJ decades/NNS ago/RB ,/, have/VBP had/VBD a/DT significant/JJ impact/NN on/IN prognosis/NN and/CC outcome/NN ./.
P12574007A03
The/DT authors/NNS also/RB searched/VBD the/DT citations/NNS of/IN selected/JJ studies/NNS and/CC contacted/VBD relevant/JJ authors/NNS and/CC manufacturers/NNS ./.
P12577161A02
Sepsis/NN is/VBZ the/DT systemic/JJ inflammatory/JJ response/NN to/TO infection/NN ,/, often/RB associated/VBN with/IN hypoperfusion/NN followed/VBN by/IN tissue/NN injury/NN and/CC organ/NN failure/NN ./.
P12578514A09
CONCLUSIONS/NNS :/: Lipid/NN therapy/NN with/IN statins/NNS can/MD reduce/VBP CVD/NN morbidity/NN and/CC mortality/NN as/IN demonstrated/VBN in/IN a/DT number/NN of/IN clinical/JJ trials/NNS ./.
P12587942A05
The/DT data/NN for/IN its/PRP$ effective/JJ use/NN in/IN the/DT medical/JJ phase/NN of/IN therapy/NN for/IN patients/NNS with/IN acute/JJ coronary/JJ syndromes/NNS ,/, however/WRB ,/, is/VBZ not/RB as/RB consistent/JJ ./.
P12595913A04
However/WRB ,/, more/DT controlled/JJ studies/NNS addressing/VBG this/DT issue/NN are/VBP needed/VBN ./.
P12602664A06
The/DT combination/NN of/IN a/DT leukotriene/NN receptor/NN antagonist/NN and/CC an/DT antihistamine/NN has/VBZ not/RB been/VBN proven/VBN to/TO be/VB more/RB effective/JJ than/IN either/DT agent/NN alone/JJ ./.
P12612871A07
RESULTS/NNS :/: Documentation/NN of/IN low-density/NN lipoprotein/NN (/( LDL/NN )/) cholesterol/NN was/VBD significantly/RB lower/JJR in/IN patients/NNS with/IN CAD+HF/NN (/( 53/CD %/SYM )/) compared/VBN with/IN those/PRP with/IN CAD/NN alone/JJ (/( 69/CD %/SYM )/) ./.
P12617510A13
Vaccinia/NN can/MD be/VBP transmitted/VBN from/IN a/DT vaccinee/NN 's/POS unhealed/JJ vaccination/NN site/NN to/TO other/JJ persons/NNS by/IN close/JJ contact/NN and/CC can/MD lead/VBP to/TO the/DT same/JJ adverse/JJ events/NNS as/IN in/IN the/DT vaccinee/NN ./.
P12622601A05
The/DT quality/NN of/IN retrieved/JJ articles/NNS was/VBD rated/VBN as/IN "/`` good/JJ ,/, "/'' "/`` fair/JJ ,/, "/'' or/CC "/`` poor/JJ ,/, "/'' and/CC sensitivity/NN ,/, specificity/NN ,/, and/CC diagnostic/JJ yield/NN of/IN tests/NNS were/VBD calculated/VBN ./.
P12628892A11
CONCLUSION/NN :/: Based/VBN on/IN surrogate/JJ markers/NNS ,/, heliox/NN may/MD offer/VBP mild-to-moderate/JJ benefits/NNS in/IN patients/NNS with/IN acute/JJ asthma/NN within/IN the/DT first/JJ hour/NN of/IN use/NN ,/, but/CC its/PRP$ advantages/NNS become/VBP less/RB apparent/JJ beyond/IN 1/CD h/NN ,/, as/IN most/DT conventionally/RB treated/JJ patients/NNS improve/VBP to/TO similar/JJ levels/NNS ,/, with/IN or/CC without/IN it/PRP ./.
P12633191A10
DATA/NNS SYNTHESIS/NN :/: Randomized/JJ controlled/JJ trials/NNS have/VBP shown/VBN that/IN fecal/JJ occult/JJ blood/NN testing/NN can/MD reduce/VBP colorectal/JJ cancer/NN incidence/NN and/CC mortality/NN ./.
P12637112A16
Current/JJ evidence/NN supports/VBZ their/PRP$ use/NN as/IN adjuncts/NNS to/TO lifestyle/NN modifications/NNS in/IN the/DT treatment/NN of/IN obesity/NN ./.
P12641480A03
However/WRB ,/, until/IN recently/RB ,/, there/EX has/VBZ been/VBN uncertainty/NN about/IN the/DT consistency/NN of/IN such/DT benefits/NNS across/IN different/JJ patient/NN groups/NNS and/CC in/IN particular/NN ,/, for/IN older/JJR people/NNS and/CC in/IN those/PRP with/IN a/DT history/NN of/IN stroke/NN ./.
P12644345A06
The/DT Antithrombotic/JJ Trialists/NNS '/POS Collaboration/NN found/VBD a/DT 46/CD %/SYM reduction/NN in/IN vascular/JJ events/NNS with/IN antiplatelet/NN therapy/NN (/( mostly/RB aspirin/NN )/) ./.
P12646338A05
Also/RB ,/, in/IN comparisons/NNS with/IN simvastatin/NN 20/CD mg/NN and/CC pravastatin/NN 20/CD mg/NN ,/, 86/CD %/SYM of/IN patients/NNS treated/VBN with/IN rosuvastatin/NN 10/CD mg/NN achieved/VBD ATP/NN III/CD goals/NNS ,/, compared/VBN with/IN 64/CD %/SYM of/IN simvastatin-treated/JJ patients/NNS and/CC 49/CD %/SYM of/IN pravastatin-treated/JJ patients/NNS (/( p/NN </SYM 0.001/CD )/) ./.
P12656536A01
OBJECTIVES/NNS :/: The/DT recognition/NN that/IN alveolar/JJ overdistension/NN rather/RB than/IN peak/JJ inspiratory/JJ airway/NN pressure/NN is/VBZ the/DT primary/JJ determinant/NN of/IN lung/NN injury/NN has/VBZ shifted/VBN our/PRP$ understanding/NN of/IN the/DT pathogenesis/NN of/IN ventilator-induced/JJ side/NN effects/NNS ./.
P12660659A07
Despite/IN the/DT overall/JJ safety/NN and/CC efficacy/NN of/IN these/DT agents/NNS ,/, many/DT patients/NNS undergoing/VBG statin/NN therapy/NN fail/VBP to/TO achieve/VB the/DT treatment/NN goals/NNS specified/VBN in/IN the/DT National/JJ Cholesterol/NN Education/NN Program/NN Adult/NN Treatment/NN Panel/NN III/CD guidelines/NNS ,/, often/RB because/IN of/IN suboptimal/JJ use/NN ,/, tolerability/NN problems/NNS ,/, or/CC lack/NN of/IN compliance/NN ./.
P12662126A08
In/IN approximately/RB 10/CD %/SYM of/IN patients/NNS ,/, however/WRB ,/, severe/JJ infusion-related/JJ reactions/NNS develop/VBP (/( e.g./IN bronchospasm/NN ,/, hypotension/NN )/) ./.
P12664086A09
Sensitivity/NN analysis/NN suggests/VBZ that/IN this/DT effect/NN is/VBZ largely/RB dependent/JJ on/IN the/DT results/NNS of/IN a/DT single/JJ trial/NN (/( weighted/JJ mean/NN difference/NN :/: -0.9/CD kg/NN ;/: 95/CD %/SYM CI/NN :/: -2.0/CD to/TO 0.2/CD kg/NN ,/, n=335/NN )/) ./.
P12667273A13
Prophylactic/JJ measures/NNS include/VBP rigorous/JJ infection/NN control/NN and/CC administration/NN of/IN polyclonal/JJ (/( RSV-IGIV/NN [/( respiratory/JJ syncytial/JJ virus/NN -/: immunoglobulin/NN intravenous/JJ ]/) )/) and/CC monoclonal/JJ (/( palivizumab/NN )/) antibodies/NNS ./.
P12668909A11
This/DT review/NN discusses/VBZ the/DT diagnosis/NN and/CC management/NN of/IN the/DT metabolic/JJ syndrome/NN and/CC examines/VBZ the/DT potential/NN of/IN future/JJ treatment/NN options/NNS ./.
P12672771A17
Safety/NN data/NNS from/IN 50/CD trials/NNS yielded/VBD estimates/NNS of/IN 2.2-/CD to/TO 3.6-fold/NN increases/NNS in/IN odds/NNS of/IN psychiatric/JJ ,/, autonomic/JJ ,/, or/CC gastrointestinal/JJ symptoms/NNS ,/, and/CC heart/NN palpitations/NNS ./.
P12678337A04
We/PRP included/VBD any/DT randomized/JJ clinical/JJ trial/NN comparing/VBG different/JJ types/NNS of/IN antibiotic/JJ prophylaxis/NN with/IN placebo/NN or/CC no/DT intervention/NN in/IN inpatients/NNS with/IN cirrhosis/NN ./.
P12685059A06
Few/JJ diagnostic/JJ strategies/NNS have/VBP been/VBN assessed/VBN in/IN ICU/NN patients/NNS with/IN suspected/JJ PE/NN ./.
P12690649A13
In/IN leukemia/NN and/CC lymphoma/NN ,/, the/DT coagulopathy/NN is/VBZ typically/RB acute/JJ DIC/NN that/WDT can/MD lead/VBP to/TO systemic/JJ and/CC brain/NN hemorrhages/NNS ./.
P12692171A17
However/WRB ,/, they/PRP should/MD remind/VBP patients/NNS of/IN the/DT importance/NN of/IN communicating/NN test/NN results/NNS to/TO family/NN members/NNS ,/, as/IN part/NN of/IN pretest/NN counseling/NN and/CC informed/JJ consent/NN discussions/NNS ./.
P12696988A09
We/PRP put/VBP forward/RB recommendations/NNS for/IN relevant/JJ outcome/NN measures/NNS ,/, timeframes/NNS ,/, endpoints/NNS and/CC epidemiologic/JJ data/NNS sources/NNS ./.
P12704479A02
Although/IN quality/NN indicators/NNS have/VBP been/VBN developed/VBN in/IN other/JJ countries/NNS ,/, Canadian/JJ cardiovascular/JJ disease/NN indicators/NNS do/VBP not/RB exist/VBP ./.
P12708950A01
OBJECTIVE/NN :/: To/TO review/VB the/DT pharmacology/NN ,/, pharmacokinetics/NNS ,/, efficacy/NN ,/, and/CC tolerability/NN of/IN extended-release/NN (/( ER/NN )/) metoprolol/NN succinate/NN and/CC its/PRP$ role/NN in/IN the/DT management/NN of/IN chronic/JJ heart/NN failure/NN ./.
P12710848A02
The/DT systemic/JJ nature/NN of/IN the/DT disease/NN is/VBZ reflected/VBN in/IN the/DT fact/NN that/IN individuals/NNS with/IN PAD/NN or/CC carotid/JJ artery/NN disease/NN are/VBP more/RB likely/RB to/TO have/VB CAD/NN than/IN those/PRP without/IN ./.
P12715671A07
We/PRP also/RB searched/VBD the/DT Cochrane/NNP Controlled/JJ trials/NNS Register/VBP (/( Cochrane/NNP Library/NN issue/NN 1/CD ,/, 2000/CD )/) the/DT Science/NN Citation/NN Index/NN ,/, BIOSIS/NN ,/, CAB-Health/NN ,/, Health/NN star/NN and/CC Economic/JJ databases/NNS ./.
P12719677A02
A/DT search/NN was/VBD conducted/VBN of/IN all/DT published/JJ literature/NN on/IN conventional/JJ search/NN engines/NNS (/( PubMed/NN ,/, EMBASE/NN ,/, the/DT Cochrane/NNP Registry/NN ,/, CINAHL/NN ,/, LILACS/NN )/) and/CC alternative/JJ medicine/NN databases/NNS (/( Natural/JJ Medicines/NNS Comprehensive/JJ Database/NN ,/, Longwood/NNP Herbal/NN Taskforce/NN ,/, and/CC Alternative/JJ Medicine/NN Alert/NN )/) ,/, for/IN all/DT studies/NNS of/IN the/DT five/CD most/RBS commonly/RB used/JJ CAM/NN treatments/NNS of/IN vaginitis/NN ./.
P12725011A05
There/EX are/VBP no/DT well-conducted/JJ ,/, randomized/JJ clinical/JJ trials/NNS to/TO guide/VB practitioners/NNS ./.
P12729427A04
DATA/NNS SOURCES/NNS :/: Accuracy/NN and/CC complications/NNS of/IN diagnostic/JJ tests/NNS were/VBD estimated/VBN by/IN using/NN meta-analysis/NN and/CC literature/NN review/NN ./.
P12735123A17
Although/IN many/DT clinicians/NNS share/VBP a/DT nihilistic/JJ view/NN regarding/VBG the/DT potential/JJ usefulness/NN of/IN mechanical/JJ ventilation/NN in/IN elderly/JJ patients/NNS few/JJ data/NNS warrant/VBP this/DT negative/JJ prognostication/NN and/CC more/DT outcome/NN studies/NNS are/VBP needed/VBN to/TO delineate/VB the/DT optimum/NN application/NN of/IN this/DT element/NN of/IN supportive/JJ care/NN ./.
P12738981A10
In/IN the/DT properly/RB selected/JJ woman/NN with/IN symptomatic/JJ fibroids/NNS ,/, the/DT result/NN from/IN the/DT selected/JJ treatment/NN should/MD be/VBP an/DT improvement/NN in/IN the/DT quality/NN of/IN life/NN ./.
P12742289A04
METHODS/NNS :/: Both/CC MEDLINE/NN (/( 1966/CD to/TO December/NN 2001/CD )/) and/CC EMBASE/NN (/( 1980/CD to/TO December/NN 2001/CD )/) were/VBD searched/VBN ,/, with/IN supplementation/NN by/IN reference/NN list/NN searches/NNS ./.
P12749504A04
METHODS/NNS :/: The/DT English-language/NN literature/NN was/VBD searched/VBN using/VBG the/DT EMBASE/NN and/CC MEDLINE/NN databases/NNS ./.
P12751912A10
Furthermore/RB ,/, the/DT total/JJ cost/NN of/IN a/DT screening/JJ programme/NN is/VBZ difficult/JJ to/TO define/VB since/IN it/PRP extends/VBZ well/RB beyond/IN the/DT initial/JJ test/NN ./.
P12759325A09
DATA/NNS SYNTHESIS/NN :/: Data/NNS were/VBD combined/VBN from/IN 42/CD clinical/JJ trials/NNS that/WDT included/VBD 192478/CD patients/NNS randomized/VBN to/TO 7/CD major/JJ treatment/NN strategies/NNS ,/, including/VBG placebo/NN ./.
P12769045A05
DATA/NNS EXTRACTION/NN METHODS/NNS :/: Articles/NNS were/VBD categorized/VBN as/IN Intervention/NN ,/, Population/NN (/( stage/NN distribution/NN )/) ,/, or/CC Validation/NN studies/NNS ./.
P12773077A12
For/IN patients/NNS undergoing/VBG primary/JJ PCI/NN for/IN the/DT management/NN of/IN STEMI/NN ,/, the/DT available/JJ evidence/NN supports/VBZ the/DT use/NN of/IN abciximab/NN ,/, albeit/IN further/JJ investigation/NN is/VBZ warranted/VBN ./.
P12777595A16
Many/JJ characteristics/NNS of/IN families/NNS have/VBP changed/VBN during/IN the/DT past/NN 3/CD to/TO 5/CD decades/NNS ./.
P12778842A01
Depression/NN and/CC bipolar/JJ disorder/NN are/VBP frequently/RB chronic/JJ disorders/NNS ,/, with/IN onset/NN often/RB beginning/NN in/IN childhood/NN ./.
P12781904A04
In/IN the/DT Heart/NN Outcomes/NNS Prevention/NN Evaluation/NN (/( HOPE/NN )/) study/NN ,/, ramipril/NN treatment/NN in/IN high-risk/NN patients/NNS was/VBD associated/VBN with/IN a/DT 20/CD %/SYM reduction/NN in/IN the/DT risk/NN for/IN myocardial/JJ infarction/NN ;/: mean/NN reduction/NN in/IN blood/NN pressure/NN was/VBD 3/CD mm/NN Hg/NN for/IN systolic/JJ blood/NN pressure/NN and/CC 1/CD mm/NN Hg/NN for/IN diastolic/JJ blood/NN pressure/NN ./.
P12784781A09
The/DT odds/NNS ratios/NNS for/IN stenting/NN vs/CC CABG/NN were/VBD 0.82/CD (/( 95/CD %/SYM confidence/NN interval-CI/NN 0.57-1.18/CD ,/, p/NN =/SYM 0.3/CD )/) for/IN the/DT occurrence/NN of/IN death/NN ,/, non-fatal/JJ myocardial/JJ infarction/NN or/CC stroke/NN ,/, 4.6/CD (/( 95/CD %/SYM CI/NN 3.5-5.9/CD ,/, p/NN </SYM 0.00001/CD )/) for/IN repeat/NN revascularization/NN ,/, and/CC 2.3/CD (/( 95/CD %/SYM CI/NN 1.8-2.8/CD ,/, p/NN </SYM 0.00001/CD )/) for/IN symptomatic/JJ angina/NN ./.
P12788842A03
Observational/JJ studies/NNS suggest/VBP a/DT protective/JJ role/NN of/IN estrogen/NN ,/, whereas/IN recent/JJ randomized/JJ controlled/JJ trials/NNS report/VBP a/DT negative/JJ role/NN for/IN oral/JJ estrogen/NN in/IN primary/JJ and/CC secondary/JJ prevention/NN of/IN cardiovascular/JJ events/NNS ./.
P12793924A07
High-risk/NN categories/NNS include/VBP congenital/JJ and/CC acquired/JJ immunodeficiency/NN ,/, younger/JJR age/NN ,/, transfusion/NN of/IN blood/NN donated/VBN by/IN family/NN members/NNS ,/, and/CC transfusion/NN with/IN fresh/JJ whole/JJ blood/NN ./.
P12796751A01
BACKGROUND/NN :/: Coronary/JJ stent/NN placement/NN has/VBZ replaced/VBN balloon/NN angioplasty/NN as/IN the/DT percutaneous/JJ coronary/JJ intervention/NN (/( PCI/NN )/) method/NN of/IN choice/NN ,/, primarily/RB because/IN of/IN its/PRP$ lower/JJR restenosis/NN rate/NN ./.
P12800564A35
When/WRB historical/JJ data/NNS are/VBP not/RB available/JJ ,/, the/DT Six/CD Sigma/NN team/NN must/MD collect/VBP baseline/NN data/NNS as/IN one/CD of/IN their/PRP$ earliest/JJS tasks/NNS ./.
P12804385A15
In/IN the/DT bupropion/NN trials/NNS ,/, 18/CD had/VBD a/DT placebo/NN arm/NN ,/, two/CD of/IN which/WDT tested/VBD long-term/NN use/NN to/TO prevent/VB relapse/NN ./.
P12804392A22
Clinicians/NNS should/MD weigh/VBP the/DT moderate/JJ benefits/NNS of/IN antibiotic/JJ treatment/NN against/IN the/DT potential/NN for/IN adverse/JJ effects/NNS ./.
P12804400A08
Analysis/NN was/VBD on/IN an/DT intention-to-treat/NN basis/NN ./.
P12804406A27
Combined/JJ oestrogen/NN and/CC progesterone/NN appeared/VBD to/TO reduce/VB the/DT likelihood/NN of/IN cure/NN or/CC improvement/NN ./.
P12804410A17
Subgroups/NNS of/IN patients/NNS may/MD gain/VBP benefit/NN ,/, but/CC it/PRP appears/VBZ difficult/JJ to/TO predict/VB responders/NNS ./.
P12804416A17
REVIEWER/NN 'S/POS CONCLUSIONS/NNS :/: We/PRP did/VBD not/RB find/VBP convincing/JJ evidence/NN that/IN BCAA/NN had/VBD a/DT significant/JJ beneficial/JJ effect/NN on/IN patients/NNS with/IN hepatic/JJ encephalopathy/NN ./.
P12804421A18
Since/IN no/DT clear/JJ rationale/NN exists/VBZ for/IN biphasic/JJ pills/NNS and/CC since/RB extensive/JJ evidence/NN is/VBZ available/JJ for/IN monophasic/JJ pills/NNS ,/, the/DT latter/NN are/VBP preferred/VBN ./.
P12804425A02
OBJECTIVES/NNS :/: To/TO determine/VB the/DT benefit/NN of/IN methylxanthines/NNS compared/VBN to/TO placebo/NN for/IN COPD/NN exacerbations/NNS ./.
P12804428A14
The/DT rehabilitation/NN program/NN was/VBD required/VBN to/TO be/VB multidisciplinary/JJ ,/, i.e./CC ,/, it/PRP had/VBD to/TO consist/VB of/IN a/DT physician/NN 's/POS consultation/NN plus/IN either/CC a/DT psychological/JJ ,/, social/JJ or/CC vocational/JJ intervention/NN ,/, or/CC a/DT combination/NN of/IN these/PRP ./.
P12804436A02
OBJECTIVES/NNS :/: To/TO determine/VB whether/IN there/EX is/VBZ evidence/NN to/TO support/VB the/DT use/NN of/IN KMC/NN in/IN LBW/NN infants/NNS as/IN an/DT alternative/NN to/TO conventional/JJ care/NN after/IN the/DT initial/JJ period/NN of/IN stabilization/NN with/IN conventional/JJ care/NN ./.
P12804442A20
Subgroup/NN analyses/NNS failed/VBD to/TO identify/VB a/DT disproportionate/JJ benefit/NN of/IN treatment/NN according/VBG to/TO the/DT allergen/NN administered/VBN ./.
P12804447A09
An/DT update/NN search/NN was/VBD conducted/VBN on/IN 12th/JJ August/NN 2002/CD ./.
P12804453A06
The/DT Cochrane/NNP Effective/JJ Practice/NN and/CC Organisation/NN of/IN Care/NN Specialised/JJ Register/NN ,/, the/DT Cochrane/NNP Rehabilitation/NN Specialist/NN Register/NN ;/: Cochrane/NNP Controlled/JJ Trials/NNS Register/NN (/( CCTR/NN )/) ;/: MEDLINE/NN (/( 1966-2000/CD )/) ;/: EMBASE/NN (/( 1980-2000/CD )/) ,/, Cumulative/JJ Index/NN to/TO Nursing/NN and/CC Allied/NN Health/NN Literature/NN (/( CINAHL/NN )/) (/( 1982-2000/CD )/) :/: Science/NN Citation/NN Index/NN (/( 1982-2000/CD )/) ;/: Social/JJ Science/NN Citation/NN Index/NN (/( 1982-2000/CD )/) ;/: Best/JJS Evidence/NN (/( 1991-2000/CD )/) ;/: HMIC/NN (/( 1979-2000/CD )/) ;/: PsycINFO/NN (/( 1967-2000/CD )/) ;/: ASSIA/NN (/( 1987-2000/CD )/) ;/: Ageline/NN (/( 1978-2000/CD )/) ;/: AgeInfo/NN (/( 1971-2000/CD )/) ;/: Sociological/JJ Abstracts/NNS (/( 1963-2000/CD )/) ;/: System/NN for/IN Information/NN on/IN Grey/JJ Literature/NN (/( SIGLE/NN )/) (/( 1980-2000/CD )/) ;/: UK/NNP National/JJ Research/NN Registers/NNS Project/NN Database/NN (/( Issue/NN 12001/CD )/) ;/: Architecture/NN Publication/NN Index/NN (/( 1977-2000/CD )/) ./.
P12804456A24
These/DT results/NNS were/VBD not/RB sensitive/JJ to/TO the/DT assumption/NN made/VBN because/IN the/DT overall/JJ benefit/NN estimated/VBN was/VBD still/RB significant/JJ when/WRB the/DT correlation/NN was/VBD assumed/VBN to/TO be/VB less/RB than/IN 0.1/CD ./.
P12804461A13
The/DT reviewers/NNS assumed/VBD that/IN people/NNS who/WP died/VBD or/CC dropped/VBD out/RP had/VBD no/DT improvement/NN and/CC tested/VBD the/DT sensitivity/NN of/IN the/DT final/JJ results/NNS to/TO this/DT assumption/NN ./.
P12804466A08
SELECTION/NN CRITERIA/NNS :/: All/DT randomised/JJ and/CC quasi-randomised/JJ trials/NNS involving/VBG agents/NNS that/WDT reduce/VBP gastric/JJ acidity/NN compared/VBN to/TO placebo/NN or/CC a/DT comparator/NN treatment/NN ./.
P12804469A20
The/DT incidence/NN of/IN decreased/JJ urine/NN output/NN (/( </SYM 1cc/NN //SYM kg/NN //SYM hr/NN )/) was/VBD lower/JJR in/IN the/DT ibuprofen/NN group/NN as/IN compared/VBN to/TO the/DT indomethacin/NN group/NN [/( NNT/NN 9/CD (/( 95/CD %/SYM CI/NN 5-14/CD )/) ]/) ./.
P12804475A10
We/PRP entered/VBD and/CC analyzed/VBD data/NNS with/IN RevMan/NN 4.1/CD ./.
P12804481A11
MAIN/JJ RESULTS/NNS :/: 18/CD trials/NNS involving/VBG 1891/CD people/NNS were/VBD included/VBN ./.
P12804486A29
Neuropsychiatric/JJ and/CC cognitive/JJ adverse/JJ events/NNS occur/VBP more/RB frequently/RB on/IN anticholinergics/NNS than/IN on/IN placebo/NN and/CC are/VBP a/DT more/RB common/JJ reason/NN for/IN withdrawal/NN than/IN lack/NN of/IN efficacy/NN ./.
P12804493A04
Several/JJ surgical/JJ techniques/NNS have/VBP been/VBN developed/VBN to/TO regenerate/VB periodontal/JJ tissues/NNS including/VBG guided/JJ tissue/NN regeneration/NN (/( GTR/NN )/) ,/, bone/NN grafting/NN (/( BG/NN )/) and/CC the/DT use/NN of/IN enamel/NN matrix/NN derivative/NN (/( EMD/NN )/) ./.
P12804498A11
The/DT data/NNS selected/VBN would/MD reflect/VBP cognitive/JJ ,/, behavioural/JJ ,/, physical/JJ and/CC psychological/JJ domains/NNS of/IN AD/NN ./.
P12804502A13
Substantial/JJ statistical/JJ heterogeneity/NN was/VBD observed/VBN (/( p/NN </SYM 0.001/CD )/) ./.
P12804506A08
DATA/NNS COLLECTION/NN AND/CC ANALYSIS/NN :/: Two/CD trials/NNS (/( 418/CD subjects/NNS )/) met/VBD the/DT inclusion/NN criteria/NNS for/IN this/DT review/NN ./.
P12804510A01
BACKGROUND/NN :/: Therapeutic/JJ exercise/NN is/VBZ used/VBN as/IN one/CD modality/NN to/TO treat/VB people/NNS with/IN osteoarthritis/NN (/( OA/NN )/) ./.
P12806450A11
Participants/NNS in/IN the/DT studies/NNS were/VBD primiparous/JJ women/NNS ./.
P12812622A03
Because/IN there/EX is/VBZ no/DT cure/NN for/IN this/DT costly/JJ disease/NN ,/, goals/NNS of/IN therapy/NN include/VBP ;/: slowing/NN progression/NN ,/, increasing/NN patient/NN survival/NN ,/, minimizing/NN symptoms/NNS ,/, improving/NN patient/NN functional/JJ capacity/NN ,/, and/CC decreasing/NN ER/NN visits/NNS ,/, hospital/NN admissions/NNS ,/, and/CC readmissions/NNS ./.
P12816555A02
This/DT final/JJ article/NN reviews/VBZ the/DT role/NN of/IN long-term/NN HRT/NN in/IN stroke/NN ,/, Alzheimer/NNP 's/POS disease/NN (/( AD/NN )/) ,/, and/CC overall/JJ mortality/NN as/RB well/RB as/IN strategies/NNS to/TO guide/VB decision-making/NN for/IN the/DT individual/JJ patient/NN ./.
P12820712A30
Therefore/RB ,/, for/IN patients/NNS with/IN sufficient/JJ cardiopulmonary/JJ reserve/NN who/WP can/MD be/VBP clinically/RB staged/VBN as/IN IA/NN or/CC IB/NN ,/, either/CC by/IN good/JJ quality/NN CT/NN with/IN contrast/NN or/CC increasingly/RB with/IN 18-FDG/NN PET/NN ,/, the/DT initial/JJ tissue/NN diagnosis/NN may/MD be/VBP at/IN the/DT time/NN of/IN surgery/NN ,/, when/WRB a/DT frozen/JJ section/NN preceding/VBG a/DT complete/JJ lobectomy/NN with/IN lymph/NN node/NN sampling/NN will/MD combine/VBP diagnosis/NN and/CC therapy/NN ./.
P12825147A03
The/DT pharmacologic/JJ options/NNS are/VBP divided/VBN into/IN initiators/NNS versus/CC conditioners/NNS and/CC central-/JJ or/CC peripheral-acting/JJ drugs/NNS ./.
P12829553A01
OBJECTIVES/NNS :/: To/TO determine/VB the/DT combination/NN of/IN drugs/NNS and/CC vitamins/NNS ,/, and/CC their/PRP$ doses/NNS ,/, for/IN use/NN in/IN a/DT single/JJ daily/JJ pill/JJ to/TO achieve/VB a/DT large/JJ effect/NN in/IN preventing/NN cardiovascular/JJ disease/NN with/IN minimal/JJ adverse/JJ effects/NNS ./.
P12834569A03
Current/JJ positive/JJ inotropes/NNS (/( eg/IN ,/, dobutamine/NN and/CC phosphodiesterase/NN inhibitors/NNS )/) provide/VBP symptomatic/JJ relief/NN ,/, but/CC newer/JJR agents/NNS may/MD have/VBP a/DT better/JJR adverse/JJ effect/NN profile/NN ./.
P12841826A03
OBJECTIVE/NN :/: To/TO provide/VB a/DT concise/JJ state-of-the-art/NN review/NN of/IN the/DT most/RBS commonly/RB used/JJ automated/JJ signal/NN detection/NN procedures/NNS ,/, including/VBG the/DT underlying/JJ statistical/JJ concepts/NNS ,/, performance/NN characteristics/NNS ,/, and/CC outstanding/JJ limitations/NNS ,/, and/CC issues/NNS to/TO be/VB resolved/VBN ./.
P12848590A04
Erlotinib/NN is/VBZ undergoing/VBG clinical/JJ development/NN as/IN an/DT oral/JJ tablet/NN by/IN an/DT alliance/NN between/IN OSI/NN Pharmaceuticals/NNS ,/, Genentech/NN and/CC Roche/NNP ./.
P12852701A02
The/DT fixed-dose/NN combination/NN of/IN trandolapril/NN and/CC verapamil/NN extended/JJ release/NN (/( ER/NN )/) is/VBZ approved/VBN for/IN the/DT treatment/NN of/IN hypertension/NN only/RB ./.
P12853542A16
CONCLUSIONS/NNS :/: This/DT meta-analysis/NN of/IN 3/CD months/NNS of/IN NIPPV/NN in/IN patients/NNS with/IN stable/JJ COPD/NN showed/VBD that/IN ventilatory/JJ support/NN did/VBD not/RB improve/VBP lung/NN function/NN ,/, gas/NN exchange/NN ,/, or/CC sleep/NN efficiency/NN ./.
P12858126A05
Among/IN available/JJ dyslipidemic/JJ therapies/NNS ,/, although/IN statins/NNS remain/VBP the/DT mainstay/NN for/IN lowering/NN low-density/NN lipoprotein/NN cholesterol/NN and/CC clinical/JJ events/NNS ,/, niacin/NN is/VBZ currently/RB the/DT most/RBS effective/JJ agent/NN for/IN increasing/NN low/JJ high-density/NN lipoprotein/NN cholesterol/NN levels/NNS ./.
P12862115A27
There/EX is/VBZ need/VBP to/TO combine/VB data/NNS collection/NN methods/NNS ,/, such/JJ as/IN interview/NN surveys/NNS ,/, hospital/NN records/NNS ,/, police/NN records/NNS ,/, focus/NN group/NN discussions/NNS and/CC key/JJ informant/NN interviews/NNS ./.
P12879083A08
Nine/CD trials/NNS evaluated/VBD protein/NN and/CC energy/NN supplementation/NN (/( five/CD oral/JJ and/CC four/CD nasogastric/JJ feeding/NN )/) ,/, and/CC a/DT further/JJ three/CD trials/NNS tested/VBD oral/JJ protein/NN supplementation/NN ./.
